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Abstract
The five studies presented in this thesis consider different aspects of the long-term 
prognosis of epilepsy and febrile seizures. The studies were:  
1). A systemic review to examine a) how the risk of premature mortality in an individual 
with epilepsy changes over time and b) whether population mortality rates due to epilepsy 
have changed over time. (Study 1)
2). An extension of the National General Practice Study of Epilepsy (NGPSE), a 
prospective community-based incident cohort study to examine a) long-term seizure 
prognosis and mortality in people with epilepsy and b) seizure prognosis in children with 
febrile seizures (Study 2)
3). Two retrospective hospital-based cohort studies examining prognosis of chronic 
epilepsy with regard to a) frequency of different seizure patterns (Study 3) and medium-
term seizure outcome following anti-epileptic drug changes (Study 4). 
4). A systematic review examining the impact of aetiology and others factors on outcome in 
status epilepticus (Study 5).
Amongst the findings were: 
1): There is no conclusive evidence that either the overall standardised mortality ratio 
(SMR) or the mortality rate of people with epilepsy has changed significantly over time. 
The SMR is highest soon after diagnosis and subsequently decreases with a possible late 
increase after 10 years. In the NGPSE cohort the SMR remains significantly elevated after 
20 years despite over 80% currently being in terminal remission. 
2): 6.7% (95% CI 4, 11%) of children with febrile seizures developed epilepsy after 20 
years. 
3):  Approximately one-third of people with chronic epilepsy have a history of at least one 
significant period of seizure freedom (two or more years) while a comparable number with 
apparent drug-resistant epilepsy attain at least one year of seizure freedom after medication 
change, although approximately half subsequently relapse. 
44
4). Aetiology and, to a lesser extent, age are the primary determinants of prognosis in status 
epilepticus. 
55
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Chapter 1: Introduction and literature review
1.1 Introduction
Epilepsy is the most common neurological condition affecting people of all ages, races 
and social classes. Worldwide it is estimated that over 50 million people have epilepsy 
of whom up to 75% live in resource-poor countries with little or no access to medical 
services and treatment (Meinardi et al., 2001; Ngugi et al., 2010). 
Epidemiology is the study of health determinants, and the distribution and natural 
history of disease in human populations. Epidemiological studies can be descriptive, 
analytical or experimental. Descriptive epidemiology is concerned with the distribution 
and vital statistics (incidence and prevalence) of a condition in a population, without 
regard to causation or other hypothesis and usually involves observational studies. 
Analytical epidemiology tests hypotheses, for example examining whether a certain 
exposure is a risk factor for a particular disease. This is normally examined by means of 
cohort and case control studies. Experimental epidemiology consists of studies in which 
the investigator is able to control relevant risk factors. Epidemiological studies in 
epilepsy are mostly descriptive and analytical with few experimental epidemiological 
studies conducted (Jallon, 2002; Sander, 2003).
Until the 1960s studies in epilepsy were carried out in tertiary referral centres; this 
favoured the belief that epilepsy was a chronic, progressive, incurable condition with 
little chance of remission (Sander ,1993; Berg and Shinnar, 1994). This view was 
endorsed in the 19th century - “The spontaneous cessation of the disease is an event too 
20
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rare to be reasonably anticipated in any given case” (Gowers, 1881) and reiterated years 
later, with epilepsy portrayed as “a chronic condition prone to relapse” (Rodin, 1968).
Since then many epidemiological studies have been published from both the resource-
poor and the developed world. Methodological differences, lack of standardised 
classification, problems with case ascertainment and diagnostic accuracy resulted in 
disparity in study findings as well as reflecting the heterogeneous nature of epilepsy.
Diagnostic accuracy is a particular problem in epilepsy as seizures are a symptom of 
diverse underlying cerebral aetiologies and may not have any permanent physical 
manifestations (Sander and Shorvon, 1987). This is further complicated by the lack of 
validated criteria for the diagnosis of an epileptic seizure. As a result a diagnosis of a 
seizure disorder is dependent on the chance recording of an event, the availability of a 
detailed eye-witness account (which may itself be misleading; Rugg-Gunn et al., 2001)
and the expertise and experience of the diagnosing specialist, with opinions differing in 
ambiguous cases (Stroink et al., 2004; van Donselaar et al., 1989). Consequently a 
definitive diagnosis of epilepsy is often only made after an extended period of follow-up 
(Hauser and Kurland, 1975; Sander et al., 1990a). Moreover 20-30% of those attending 
tertiary referral centres with refractory epilepsy do not in fact have epilepsy (Lesser, 
1996; Smith et al., 1999) with the most common differential diagnoses being 
dissociative seizures and syncope. As expected, neurologists are better at diagnosing 
epilepsy than non-specialists (mistake rate 5.6% versus 18.9%) (Leach et al., 2005) but 
at least 5% of diagnoses may be wrong. 
Many people with epilepsy may not come to medical attention, either through ignorance 
or lack of awareness of the symptoms. This is particularly true of absence and minor 
21
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complex partial seizures which may only be recognised in retrospect following 
presentation with a generalised seizure (Hauser et al., 1990). Indeed, one general 
practice study found that only 20% of patients with seizures suspected the diagnosis 
prior to medical consultation (Hopkins and Scambler, 1977). In a community study in 
Warsaw where identification of cases was supplemented with a door to door survey, it 
was found that one quarter of people with seizures had not sought medical attention 
(Zielinski, 1974a).
People with epilepsy may also try to conceal it for fear of stigmatisation. This may be a 
particular problem in certain communities as seen in a door to door survey in Sicily 
where the low prevalence rate was interpreted as being the result of concealment (Rocca 
et al., 2001). In Australia, 10% of those with a confirmed diagnosis of epilepsy (defined 
as having three seizures diagnosed by a doctor) denied having seizures (Beran et al., 
1985).
Thus epidemiological studies of epilepsy should ideally be community-based, 
prospective (to identify risk factors) and independent of existing medical records (or 
supplemented by use of door to door surveys, questionnaires or interview) to allow as 
complete as possible case ascertainment (Sander and Shorvon, 1987).
1.1.1 Definitions
To allow meaningful comparisons of incidence and prevalence rates from different 
countries, the same definition of epilepsy and a standardised classification of seizures 
need to be applied across all studies. The International League Against Epilepsy (ILAE) 
(Commission on Epidemiology and Prognosis ILAE, 1993) provides guidelines for 
epidemiological studies on epilepsy. Epilepsy is defined as a condition characterised by 
recurrent seizures (two or more) which are unprovoked by any identifiable cause. 
22
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Febrile seizures and neonatal seizures (within the first four weeks of life) are excluded. 
A single or isolated seizure is defined as one seizure or as multiple seizures occurring 
within a 24 hour period. A prevalent case of active epilepsy is defined as a person with 
known epilepsy who has had at least one unprovoked seizure in the previous five years 
irrespective of treatment status while a prevalent case of epilepsy in remission is defined 
as a person with known epilepsy who has had no seizures in five or more years 
regardless of treatment. 
Epidemiological studies in epilepsy are typically divided into studies from resource-rich 
and -poor countries because of differences in aetiologies and medical services; this 
division is somewhat arbitrary. 
23
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1.2 Incidence studies 
The incidence of epilepsy is defined as the number of new cases of epilepsy or seizures 
in a well-defined population during a specified time period (usually one year) and is 
normally expressed as the number of cases per 100,000 people in the population per 
year. Incidence studies are important for identifying risk factors as well as providing 
information on prognosis. Most incidence studies have been carried out in more 
developed countries and are retrospective, although some recent studies have been 
population-based prospective studies as recommended by the ILAE Commission on 
Epidemiology (1997). 
Studies documenting the incidence of a first epileptic seizure (per 100,000) are shown in 
Table 1.
24
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Author
(reference)
Population Total Provoked Unprovoked Single Study Design
France
(Loiseau et al. 1990)
1, 128,164 71.3 29.0 42.3 18.3 Prospective
USA
(Hauser et al. 1993)
2, 003,357 100 35.0 61.0 NA Retrospective
Sweden
(Forsgren et al.1996)
101,583 76.0 20.0 56.0 NA Prospective
Switzerland
(Jallon et al. 1997)
384,657 70.8 25.2 45.6 NA Prospective
Martinique
(Jallon et al.  1999)
383,596 80.5 16.4 64.1 NA Prospective
UK
(MacDonald et al. 
2000)
100,230 NA NA 57.0 11.0 Prospective
Iceland
(Olafsson et al.2005)
272,512 NA NA 56.8 23.5 Prospective
USA
(Benn et al. 2008)
270,677 NA NA 40.3 16.4 Prospective
Sweden
(Adelöw et al. 2009)
998,500 NA NA 33.9 14.4 Prospective
Table 1: Incidence of first epileptic seizure (per 100,000 people) 
1.2.1 Incidence of epilepsy in more developed countries
Incidence studies of epilepsy have been carried in many European countries as well as 
in the USA with remarkable consistency across different countries. In general, the 
incidence of epilepsy in the western world is taken to be around 50 (range 40 to 70) per 
25
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100,000/year (Sander, 2003). In a systemic review of incidence studies, 40 studies were 
identified, of which nine were prospective and seven were from resource-poor 
countries. The median annual incidence of epilepsy was 47.4 per 100,000 and of 
unprovoked seizures was 56 per 100,000. When the analysis was limited to studies of 
the highest quality, the median annual incidence of epilepsy decreased to 45 per 
100,000 and for unprovoked seizures to 50.8 per 100,000 (Kotsopoulos et al., 2002).
In a systemic review of European epidemiological studies, annual incidence rates 
ranged from 43 to 47 per 100,000 person years (Forsgren et al., 2005a). Two more 
recent studies provide annual incidences of 33.3 per 100,000 (Iceland; Olafsson et al., 
2005) and 68.8 per 100,000 (Denmark; Christensen et al., 2007b).
A summary of the main prospective incidence studies in developed countries are shown 
in Table 2.
Incidence studies in resource-poor countries are shown in Table 3.
The incidence of the main epilepsy syndromes are summarised in Table 4. 
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Authors Country Number 
of cases
Age-adjusted 
incidence rate per 
100,000
Comments
Forsgren
(1990)
Sweden 67
40 (SS)
33.6*
23.2**
Population study (1985-87)
Ages  17
Hauser et al.
(1993)
US 880 44 Comprehensive medical 
review (1935-84)
Sidenvall et al. 
(1993)
Sweden 61 73 Ages 0-15
All children with newly 
diagnosed within a 20 
month period
Forsgren et al. 
(1996a)
Sweden 160 56 Population register
SS Included
Age > 16
Olafsson et al. 
(1996)
Iceland 42 47 Medical record review 
(1993)
Zarrelli et al. 
(1999)
US 157 52.3 Comprehensive medical 
review (1980-84)
Annegers et al. 
(1999)
US 197
275 (SS)
35.5
50.9 (SS)
HMO population (1988-94)
Ages 0-64 years
Beilmann et al. 
(1999)
Estonia 216 45 1995-1997 
Ages 1 month -19 years
Oun et al. 
(2003)
Estonia 81 35.4 Database review (1994-97)
Ages 20
Olafsson et al. 
(2005)
Iceland 294
207 (SS)
32.4
22.8 (SS)
Nationwide surveillance 
system (1995-99)
Christensen et al. 
(2007)
Denmark 88,616 68.8 Database review (1977-
2002)
All ages
Adelow et al. 
(2009)
Sweden 585
430 (SS)
33.9* Incidence Registry (2001-
04)
All ages
Table 2: Prospective population-based incidence studies
SS= Single Seizure; HMO= Health maintenance organisation 
* All first unprovoked seizures, ** Single and acute symptomatic seizures
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Authors Country Number of 
cases
Age-adjusted 
incidence rate per 
100,000
Comments
Li et al 
(1985)
China 16 35 Small number. Wide 
confidence interval
Placencia et al. 
(1992)
Ecuador 137 122-190 Well designed study. 
Wide geographical 
variation
Lavados et al. 
(1992)
Chile 102 113 
Rwiza et al. 
(1992)
Tanzania 122 55 Crude incidence 73.3 per 
100,000
Tekle-Haimanot 
et al. (1997)
Ethiopia 139 49 Crude incidence 64 per 
100,000
Kaiser et al. 
(1998)
Uganda 80 156 Crude incidence 215 per 
100,000
Mani et al. 
(1998) 
India 32 49.3 
Sawhney et al. 
(1999)
India 34 60.0
Wang et al. 
(2002)
China 16 28.8 Door to door survey in 
rural areas of 5 provinces
Dogui et al. 
(2003)
Tunisia 157 102.1 Paediatric study
Idro et al. 
(2008)
Kenya 900 425 Ages 0-13 years. 
Incidence 875 per 
100,000 in children <5 
Mung’ala-Odera 
et al. (2008)
Kenya 39 187 Incidence calculated for 
children aged 6-12 years
Mignard et al.
(2009)
La Réunion 766 115.4 Newly diagnosed 
epileptic seizures (17.6% 
provoked)
Table 3: Incidence studies in resource poor countries
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South-West France 
(Loiseau et al., 
1990)
Rochester, USA
(Zarrelli et al., 
1999)
Iceland 
(Olafsson et al., 
2005)
Localisation-
related 
epilepsies
Total 15.3 34.9 18.6
Idiopathic 
partial epilepsies
1.7 0.2 1.6
Symptomatic 
partial epilepsies
13.6 17.2 8.4
Cryptogenic 
partial epilepsies
- 17.5 8.6
Generalised 
epilepsies
Total 7.2 7.7 3.9
Idiopathic 6.1 3.7 3.1
Cryptogenic or 
symptomatic
1.1 1.7 0.7
Symptomatic - 2.3 0.1
Epilepsies with 
both generalised 
and focal 
features
- 1.7 0.8
Epilepsies 
without 
unequivocal 
focal or 
generalised 
features
1.9 8.0 8.5
Isolated 
unprovoked 
seizures
18.3 - 22.8
Table 4: Incidences of epileptic syndromes (per 100,000 person-years) 
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1.3 Prevalence
Prevalence is defined as the number of people with a disease in a defined population as a 
proportion of the total population and is usually expressed as the number of cases per 1,000 
people in the population. Point prevalence is the number of existing cases (usually active 
epilepsy) in the population at a particular point in time while period prevalence is the 
prevalence over a particular period (usually one year). Information about a disease’s 
prevalence is important for service provision and planning. As prevalence studies are 
performed by means of cross-sectional studies they are fairly quick and easy to perform and 
much less expensive than cohort studies. Consequently a far greater number of prevalence 
studies than incidence studies have been performed. Most studies are carried out using a 
door to door survey using a standardised validated screening questionnaire as this is 
considered the gold standard methodology.
1.3.1 Prevalence in developed countries
Prevalence studies of epilepsy have been performed in many European countries, Japan, 
Australia and USA. Studies have shown a prevalence of active epilepsy of between 4 and 
10 per 1,000 (Sander and Shorvon, 1996) although most studies give a prevalence rate of 
active epilepsy of 4 to 7 per 1,000 (5.7 per 1,000 (Forsgren, 1992), 4.2 per 1,000 (Sidenvall 
et al., 1996), 4.8 per 1,000 (Olafsson and Hauser, 1999)). The lowest prevalence rate 
reported in an industrialized country was in Japan at 1.5 per 1,000 although more recent 
studies from Japan have estimated prevalence rates of active epilepsy more in concordance 
with other western countries (5.3 per 1,000 (Oka et al., 2006)). A systematic review 
(Forsgren et al., 2005a) found that the range of prevalence rates in Europe was 3.3 to 7.8 
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per 1,000 with a median prevalence of active epilepsy 5.2 per 1,000. European studies with 
the lowest reported prevalence rates were from Italy; 3.3 per 1,000 in Sicily (Rocca et al., 
2001) and 3.01 per 1,000 in the Aeolian Islands (Gallitto et al., 2005) although the authors 
of both studies suggested that the low reported prevalence rates may have resulted from 
people’s desire to conceal the diagnosis to avoid perceived social disadvantages as a result 
of prejudice towards people with epilepsy. In the Rochester study the prevalence of active 
epilepsy, calculated at 10 year intervals over 50 years ranged from 2.7 per 1,000 in 1940 to 
6.8 per 1,000 in 1980 (Hauser et al., 1991). 
More recent studies using patient reports from Norway (crude prevalence rate 11.7 per 
1000; active epilepsy 6.7 per 1,000; Brodtkorb and Sjaastad, 2008) and Ireland (life 
prevalence 10 per 1,000; treated epilepsy 8.3 to 9 per 1,000; Linehan et al., 2010) suggest 
higher prevalence rates in some western countries.  
The median lifetime prevalence in developed countries has been estimated to be 5.8 per 
1,000 (range 2.7 to 12.4) with a median prevalence of active epilepsy of 4.9 per 1,000 
(range 2.3 to 10.3; Ngugi et al., 2010).
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Studies of the prevalence of epilepsy in resource-poor countries are shown in Table 5. 
Author Country Prevalence per 1,000 
people (range)
Number of cases
Placencia et al (1992) Ecuador 6.7-8.0 575
Aziz et al (1999) Pakistan and 
Turkey
9.98 (Pakistan)
7.0 (Turkey)
24,130 (Pakistan)
11,497 (Turkey)
Nicoletti et al (1999) Bolivia 12.3
11.1 active epilepsy
124
Sridharan and 
Murthy (1999)
India 5.35 3,27
Wang et al (2003) China 7.0
4.6 active epilepsy
387
Burneo et al (2005) Latin America
(1974-2002)
17.8 (6-43.2) Pooled analysis of 32 
prevalence studies
Medina et al (2005) Rural 
Honduras
23.3 151
Preux et al (2005) Sub-Saharan
Africa
(1986-2004)
15.0 (5.2-70.0) Pooled analysis of 26 door 
to door surveys in 15 
countries. All but 3 rural 
populations 
Ndoye et al (2005) Senegal 14.2 64
Dent et al (2005) Tanzania 7.4 active epilepsy 42
Almu et al (2006) Ethiopia 29.5 82
Velez & Cobos 
(2006)
Columbia 11.3 (9.2-13.8)
10.1 (8.1-12.4)
92
Mac et al (2007) Asia
(1985-2006)
6.0 (1.5-14.0) Pooled analysis of 20 
studies from 12 countries
Edwards et al (2008) Kenya 4.5 active epilepsy 466
(Tuan et al., 2008) Vietnam 4.4 active epilepsy 206
Table 5: Selected prevalence studies from resource-poor countries
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1.4 Risk factors for epilepsy
The relative frequencies of specific aetiologies of any chronic condition are best determined 
by use of population-based studies of newly diagnosed cases, with incidence studies 
preferable to prevalence studies. Prevalence studies of active epilepsy will miss many cases 
at both ends of the severity spectrum (the severe cases with causes associated with 
increased mortality and the more benign cases with causes leading to early remission). 
Unprovoked seizures or epilepsy are divided into different categories by presumed 
causation; remote symptomatic, progressive symptomatic, idiopathic (presumed genetic) 
and cryptogenic or unknown. Some studies, particularly from resource-poor countries, also 
include people with provoked seizures (acute symptomatic seizures) in studies of epilepsy 
thereby artificially increasing incidence and prevalence figures.
  
In population-based studies the epilepsy is most frequently cryptogenic or idiopathic, 
ranging from 44.5% (Oun et al., 2003) to 67% (Olafsson et al., 2005), with the proportion 
of other causes determined increasing with age. The number of cases classified as 
cryptogenic has remained broadly similar over the past twenty years despite significant 
improvements in neuro-imaging. In a recent study in New York (Benn et al., 2008) 55% of 
people were defined as having idiopathic/cryptogenic epilepsy, similar to the 61% in the 
NGPSE (Sander et al., 1990) almost twenty years previously. Risk factors or associated 
factors linked to the subsequent development of epilepsy, such as cerebro-vascular disease, 
head trauma, neurodegenerative disease, CNS infections, neoplasms and learning disability,
predominate in identified aetiologies in population-based incidence studies. Aetiologies 
tend to be age-specific with cerebral palsy, congenital brain damage and learning disability 
33
33
predominating in the young while tumours, neurodegenerative disorders and especially
cerebrovascular disease dominate in the elderly.
1.4.1 Neoplasms 
Neoplasms are found to be the cause of seizures in four percent of people with epilepsy
(Olafsson et al., 2005). At least thirty percent of people with brain tumours will develop 
epilepsy, which for many is the first clinical presentation of the underlying malignancy 
(Hauser et al., 1993). Slow growing tumours, such as low-grade astrocytomas, appear to be 
more epileptogenic than high grade tumours although this may be related to their increased 
survival times (Herman, 2002). Seizures occur in 20 to 35% of those with cerebral 
metastasis (Herman, 2002).
1.4.2 Stroke
Stroke is the most commonly identified antecedent factor in population-based studies, 
accounting for up to 30% of cases overall (Forsgren et al., 1996a), with a higher rate in the 
elderly (44%; Ruggles et al., 2001).
The overall incidence of seizures is two to three percent within the first 24 hours following 
an acute stoke (Burn et al., 1997; Szaflarski et al., 2008), 4 to 6% in the first week 
(Labovitz et al., 2001; So et al., 1996) and 5% in the first two weeks (Bladin et al., 2000).
Risk factors for the development of early seizures (within two weeks) are anterior 
hemisphere location (Burn et al., 1997; So et al., 1996), cortical or lobar location of 
infarction (Bladin et al., 2000; Labovitz et al., 2001), stroke severity (Bladin et al., 2000; 
Burn et al., 1997), cardio-embolic versus small or large vessel aetiology, younger age and 
pre-existing disability (Szaflarski et al., 2008).
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Patients with haemorrhagic stroke (intra-cranial haemorrhage (ICH)/Sub-arachnoid 
haemorrhage (SAH)) have an almost 2-fold increase in risk of seizure compared with the 
general population (HR1.85; 95% CI 1.26, 2.73) (Bladin et al., 2000). One study found that 
the risk of seizure following ICH/SAH was 8.4% compared with 2.9% for those with 
infarction (Szaflarski et al., 2008) while another found that the risk of seizures in those with 
ICH/SAH was increased compared with infarction (hazard ratio for ICH vs cerebral 
infarction 10.2; 95% CI 3.7,27.9) (Burn et al., 1997).
The risks of early seizures following acute stroke differ by location and stroke subtype and 
in one study were 1% for deep infarction, 4% for deep ICH, 6% for lobar infarction, 8% for 
SAH and 14% for lobar ICH.  One quarter of those with early seizures had status 
epilepticus (Labovitz et al., 2001). In a recent review of seizures and ischaemic stroke 
(Menon and Shorvon, 2009), the most consistent risk factors identified for the development 
of post-ischaemic stroke epilepsy were cortical involvement, stroke severity (or disability) 
and male gender.
The cumulative risk of late seizures after stroke is 3% at one year, 4.7% at two years, 7.4% 
at five years and 8.9% by ten years (So et al., 1996). Risk factors for the subsequent 
development of epilepsy are early seizures and stroke recurrence, (So et al., 1996) and late 
onset (after two weeks) of seizures was found to be an independent risk for the 
development of epilepsy after ischaemic but not haemorrhagic stroke (Bladin et al., 2000). 
Overall 10-12% of stroke survivors will have had a seizure by five years of follow-up, with 
36% of those with early seizures going on to develop epilepsy. Only 3% of those seizure-
free at one month had a seizure between one month and five years (Burn et al., 1997).
For those with SAH 7% had developed epilepsy at 12 months follow-up (4% had a single 
seizure). Independent factors associated with the development of epilepsy following SAH 
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were presence of subdural hematoma (OR 9.9, 95% CI 1.9, 52.8) or cerebral infarction (OR 
3.9, 95% CI 1.4, 11.3) (Claassen et al., 2003). After 11 years of follow-up, 25% of those 
with SAH had developed epilepsy, all within the first four years. 70% of those with early 
seizures developed epilepsy which was more frequent in those with severe neurological 
deficits than in those without (48% vs 20%) (Olafsson et al., 2000).
1.4.3 Neurodegenerative disorders
Degenerative disease, most notably Alzheimer’s disease (AD), is a commonly identified 
risk factor for seizures in population-based studies, typically responsible for 5-6% of cases 
overall but for a much higher proportion of those over 65 (Olafsson et al., 2005). A 
diagnosis of AD or other dementia increases the risk of unprovoked seizures six-fold with 
no difference in the relative frequencies of complex partial or generalised seizures 
(Hesdorffer et al., 1996). In a study following people with AD the cumulative incidence of 
unprovoked seizures at seven years was almost 8%, with an 87-fold increase in risk of 
unprovoked seizures in those aged 50-59 and a 3-fold increase in those aged 85+. 
Independent risk factors for seizures identified on multivariate analysis were younger age, 
more severe dementia, African-American ethnicity and focal epileptiform features on EEG 
(Amatniek et al., 2006). Overall 3.6% of people on an AD register had seizures, the 
majority of whom (72%) had complex partial seizures. Most (79%) had an excellent 
response to anti-epileptic medications (Rao et al., 2009).
1.4.4 Trauma
Head trauma is a significant risk factor for the development of seizures; 5.5% of incident 
seizures in the Rochester study were caused by trauma (Hauser et al., 1993). The risk of 
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posttraumatic seizures is related to the severity of the injury; the risk of seizures following 
severe head injury (loss of consciousness and/or post-traumatic amnesia greater than 24 
hours) was 7.1% at one year and 11.5% at five years. (The risk of post-traumatic epilepsy is 
significantly higher in open head injuries as a result of missiles). The risk was 0.7% at one 
year and 1.6% at five years after moderate head injury (skull fracture or loss of 
consciousness and/or post-traumatic amnesia between 30 minutes and 24 hours) (Annegers 
et al., 1980). A further study from the Mayo clinic looked at the risk of the development of 
seizures following traumatic brain injury over ten years. The risk of seizures was related to 
the severity of head injury and decreased over time. Overall, head injury confers a three-
fold increased risk of seizures compared with the general population. Multivariate analysis 
showed that early seizures (occurring in the first week after injury) were not predictive of 
further seizures (Annegers et al., 1988). Significant risk factors for the subsequent 
development of post-traumatic seizures found on multivariate analysis were the presence of 
subdural haematoma, skull fracture, loss of consciousness and/or post-traumatic amnesia 
for greater than 24 hours and age over 65 years. The majority (77%) of those who develop 
seizures after a head injury have recurrent seizures. The risk of post-traumatic seizures was 
highest in the early years following the trauma with the five-year cumulative risk for 
seizures following mild (loss of consciousness and/or post-traumatic amnesia less than 30 
minutes: 0.7%), moderate (1.2%) and severe (10%) head injuries. The risk of developing 
seizures returned to that of the general population five years after mild injury and ten years 
following moderate injuries while remaining higher after ten years for those with severe 
injuries (Annegers et al., 1998). 
A recent study from Denmark (Christensen et al., 2009) found that the risk of seizures 
following a head injury persisted beyond ten years with a RR of 7.4 (95% CI: 6.2, 8.9) 
following a severe head injury and 2.2 (95% CI: 2.1, 2.4) following a mild head injury. The 
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risk of post-traumatic seizures was higher in females and increased with age following mild 
and severe injuries. People with a family history of epilepsy were at significantly higher 
risk of developing seizures following mild (RR=5.8, 95% CI: 4.6, 7.3) and severe 
(RR=10.1, 95% CI: 4.2, 24.3) injuries, emphasising the fact that the causation of epilepsy is 
often multi-factorial.
1.4.5 Seizures and bacterial meningitis/encephalitis
Seizures are common in the setting of acute infection accounting for 15% of those with 
acute symptomatic seizures in Rochester (Annegers et al., 1995). While infections are the 
identified aetiology in only a small number of cases (2.5% in Rochester; Hauser et al., 
1993) in the developed world, their importance as an aetiological factor is far greater in 
resource-poor countries.
In a population-based study, the 20-year risk of unprovoked seizures following encephalitis 
or meningitis was 6.8% overall. The risk was highest in the first five years (Standardised 
Morbidity Rate (SMR) 10.3) but remained elevated throughout follow-up. The cumulative 
risk of unprovoked seizures varied with the type of CNS infection and the presence or 
absence of seizures in the acute setting of the infection. The 20-year risk of developing 
unprovoked seizures was highest in those with viral encephalitis, 22% in people with early 
seizures and 10% in those without early seizures. In people with bacterial meningitis who 
survived, the risk of unprovoked seizures was 13% with and 2.4% without early seizures. 
The 20-year cumulative risk of seizures following aseptic meningitis was not significantly
increased (2.4%) over the general population rate (Annegers et al., 1988).
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1.4.6 Seizures and other CNS infections and infestations
Malaria is a major problem worldwide affecting millions annually, particularly in resource-
poor countries.  In a matched case-control study of 296 patients with cerebral malaria (CM) 
in Gabon (Ngoungou et al., 2006b), the adjusted odds ratio for developing epilepsy after 
CM was 3.9 (95% CI 1.7, 8.9) with additional risk factors identified as positive family 
history of epilepsy and antecedent history of febrile convulsions. In a similar study from 
Mali of 110 people with a history of CM and 222 controls (Ngoungou et al., 2006a), the 
incidence of epilepsy was 1,700 per 100,000 person-years for those who had CM compared 
with 180 per 100,000 person-years for those with no history of CM. The age-adjusted 
relative risk for developing epilepsy was 14.3 (95% CI, 1.6, 13.2; p=0.01) underlying the 
fact that CM-related epilepsy may be a significant problem in malaria endemic areas.
The impact of other infestations such as onchocerciasis (caused by the filarial helminth 
Onchocerca volvulus) has also been noted in areas such as West Uganda where there was a 
marked difference in the incidence of epilepsy in high endemic compared with low 
endemic areas (232 compared with 77 per 100,000) (Kaiser et al., 1998).
Neurocysticercosis (NCC), caused by the larvae of the pork tapeworm Taenia solium, while 
uncommon in the western world, has a very high prevalence in the developing world where 
it is considered one of the major risk factors for the development of epilepsy (Commission 
on Tropical Diseases of the ILAE, 1994).  There was an association between seropositivity 
(antibodies against T. Solium) and epilepsy with an odds ratio for epilepsy of 1.85 (95% 
CI, 0.99, 3.4) for all cases, with a stronger association in those with partial seizures (OR 
2.75, 95% CI 1.44, 6.61) and late onset seizures (15 years and older, OR 3.66, 95% CI 1.1, 
12.1) in a study in rural Bolivia (Nicoletti et al., 2002). In rural Peru, seropositivity for 
39
39
NCC was associated with seizures (OR 2.14, 95% CI 1.08, 4.2) (Montano et al., 2005)
while in India NCC was found to be the cause of active epilepsy in almost one third of 
people with seizures with no significant differences between rural and urban areas in the 
prevalence of NCC causing active epilepsy (Rajshekhar et al., 2006).
A study of the association between toxocariasis (caused by the roundworm Toxocara canis 
in dogs) and epilepsy found a positive association between seropositivity for T. Canis and 
epilepsy for all cases (OR 2.7, 95% CI 1.41, 5.19) with a much stronger association for 
those with late onset partial seizures (OR 18.22, 95% CI 2.1, 158.1) (Nicoletti et al., 2008).
1.4.7 Learning disability and cerebral palsy
Epilepsy is a common problem in those with learning disability (LD) with the risk and 
severity of epilepsy increasing with the degree of the cognitive deficit. Prevalence ranges 
from six percent amongst children with mild LD (IQ 50-70) to 24% in severe LD (IQ < 50) 
and 50% in those with profound LD (IQ <20) (Lhatoo and Sander, 2001). In eight percent
of cases identified in the Rochester study, the seizures were attributed to LD or cerebral 
palsy (CP). The cumulative risk of epilepsy in children with LD was 21% by the age of 22 
with the risk five-fold greater in those with severe LD than in those with mild LD
(Airaksinen et al., 2000). 
In a prospective study of children with LD followed from birth in Scotland (Goulden et al., 
1991), the cumulative risk of epilepsy by age 22 was 15% overall. In children with LD 
without associated disabilities the cumulative risk was 5.2% while for children with LD and 
associated CP the cumulative risk was 38%. The highest risk of epilepsy was for children 
with LD associated with a postnatal injury, at 66% (10 and also 15 years after injury). 
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In a study examining the prevalence of epilepsy in adults with and without LD in two 
primary care practices in the US (McDermott et al., 2005), the prevalence of epilepsy was 
one percent for the general population, 13% for those with CP, 14% for those with Down 
Syndrome, 25.4% for those with autism, 25.5% in those with LD alone, and 40% for those 
with both LD and CP. The prevalence of epilepsy decreased with increasing age in patients 
with CP and LD while increasing in people with Down syndrome and the general 
population.  
The risk of epilepsy varies with different subtypes of CP. A study using the CP registry in 
Norway found that 28% of children with CP had active epilepsy and 31% had LD. 19% of 
children with unilateral CP had active epilepsy compared with 30% of children with spastic 
bilateral CP (p=0.05) and 42% of children with dyskinetic CP (p=0.07) (Andersen et al., 
2008).
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1.5 Prognosis
For people with seizures, prognosis is the risk of further seizures after a single unprovoked 
seizure or the likelihood of achieving seizure freedom or terminal remission after a pattern 
of recurring seizures has been established (Sander, 1993). In discussing the prognosis of 
epilepsy, various aspects need to be considered: the likelihood of recurrence following a 
single seizure, the impact of early versus late treatment, the probability of relapse after 
prolonged remission, following epilepsy surgery or following anti-epileptic medication 
withdrawal and the associated morbidity and mortality associated with epilepsy.
1.5.1 Recurrence after a single seizure
Prospective population studies of single seizures are difficult as many seizures go 
unrecognised or are un-witnessed and in some instances individuals do not present to 
medical attention unless the seizure is convulsive. The overall risk of recurrence following 
a single seizure has been reported as 27 to 71%. A meta-analysis of 13 studies found that 
the average risk of seizure recurrence was 40% in prospective studies and 52% in 
retrospective studies (Berg and Shinnar, 1991). The time interval between the seizure and 
inclusion in a follow-up study of people with single seizures influences the recurrence rate, 
as many people have a recurrence within weeks of the index seizure, and are therefore 
classified as having epilepsy, thus artificially lowering the estimated recurrence rate 
following a single seizure (Hopkins et al., 1988). The risk of subsequent seizures decreases 
with time, with up to 80% of recurrences occurring within two years of the initial seizure;
recurrence rates are 36% in prospective studies and 47% in retrospective studies at two 
years (Berg and Shinnar, 1991). In the NGPSE, 67% of those with a single seizure had a 
recurrence within 12 months and 78% within 36 months (Hart et al., 1990).
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In a prospective study of 407 children with a first unprovoked seizure, 182 (45%) had a 
second seizure with a median time to recurrence of 6.2 months. The cumulative risk of a 
second seizure was 22% (6 months), 29% (one year), 37% (two years), 43% (five years) 
and 46% (ten years) (Shinnar et al., 2000). In the Dutch study of epilepsy in childhood 
(Stroink et al., 1998) 156 children, none of whom received treatment, were followed up 
from the time of a first unprovoked seizure; 54% had had a recurrence by two years. 
Similarly another study (Lindsten et al., 2001b) found a recurrence rate of 58% at 750 days 
in 107 people aged 17 or older. No person who was free of seizures in the first 750 days 
after the index seizure had a recurrence thereafter during a median follow-up of 10.3 years, 
underlying the impression that the risk of seizure recurrence is highest in the first one to 
two years following the seizure.  
1.5.2 Recurrence after a second seizure 
The risk of recurrent seizures following a second seizure was investigated in a 
predominantly adult population (Hauser et al., 1998). In those patients with a second 
seizure, the risk of a further seizure was 32% at three months, 41% at six months, 57% at 
one year and 74% at four years. Of those who did not have a recurrence after the second 
seizure within the first four years of follow-up, none had a relapse in the subsequent three
years. The majority (63%) of those with a third seizure had a further seizure with the risk of 
a fourth seizure being 31% at three months, 48% at six months, 61% at one year and 78% at 
three years. As with single seizures, the risk of further seizures is highest immediately after 
the last one. Similarly for children, the risk of a third seizure was 57% at one year, 63% at 
two years and 72% at five years after having a second seizure (Shinnar et al., 2000).  
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1.5.3 Short and medium term prognosis
It is usually accepted that the prognosis of epilepsy is generally favourable with 60-70% 
achieving remission (Sander, 1993). In a prospective study of children with newly 
diagnosed epilepsy followed for a median of five years from the time of diagnosis, 74% had 
achieved a period of remission (≥ two years seizure freedom), following which 24% had a 
further seizure. In those who had a relapse, approximately 50% occurred when anti-
epileptic medication was being withdrawn or had been stopped (Berg et al., 2001).  In the 
NGPSE after nine years, 86% of those with definite epilepsy had achieved a remission of 
three years and 68% a remission of five years. Sixty eight percent were in three year
terminal remission and 54% in five year terminal remission by nine years (Cockerell et al., 
1997). In a study of 107 patients aged ≥17 with newly diagnosed epilepsy, at ten years 
follow-up the cumulative remission rates were 68% (one year), 64% (three years) and 58% 
(five years) (Lindsten et al., 2001a).   
1.5.4 Long -term prognosis
Few studies have looked at the long-term prognosis of people with epilepsy and most are 
retrospective. 
In the Rochester study (Annegers et al., 1979a), 65% had achieved a five year period of 
remission at ten year follow-up and 76% at twenty years. At ten years after diagnosis 61% 
were in terminal remission, with 70% in terminal remission at 20 years. Of people in 
remission, 20% remained on anti-epileptic medication while 50% had successfully 
discontinued medication and remained seizure-free for five or more years.  A cohort of 
children with active epilepsy was followed for 12 years at which stage 64% were in 
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terminal remission (defined as three or more years seizure free) (Brorson and Wranne, 
1987).  
Of 144 children with epilepsy followed for an average of 37 years, 67% were in terminal 
remission, on or off medication at end of follow-up.  Early remission, occurring within the 
first year of treatment was achieved by 45 (31%), and the remission continued to terminal 
remission in 23 (51%) of these. Remission without relapse occurred in another 72 (50%) 
with a mean delay of nine years. Twenty (14%) entered remission but subsequently 
relapsed with further remission indicating a relapse-remitting pattern while 27 (19%) 
continued with seizures from the onset (Sillanpaa and Schmidt, 2006a). 
Of 102 children from the same cohort followed up for a median of 40 years, 95 (93%) had 
one or more periods of remission (one year) (Sillanpaa and Schmidt, 2009), emphasising 
the overall excellent prognosis of childhood epilepsy.
One of the major aims of this thesis is to examine the long-term prognosis after 25 years in 
a prospective incident cohort with regard to premature mortality and seizure outcomes.
Outcomes in long-term studies are summarised in Table 6.
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Author
(publication year)
Number 
in cohort
Follow-up 
(years)
Proportion 
5YR TR 
(%)
Proportion 
5YR TR off 
AEDs (%)
Study 
Design
Annegers et al 
(1979)
457 20 70% 50% Historic Incident 
Cohort
Okuma et al 
(1981)
1,868 10 58.3% N/A Retrospective
Multi-institutional 
study (P)
Brorson and 
Wranne (1987)
194 12 64% 40% Retrospective (P)
Oka et al (1989) 730 10-15 79.1% N/A Retrospective (P)
Wakamoto et al 
(2000) 
143 18.9 62.8% 54.7% Retrospective (P)
Lindsten et al 
(2001) 
107 10 64% 17.5% Prospective (All > 
17 years)
Sillanpaa and 
Schmidt (2006)
144 40 67% 58% Prospective (P)
Geerts et al 
(2010)
413 14.8 70.9% 61.9% Prospective (P)
P=Paediatric Study; 5YR TR=5 year terminal remission rate
Table 6: Long-Term Follow-up Studies in Epilepsy
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1.5.5 Prognostic factors
Many studies have looked at possible predictors of seizure prognosis, including age of 
onset, gender, aetiology, seizure type, EEG patterns, number of seizures prior to treatment 
and early response to treatment (Sander, 2003). In people presenting with a first-ever 
seizure, the presence of multiple discrete seizures within 24 hours is not associated with a 
worse prognosis compared with those with a single seizure (Kho et al., 2006). Remote 
symptomatic epilepsy, the presence of a neurological birth deficit (which was associated 
with a 100% relapse rate in the NGPSE (Hart et al., 1990)) and learning disability have 
been consistently shown to be associated with a poorer prognosis. In one study (Brorson 
and Wranne, 1987) the three year remission rate was 89% for those with idiopathic epilepsy 
and normal examination compared with only 49% in those with a neurological deficit or 
learning disability. The number of seizures in the first six months after onset has been 
found to be a strong determinant of the probability of subsequent remission with 95% of 
those with two seizures in the first six months achieving a five year remission compared 
with only 24% of those with more than ten seizures (MacDonald et al., 2000).
A high initial seizure frequency, focal EEG slowing and acute symptomatic seizures or 
neonatal status epilepticus have all been shown to be significantly associated with an 
increased risk of developing refractory or intractable epilepsy in children (Berg et al 2001). 
Seizure type has been an inconsistent prognostic factor with some studies indicating that 
those with partial seizures have a poorer prognosis (Annegers et al., 1979a) while other 
studies have demonstrated a poorer prognosis for people with generalised onset seizures 
(Shafer et al., 1988). Individuals with multiple seizure types, as is typical in the childhood 
encephalopathies, appear to have a poorer prognosis (Collaborative Group for the Study of 
Epilepsy, 1992).
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A significant reduction or complete cessation of seizures within three months of initiating 
treatment has been shown to be a strong predictor of subsequent remission (Sillanpaa et al., 
1998). The probability of seizure remission decreases significantly with each successive 
treatment failure (Kwan and Brodie, 2000). Only 11% of patients who discontinued the first 
appropriate anti-epileptic drug (AED) due to lack of efficacy became seizure free on a 
second AED and only 4% on a third medication or on polypharmacy. This figure is,
however, contentious and one of the major themes of this thesis is the examination of the 
impact of medication changes in a cohort of people with apparent pharmaco-resistant 
epilepsy followed over several years.
Children who experience clusters of seizures during treatment were much more likely to 
have refractory epilepsy than children without clusters (42% vs 13%, p=0.01) and less 
likely to achieve five year terminal remission (p=0.004) (Sillanpaa and Schmidt, 2008). 
Children who continued to have weekly seizures during the first year of treatment had an 
eight-fold increase in the risk of developing intractable epilepsy and a two-fold increase in 
risk of never achieving one year terminal remission. (Sillanpaa and Schmidt, 2009)
1.5.6 The impact of aetiology on prognosis
When comparing the prognosis of people with epilepsy by aetiology (epilepsy syndrome), 
people with idiopathic generalized epilepsy appear to have a better prognosis than those 
with symptomatic or cryptogenic partial epilepsy.  Most (82%) people with idiopathic 
generalised seizures achieved one year seizure freedom compared with only 35% with 
symptomatic partial epilepsy and 45% with cryptogenic partial epilepsy (Semah et al., 
1998). Temporal lobe epilepsy (TLE) was associated with a poorer prognosis than extra-
temporal lobe epilepsy (36% vs 20% seizure free) (Semah et al., 1998). In people with a 
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single identified lesion, TLE with hippocampal sclerosis (HS) had a particularly poor 
prognosis (11% seizure free) compared with other aetiologies (24% with cortical dysplasia 
(CD) seizure free). Individuals with HS and another identified pathology (dual pathology) 
had the worst prognosis (3% seizure free) (Semah et al., 1998). In contrast, others found no 
difference in prognosis between those with symptomatic and cryptogenic partial epilepsy 
(58% vs 56% at least 1 year seizure free). Comparing patients by aetiology, they found that 
mesial TLE had the worst prognosis (42% seizure free) with seizure freedom rates of 54% 
(CD), 55% (cerebral atrophy), 57% (cortical gliosis), 63% (cerebral infarctions) and 78% 
(arterio-venous malformations) (Stephen et al., 2001).
Children with remote symptomatic epilepsy or abnormal neurological development have a 
poorer prognosis and are at high risk of developing intractable epilepsy (Berg et al., 1996; 
Sillanpaa, 1993).
1.5.7 The impact of anti-epileptic drugs on prognosis
In the western world most patients are commenced on anti-epileptic drugs (AEDs) after two
unprovoked seizures implying that prognostic studies from western countries are essentially 
those of treated epilepsy. Evidence from studies from resource-poor countries where a 
significant treatment gap exists, suggests that many people enter spontaneous remission 
with no anti-epileptic medication (Sander, 1993; Placencia et al., 1994; Nicoletti et al., 
2009), and moreover that the response to AEDs in patients with chronic longstanding 
epilepsy is comparable to that of patients with new-onset seizures (Feksi et al., 1991; Watts, 
1992; Placencia et al., 1994). Such evidence implies that the view that epilepsy is a chronic 
progressive condition (Gowers, 1881) is over-pessimistic. It has been suggested that people
with epilepsy can be sub-divided into prognostic groups based on their aetiology and 
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epileptic syndrome, which in turn determines their need and response to anti-epileptic 
treatment (Sander, 1993).
Two studies have assessed the impact of medication on the risk of recurrence after a single 
seizure. In the FIRST study, people with a first unprovoked generalised seizure were 
randomised to either immediate treatment (treated group) or to treatment only after a 
further seizure (untreated group).  While immediate treatment reduced the risk of early 
relapse, it did not affect the long-term prognosis. The two-year remission rate was 72% in 
the treated group and 57% in the untreated group, with rates of 84% vs 79% at three years 
and 85% vs 86% at ten years. The comparable probabilities of attaining five-year remission 
were 47% vs 40%, at three months, 58% vs 58% at two years and 64 vs 64% at five years 
(Leone et al., 2006).
In the MESS study (Marson et al., 2005) people with a single seizure or early epilepsy (all 
types) were randomised to receive immediate or deferred treatment. People in the 
immediate treatment group had increased time from the index seizure to a second seizure or 
a first generalised seizure, in addition to having a reduced time interval to two-year 
remission. At five-year follow-up, however, 76% in the immediate group and 77% in the 
deferred group had achieved three to five years seizure freedom. (Marson et al., 2005)
On the basis of the MESS study data, possible predictors of seizure recurrence were 
identified. The number of seizures (all types), an abnormal EEG and the presence of a 
neurological deficit were all significant risk factors for subsequent seizures with the risk 
increasing when any of these factors occurred in combination (Kim et al., 2006).
In summary, these studies have concluded that immediate treatment delays the early 
recurrence of seizures but does not affect the medium or long term prognosis.
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1.5.8 Prognosis following AED withdrawal
In the largest randomised control trial of continued treatment versus drug withdrawal in 
1,013 patients in remission (two or more years seizure free), at two years post-
randomization 41% of those who had discontinued medication had had a recurrence of 
seizures compared with 22% of those who stayed on medication. The difference in relapse 
rates between the two groups was maximal at nine months with the rate of relapse being 
higher in the discontinuation group in the first two years of follow-up, but by two-four 
years the risk of relapse was higher in those continuing treatment (MRC AED Withdrawal 
Study Group, 1991). Those who experienced a relapse were followed up and by three years 
95% who experienced a relapse had a further one year remission and by five years, 90% 
had had a further two year remission period. This indicates that the long-term prognosis is
similar in those who relapsed and in those who did not have a relapse within two years 
following AED withdrawal. . 
A further analysis of the data from the MRC AED withdrawal study using regression 
modelling has recently been reported (Bonnett et al., 2011). The recurrence risk within the 
first 12 months following AED withdrawal was 30% (95% CI 25, 35) while the risk of 
recurrence within the next 12 months for those remaining seizure-free at three months after 
AED withdrawal was 15% (95% CI 10, 19) and for those still seizure-free at six months 
was nine percent (95% CI 5, 13). For those who had had a seizure recurrence and who then 
restarted AED treatment, after three months of seizure freedom after recommencing 
treatment the risk of seizure recurrence within the next 12 months was 26% (95% CI  17, 
35) while at 6 months seizure freedom after treatment reinstatement, the risk of recurrence 
in the next 12 months was 18% (95% CI 10, 27) (Bonnett et al., 2011).
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An analysis of 14 AED withdrawal studies (Schmidt and Loscher, 2005) found that the 
recurrence rate following AED discontinuation ranged from 12 to 66% (mean 34%; 95% 
CI: 27, 43) and reinstatement of treatment was successful in obtaining further remission in, 
on average, 80% (95% CI: 75, 85) with no significant differences between age groups. A 
second remission may, however, take many years to achieve while in an average of 19% 
(95% CI: 15, 24%) the reintroduction of the medication did not control the seizures as 
before. Up to 23% of those discontinuing treatment go on to develop intractable epilepsy. 
Risk factors for subsequent poor treatment outcome were symptomatic focal epilepsy and 
cognitive deficits (Schmidt and Loscher, 2005). 
Ninety children who discontinued treatment following remission were followed for an 
average of 32 years from seizure onset (Sillanpaa and Schmidt, 2006b). Seizure relapse 
occurred in 37% (33) with 36% of relapses occurring within the first year, 46% within the 
second year and 67% within the third year. The last relapse occurred after 28 years follow-
up. Eight opted to restart treatment with two achieving subsequent five-year terminal 
remission with a delay of 10-19 years after restarting treatment. The other six individuals
did not achieve five-year terminal remission, with two considered to have drug-resistant 
epilepsy. Factors associated with failure to achieve five-year terminal remission following 
reinstatement of treatment were symptomatic and localisation related aetiology (Sillanpaa 
and Schmidt, 2006b).
Despite the risk of seizure recurrence, people with epilepsy may choose to discontinue 
treatment because of the impact of continuing anti-epileptic medication on quality of life. In 
one study (the Akershus study), the effect of AED withdrawal on quality of life was 
assessed. At one-year seizure recurrence had occurred in 15% of the withdrawal group 
compared with 7% in the non-withdrawal group (RR 2.46; 95% CI: 0.85, 7.08). The 
proportion of people having completely normal neuropsychological findings increased from 
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11% to 28% in the withdrawal group - while decreasing from 11% to 9% in the non-
withdrawal group. (Fifteen neuropsychological tests were applied examining immediate 
and delayed verbal and visual memory; attention and psychomotor speed, executive 
functions such as verbal fluency, response inhibition and divided attention; simple reaction 
time with both hands and choice reaction time with lexical and figurative stimuli; motor 
speed and complex coordination with both hands). No differences in quality of life were 
observed between the two groups. At 41 months follow-up, predictors of continued seizure 
freedom following treatment withdrawal were prior use of carbamazepine (approximately 
three-fold increase in likelihood of remaining seizure-free compared with people on any 
other drug (OR 2.86; 95% CI 1.3, 6.3)) and a normal neurological examination (Lossius et 
al., 2008).
1.5.9 Patterns of relapse and remission in epilepsy
Seizures continue in up to a third of people despite treatment. For the majority of these, 
new AEDs offer the only hope of seizure freedom as only a few are candidates for epilepsy 
surgery (Lhatoo et al., 2003). In high-income countries most people are treated after 
presentation of the first or second seizure and so any assessment of the natural history of 
epilepsy is that of treated epilepsy (Goodridge and Shorvon 1983; Sander and Shorvon 
1987; Sillanpaa and Schmidt 2006; Berg et al., 2009; Geerts et al., 2010).  Studies from 
resource-poor countries where access to treatment is often limited allow a limited 
examination of untreated epilepsy or the “natural history of epilepsy”. These studies 
suggest that at least a third of people with epilepsy spontaneously enter remission without 
treatment (Watts 1992; Sander 1993, Placencia et al., 1994; Kwan and Sander 2004; 
Nicoletti et al., 2009).
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It has been suggested that refractory or pharmaco-resistant epilepsy is progressive and 
therefore pre-determined, with early identification of such cases possible (Kwan and Brodie 
2000; Kwan and Brodie 2002). Others have argued that pharmaco-resistance may not
always manifest early in the course of the epilepsy but can sometimes develop later (Berg
et al., 2006; Sillanpaa and Schmidt 2006).  It has also been suggested that in a minority of 
people the course of epilepsy may alternate between periods of relapse and remission 
(Goodridge and Shorvon1983; Shorvon and Sander, 1986;; Berg et al., 2004; Sillanpaa and 
Schmidt 2006), but it has not been clearly established whether, once a particular seizure 
pattern has been established, it will persist. Indeed the relative frequencies of different 
seizure patterns in people with chronic epilepsy have not been clearly established. Early 
recognition of factors that may predispose people to a seizure pattern of recurrent 
remissions and relapses is important; as such people could be counselled against future 
trials of AED withdrawals following a period of prolonged seizure freedom. Identification 
of such factors if possible, is one of the aims of this thesis.
1.5.10 The prognosis for those with intractable epilepsy
It has been suggested that failure to control seizures with the first or second AED implies 
that the probability of subsequent seizure control with further AEDs is slim (Kwan and 
Brodie, 2000). This can inevitably lend to clinical nihilism when dealing with such people
in clinic. A recent series of papers suggests that such a view is overly pessimistic. In a 
retrospective study of the effect of 265 medication changes in 155 people with uncontrolled 
epilepsy of at least five years duration, 16% of all people were rendered seizure free (12 
months or more) following a drug introduction while a further 21% had a reduction of 
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seizure frequency of 50-99%. Overall 28% of the cohort was rendered seizure free by 
medical changes (Luciano and Shorvon, 2007).
It had previously been shown that the likelihood of seizure remission in children with LD
and intractable seizures is less (1.5% per year) than in children of normal intelligence and 
intractable seizures (4% per year) (Huttenlocher and Hapke, 1990).  
A group of 246 people with refractory epilepsy was followed for three years.  Excluding 11 
(4.5%) who became seizure free because of surgery, 26 (11%) became seizure free (six-
months terminal remission) as a result of medication change (addition of a new AED or 
dose change). No single AED was associated with a statistically significant probability of 
inducing seizure freedom. People with LD were statistically less likely to achieve a 
remission (7.2% vs 18.1%). Overall approximately five percent of people became seizure 
free per year, highlighting the fact that irrespective of the number of AED previously tried, 
there is still a possibility of inducing meaningful seizure remission in this population 
(Callaghan et al., 2007).
The probability of seizure relapse following remission was retrospectively studied in a 
cohort of 186 people with intractable epilepsy who were followed for a median of 3.8 
years. Overall 20 people achieved a remission of ≥12 months with four percent becoming 
seizure-free per year. Of these, five subsequently suffered a relapse with the estimated 
cumulative probability of relapse 33% at two years and 44% at three years. No clear 
predictors of remission or subsequent relapse were identified (Choi et al., 2008).
In summary approximately four to five percent of people with refractory epilepsy will 
achieve a remission of twelve months per year following AED change, many of whom will 
subsequently relapse. It is certainly possible that new therapies (over 13 AEDs in the past 
20 years) have improved the prognosis of epilepsy and that therefore the often cited figure 
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that approximately one third of people will have pharmaco-resistant epilepsy may be overly 
pessimistic, not to mention outdated. More medium- to long-term follow-up of people with 
apparent pharmaco-resistant epilepsy are needed to confirm or refute such a hypothesis.
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1.6 Mortality
People who have been diagnosed with epilepsy need to know whether this will have any 
impact on their life expectancy. It is now accepted that people with epilepsy have a two to 
three-fold risk of dying earlier compared with the general population. This increased risk of 
premature death is stratified by aetiology and it has been consistently shown that 
children/adults with neurological deficits and symptomatic (acute and remote) seizures 
have a significantly increased risk of premature death while the risk for those with 
idiopathic or cryptogenic epilepsy appears to be broadly similar to that of the general 
population.
1.6.1 Methodological issues 
Mortality studies in epilepsy should be community-based studies of people with incident 
epilepsy. Studies of people with prevalent epilepsy may under-estimate the short-term 
mortality (as the mortality in people with epilepsy has consistently been shown to be 
highest in the early years following diagnosis) while simultaneously overestimating the 
long-term mortality (as those who have gone into remission may not be included in the 
cohort). The risk of premature death in people with epilepsy has been studied using death 
certificates, hospital or institutional records and through follow-up of community cohorts. 
Death certificates have been shown to be an unreliable source, with epilepsy being recorded 
on the death certificate in only seven percent of people known to have epilepsy (Bell et al., 
2004). This figure increased to 17% in people with frequent seizures. In a community based 
study of mortality in children with epilepsy, epilepsy was recorded on the death certificate 
in 55% of deaths directly attributable to epilepsy (Harvey et al., 1993).
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Other studies have used hospital or institution registries with the inherent risk of selection 
bias of more severe cases and therefore an overestimation of the mortality risk. 
The most commonly reported measure of mortality is the SMR which is defined as the ratio 
of the observed deaths in the cohort divided by the number of expected deaths if the age-
sex specific rates were the same as those of the standard population. This is an external 
comparison in cohort design studies and measures how much more (or less) likely a person 
in the study population is to die during a certain period of time than someone of the same 
age and sex in the standard population. 
The direct comparison of SMRs in different studies is problematic as the SMR is calculated 
by indirect standardisation using the age and gender distribution of the group with epilepsy, 
which may differ among studies. It has been argued that these potential differences may 
invalidate direct comparison of SMRs derived from distinct populations (Logroscino and 
Hesdorffer, 2005). Even taking this in account, some insight may be derived by comparing 
SMRs between studies of similar populations as a crude measure of changes of mortality 
between different time periods particularly as this is the only method of comparison 
available. 
The proportionate mortality rate (PMR) is not a direct measure of mortality but rather gives 
the proportion of deaths due to one specific cause. This is the measure of mortality used in 
case controlled studies and is influenced by both an increase of one cause of death but also 
by decreases of other causes.
Other measures used are the mortality rate (MR) which is the incidence rate of mortality in 
the cohort and the case fatality (CF) which is the proportion of the cohort dying during a 
specific time period (Logroscino and Hesdorffer, 2005).
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1.6.2 Mortality following a newly diagnosed seizure
A review of mortality following a single seizure estimated that the SMR in people with a 
newly diagnosed unprovoked seizure ranged from 2.5 to 4.1 with the highest SMRs in 
young children and in those with symptomatic seizures (Hauser and Beghi, 2008). In the 
Gironde study the SMR at one year following a single seizure was 4.1 (95% CI 2.5, 6.2) 
(Loiseau et al., 1999). Mortality risk was significantly increased in people with acute 
symptomatic seizures (SMR 10.3; 95% CI 8.3, 12.7), remote symptomatic seizures (SMR 
6.4; 95% CI 3.6, 10.3) and progressive symptomatic seizures (SMR 19.8; 95% CI 14.0, 
27.3) but not in people with idiopathic or cryptogenic epilepsy. 
In a Swedish population-based cohort study of adults the SMR was 2.5 (95% CI 1.2, 3.2) in 
people with a newly diagnosed unprovoked seizure and was markedly elevated in the first 
two years after diagnosis (SMR 7.3; 95% CI 4.4, 12.1) with a second peak at 9 to 11 years 
(SMR 5.4; 95% CI 2.7, 11.2) (Lindsten et al., 2000).  The SMR was significantly elevated 
in people with remote symptomatic epilepsy (SMR 3.3; 95% CI 2.4, 4.5) but not in people
with idiopathic epilepsy. The increased risk of mortality was most pronounced in those 
aged less than 60. 
In a prospective study of 407 children with a single unprovoked seizure followed for a 
mean of 14.2 years, it was found that treatment following a single seizure did not alter the 
mortality rate (Shinnar et al., 2005).
In the NGPSE cohort, 15% (83/564) of people with definite seizures were classified as 
having acute symptomatic seizures with an SMR of 3.0 (95% CI 2.0, 4.3) at 11-14 years 
following diagnosis (Lhatoo et al., 2001).  The 30 day CF in the Rochester study after an 
acute symptomatic seizure was 19.2% with an SMR of 149.1 (95% CI 119.9, 184.7) 
(Hesdorffer and D'Amelio, 2005).
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1.6.3 Mortality in cohort studies
The mortality of people with epilepsy has been studied in hospital based cohorts (Mohanraj 
et al., 2006; Nilsson et al., 1997; Shackleton et al., 1999), institutionalised cohorts 
(Klenerman et al., 1993; White et al., 1979) and population-based cohorts (Camfield et al., 
2002; Ding et al., 2006; Hauser et al., 1980; Lhatoo et al., 2001; Lindsten et al., 2000; 
Olafsson et al., 1998). Reported SMRs in mortality studies from developed countries range 
from 1.6 to 4.1 (Forsgren et al., 2005).
Much of the variation in reported SMRs in people with epilepsy is dependent on the source 
population. In general, studies from institutions report the highest SMRs, with the lowest 
coming from general population-based studies. In 21 identified studies, studies from
institutions showed wider variation in mortality rates (SMR 1.9 to 5.1) than population-
based studies (SMR 1.3 to 3.1) (Shackleton et al., 2002). 
1.6.4 Temporal trends in mortality in people with epilepsy
It is generally accepted that people with epilepsy are at increased risk of premature death 
compared with the general population (Cockerell et al., 1994; Hauser et al., 1980; Tomson, 
2000; Gaitatzis et al., 2004), but it has not been clearly established how this risk changes 
over the course of the condition. It is assumed that most early deaths in epilepsy are due to 
the underlying cause of the epilepsy, whereas any later increase in mortality rate is 
primarily due to the epilepsy itself (Forsgren et al., 2005; Hauser et al., 1980), despite the 
fact that the majority of people become seizure free.  If this is the case, one would expect to 
see evidence of decreasing mortality rates attributable to epilepsy in general population
studies over the past 50 years and in particular in the past 20 years when more treatment 
options for epilepsy have become available. One of the aims of this thesis is to examine 
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how the risk of premature mortality changes over the course of epilepsy with particular 
reference to the long-term mortality in people in the NGPSE cohort.
1.6.5 The impact of age and gender on mortality
Most studies have shown that males have a higher premature mortality risk than females 
although no clear explanation for this has been demonstrated.  Age also influences the risk 
with reported SMRs demonstrating an inverse relationship with age. The SMR tends to be 
high in children but this relates principally to the underlying cause of the epilepsy (remote 
symptomatic, peri-natal insults) rather than to the epilepsy itself.
In a Finnish cohort of 245 children with epilepsy identified between 1961 and 1964 and 
followed up prospectively (Sillanpaa et al., 1998), 44 had died by the end of follow-up in 
1992 of whom 75% of had remote symptomatic epilepsy with a similarly high 
representation of remote symptomatic epilepsy in childhood mortality studies from 
Australia (Harvey et al 1993) and Nova Scotia. (Camfield et al., 2002). Of those who died, 
89% were not in remission at the time of death, with a relative risk of death in those with 
active epilepsy compared with those in remission of 9.26 (95% CI 3.8, 22.7). The cause of 
death was definitely or proabably related to a seizure in 45% (20) of cases. There were 
three cases of sudden unexplained death in epilepsy (SUDEP) in people with idiopathic 
epilepsy, none of whom was in remission at the time of death (Sillanpaa et al., 1998). In the 
extended follow-up of the cohort up to 2002, 60 (24%) had died, of whom 51 (85%) were 
not in terminal remission (≥ five years seizure free) at the time of death. Those with a 
remote symptomatic aetiology were three times as likely to die as those with 
idiopathic/cryptogenic aetiologies (37% vs 12%, P<0.001). Of the 60 deaths, 33 (55%) 
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were felt to be epilepsy-related including 18 deaths from SUDEP, giving a cumulative risk 
of SUDEP of seven percent at 40 years (12% for those not in terminal remission (Sillanpaa 
and Shinnar, 2010).  
Decreasing SMRs are found with increasing age groups. The lowest SMRs are reported in 
the 75+ age group; this relates in part to the fact that this age group has a high mortality rate 
(Hauser et al., 1993).
Epilepsy is a very important non-obstetric cause of mortality in pregnant women with 
epilepsy although the number certainly represents only a small proportion of deaths in 
women with epilepsy. Epilepsy-related mortality in pregnancy was recently highlighted at 
the 29th International Epilepsy Congress in Rome in September 2011 as an area in which 
further research is needed.
1.6.6 Causes of mortality
Causes of death in people with epilepsy can be divided into epilepsy related and non-
epilepsy related deaths. For people with symptomatic epilepsy (both remote and 
progressive) the excess mortality risk relates primarily to the underlying cause of the 
epilepsy rather than to the epilepsy itself. In a study of 692 children with epilepsy followed 
up over an average of 13 years, the SMR was 5.3 with functional neurological deficit being 
the only independent predictor of mortality (occurring in 85% of cases) (Camfield et al., 
2002). In a Dutch study of mortality in people with epilepsy followed up over 40 years the 
SMR was 16 in the first two years decreasing to 2.8 thereafter (Shackleton et al., 1999).
After two years, approximately one third of deaths were directly or indirectly attributable to 
epilepsy. 
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The importance of the underlying cause as a contributor to the mortality rate in people with 
epilepsy, particularly in the early years following diagnosis, is demonstrated in the Gironde 
study where the causes of death after one year were the underlying pathology in 64%, an 
unrelated cause in 20%, unknown in 9% and seizure-related in 6%. There were no reported 
deaths in people with idiopathic generalised epilepsy. (Loiseau et al., 1999)  
Common non-epileptic causes of mortality cited in mortality studies include pneumonia, 
cerebrovascular disease, malignancy and heart disease. SMRs and PMRs are consistently 
elevated for these causes in the population-based studies and often markedly so in the first 
few years of follow-up. In a Swedish study looking at cause specific mortality in over 9,000 
adults with epilepsy, the overall SMR was 3.6 (95% CI 3.5, 3.7) with SMRs being 
increased for specific causes such as cancer (SMR 2.6; 95% CI 2.4, 2.8), respiratory disease 
(SMR 4.0; 95% CI 3.6, 4.5), heart and cerebrovascular disease (SMR 3.1; 95% CI 3.0, 3.3) 
and accidents and poisoning (SMR 5.6; 95% CI 5.0, 6.3) (Nilsson et al 1997). The risk of 
premature death with heart disease was found to be elevated in those aged 25 to 64 but not 
for those aged 65 years and over in the Rochester cohort (Annegers et al., 1984). 
Bronchopneumonia is an important cause of mortality in people with epilepsy of all ages, 
not just the elderly and was associated with the highest SMR (7.2) in the NGPSE (Lhatoo et 
al., 2001).  This may be related to aspiration during seizures but this is unproven.
The influence of LD and epilepsy was investigated in a Swedish study. The SMR was 1.6 
(95% CI 1.3, 2.0) in people with LD only but this increased to 5.0 (95% CI 3.3, 7.5) for 
those with LD and epilepsy, with the increase in mortality associated with seizure type and 
frequency. (Forsgren et al., 1996c)
63
63
In studies from institutions and hospitals where people have presumably more severe 
epilepsy, epilepsy-related deaths are more common. In one study, PMRs were cancer 
(26%), bronchopneumonia (25%), circulatory diseases (24%), seizure-related deaths (other 
than SUDEP) (12%) and SUDEP (6%) (Klenerman et al., 1993).
SMRs and PMRs for cancer have been consistently elevated in people with epilepsy even 
after excluding CNS neoplasms. Cancer mortality was compared between two cohorts with 
epilepsy, one from an institution with more severe epilepsy and the other a community 
based population with milder epilepsy. The SMRs for all cancers was elevated in the cohort 
with severe epilepsy (SMR 1.42; 95% CI 1.18, 1.69) but not in the milder group (SMR 
0.93; 95% CI 0.84, 1.03). The SMR for brain and CNS neoplasms was significantly 
elevated in the group with milder epilepsy (Singh et al., 2009).
1.6.7 Epilepsy-related deaths
Deaths directly related to epilepsy include SUDEP, status epilepticus, accidents as a 
consequence of a seizure (including drowning and aspiration pneumonia), iatrogenic (drug 
toxicity and idiosyncratic) and suicide.
1.6.7.1 SUDEP
SUDEP is defined as a sudden, unexpected death in an individual with or without evidence 
of a seizure where post-mortem does not reveal a specific cause of death (Lhatoo and 
Sander, 2005). Estimates of SUDEP rates are heavily influenced by the population under 
study with much higher rates in those with severe or refractory epilepsy. Identified risk 
factors for SUDEP include younger age of onset, long duration of epilepsy and refractory 
epilepsy (Tomson et al., 2005). In a prospective cohort study, the incidence of SUDEP was 
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1.21/1000 patient years and accounted for 18% of all deaths. Independent risk factors 
identified for SUDEP were the occurrence of tonic-clonic seizures, LD (IQ < 70) and 
treatment with greater than two AEDs, after adjustment for seizure frequency (Walczak et 
al., 2001; Langan et al., 2005).  The incidence of SUDEP was 0.35 per 1000 person years in 
the Rochester cohort (Ficker et al., 1998) while an incidence of 1:295/year was found in 
children with more severe epilepsy and LD (Nashef et al., 1995). 
1.6.7.2 Accidents
People with epilepsy may die as a result of an accident during a seizure. Based on 
attendance records of four Accident & Emergency (A&E) Departments, the risk of injury as 
a result of a seizure was estimated to be 29.5 per 100,000 population per year (Kirby and 
Sadler, 1995). Many seizure-related injuries tend to be minor with an increased risk related 
to background seizure frequency (Lawn et al., 2004), but some injuries can be fatal. In a 
one year population-based study (using inpatient records, doctors’ claims and A&E visits) 
the annual incidence of injuries was higher in people with epilepsy after adjusting for age, 
gender and co-morbidities, with 20.6% of people with epilepsy having at least one injury 
compared with 16.1% among people without epilepsy (p<0.001). In particular people with 
epilepsy were more likely to have fractures, crushing injuries, intracranial and other head 
injuries (Kwon et al., 2010). 
Similarly over a two-year period, people with epilepsy were more likely to have injuries 
inflicted on them by others (OR 1.46; 95% CI 1.04, 2.03) after adjustment for co-
morbidities but were not more likely to have motor vehicle accidents or completed or 
attempted suicide (Kwon et al., 2011).
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1.6.7.3 Drowning
People with epilepsy have an increased risk of drowning (15 to 19 fold) compared with the 
general population. In a meta-analysis of the risk of drowning, the total SMR was 18.7. The 
SMR varied depending on the population under study, with an SMR of 5.4 in community-
based incident cohorts, 18 in people with prevalent epilepsy, 25.7 in people with epilepsy 
and learning disability and 96.9 for people in institutional care (Bell et al., 2008).
1.6.7.4      Suicide
People with epilepsy have been shown to be at increased risk of suicide in some studies 
(Nilsson et al., 1997; Zielinski, 1974b) but not in others (Hauser et al., 1980; Lhatoo et al., 
2001). In a meta-analysis, the SMRs for people with epilepsy and suicide were markedly 
elevated, particularly for those with temporal lobe epilepsy (Harris and Barraclough, 1997). 
In a population-based controlled study from Denmark, 2.3% of people with epilepsy, 
committed suicide compared with 0.74% in the general population corresponding to a 3-
fold increased risk (Rate Ratio 3.17; 95% CI 2.88, 3.50). This risk was particularly high in 
people with co-morbid psychiatric illness and in the first six months following diagnosis 
(Christensen et al., 2007a). A recent meta-analysis found that the overall SMR for suicide 
in people with epilepsy was 3.3 (95% CI 2.8, 3.7), with the highest rates being in those post 
temporal lobe excision (SMR 13.9), following other forms of epilepsy surgery (SMR 6.4) 
and in people with temporal lobe epilepsy (SMR 6.4) (Bell et al., 2009a).
1.6.8 Mortality and surgery
A cohort of 299 people was retrospectively followed after temporal lobe surgery to 
establish early and late mortality (Hennessy et al., 1999). Overall 20 people died, providing 
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a mortality rate of 1 per 136 person-years and an SMR of 4.5 (95% CI 3.2, 6.6). Three 
deaths were the result of surgical complications; if these are excluded the mortality rate is 1 
per 161 persons-years and the SMR 3.7 (95% CI 2.5, 5.3). The mortality associated with 
right-sided MTS was markedly elevated compared with left sided MTS (SMR 32.0 vs 3.3). 
This suggests that the mortality rate associated with epilepsy surgery is in the order of one 
percent and that epilepsy surgery reduces but does not eliminate the excess mortality 
associated with epilepsy. 
In a prospective study of people with refractory partial epilepsy evaluated for epilepsy 
surgery at a single centre during a 19 year period, non-surgical patients were twice as likely 
to die during the follow–up period (HR 2.5; 95% CI 1.5, 4.4) and more likely to die from a 
probable epilepsy-related cause (SUDEP, drowning, status epilepticus; n=24) than the 
surgery group (n=7) (HR 4.6; 95% CI 1.9, 11.0) (Bell et al., 2010). This supports the view 
that surgery reduces the risk of premature death in people with refractory partial epilepsy, 
although it may be that some people who are intrinsically unsuitable for epilepsy surgery 
may be at the same time at higher risk of epilepsy-related death. 
1.6.9 Anti-epileptic drugs and mortality
It has been suggested that anti-epileptic treatment with more than two AEDs increases the 
risk of premature death and in particular of SUDEP (Walczak et al., 2001), though other 
studies have not shown an increased risk of SUDEP with any AED in monotherapy or in 
combination (Opeskin and Berkovic, 2003).There has been much debate on the association 
between AEDs and the risk of suicide since the U.S. Food and Drug Administration (FDA) 
issued an alert in 2008 as the result of a meta-analysis which found that there was a 1.8-fold 
increased risk of suicidality associated with all AEDs (Hesdorffer and Kanner, 2009). It 
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does however seem that the risk of suicide in people taking AEDs for epilepsy without co-
morbid depression, although slightly increased, appears to be very low (Bell et al., 2009b; 
Andersohn et al., 2010). It has been reported that long-term use of AEDs is associated with 
an increased risk of fractures particularly in women, with the risk increasing with the 
duration of treatment (Souverein et al., 2006).
Non-adherence to AEDs has been shown to be associated with an over threefold increased 
risk of death (hazard ratio 3.32; 95% CI 3.11, 3.54) after controlling for possible 
confounding factors. Non-adherence was also associated with 86% increased of hospital 
admission and a 50% increased risk of Emergency Department attendance (Faught et al., 
2008).
1.6.10 Conclusions
It is clear that a diagnosis of epilepsy is associated with an increased risk of premature 
death, particularly in the early years following diagnosis. Up to one third of such deaths can 
be directly or indirectly attributable to epilepsy. This risk is decreased but possibly not 
eliminated by rendering the person completely seizure free by treatment or surgery.
Overall people with epilepsy have been found to have a reduction in life expectancy which 
is highest at the time of diagnosis and reduces with time. This reduction can be up to two 
years in people with idiopathic/cryptogenic epilepsy and up to ten years in people with 
symptomatic epilepsy (Gaitatzis et al., 2004).
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1.7 Febrile Seizures
The ILAE defines a febrile seizure as “a seizure occurring in childhood after age one month 
associated with a febrile illness not caused by an infection of the CNS, without previous 
neonatal seizures or a previous unprovoked seizure and not meeting criteria for other acute 
symptomatic seizures” (Commission on Epidemiology and Prognosis ILAE, 1993). This 
definition is notable for the fact that there is no specified upper age limit, while also 
differing in the specified lower age limit from the definition of the American Academy of 
Paediatrics which broadly defines a febrile seizure as “a seizure accompanied by fever 
without central nervous system infection, occurring in infants and children between six
months and five years of age” (Provisional Committee on Quality Improvements, 1996). 
The definition of febrile seizures adopted throughout this thesis is that of the ILAE.
Most studies from Western countries show that febrile seizures occur in two to four percent 
of children with higher rates reported in studies from Japan and Guam (Hauser, 1994). In 
the Oakland study, the first large population study of febrile seizures in 18,500 children, 
two percent had a febrile seizure by the age of five (Van der Berg and Yerushalmy, 1969).
A slightly higher rate of febrile seizures was reported in the National Collaborative 
Perinatal Project (NCPP), where 3.5% (4.2% of African-American) of 1,706 children 
experienced at least one febrile seizure between the ages of one month and seven years 
(Nelson and Ellenberg, 1978). Similar figures have been reported in children from 
Rochester (2.3% by the age of five) (Annegers et al., 1979b), the UK (2.7%) (Verity and 
Golding, 1991) and Holland (2.7% by the age of six) (Verburgh et al., 1992).  In contrast a 
prevalence rate of 8.3% for three year old children has been reported from Japan (Tsuboi, 
1984), which while not immediately explainable, may reflect different cultural (communal) 
sleeping practices.
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A recent prospective population-based study of the incidence of febrile seizures in Finland 
found that 6.9% of children had at least one febrile seizure by the age of five with the 
authors arguing that the prospective nature of the study may give a more accurate (and 
higher) rate of febrile seizures in the population than the lower reported rates in
retrospective studies in other populations (Sillanpaa et al., 2008).
In the NCCP (and subsequent studies), febrile seizures were subdivided into simple (SFS), 
and complex types (CFS) (with febrile status epilepticus being a subtype of CFS). A SFS is 
a generalised seizure without focal features, lasting less than 15 minutes, with no 
recurrence within 24 hours and resolves spontaneously. CFSs are either longer (greater than 
15 minutes), have focal features or recur within 24 hours of the first episodes. SFS 
represent the majority of febrile seizures in the reported data (70-80%) (Annegers et al., 
1987;Berg et al., 1997; Nelson and Ellenberg, 1978; Verity and Golding, 1991).
Approximately one third of children with a febrile seizure have a recurrence and about nine 
percent have three or more seizures (Annegers et al., 1987;Berg et al., 1992; Nelson and 
Ellenberg, 1978). Factors such as young age of onset, a history of febrile seizures in a first 
degree relative, a low recorded temperature in the A&E department and a short time 
interval between the onset of the fever and the seizure are all predictors of a higher risk of 
febrile seizure recurrence (Berg et al., 1997).
1.7.1 Mortality and febrile seizures
It is generally accepted that the mortality associated with febrile seizures is very low, with 
no reported deaths in the 1,706 children with febrile seizures in the NCCP study (Nelson 
and Ellenberg, 1978) and four deaths in the Oakland study in the 246 children with febrile 
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seizures, two of whom died as a result of the infection causing the febrile convulsion and 
the other two from unrelated causes (Van der Berg and Yerushalmy, 1969). In the NGPSE 
there were no reported deaths in the cohort of 220 children with febrile seizures followed 
up for a median of 11.2 years (MacDonald et al., 1999). Similarly none of the 398 children 
in the UK National Cohort Study who developed febrile seizures died (Verity and Golding, 
1991). Overall there appears to be no associated risk of mortality with SFSs or short CFSs. 
In a recent review on the morbidity and mortality associated with febrile seizures the 
authors identified four studies where death as an outcome of febrile seizures was reported, 
ranging from 3.5% to 12.8%. Moreover in 28 studies with 2,471 children with febrile 
seizures (SFS and CFSs) there were 21 deaths giving an overall mortality rate of 0.85%. In 
a sub-analysis of 876 children with febrile status epilepticus (FSE) in 14 studies, there were 
18 deaths giving a mortality rate from FSE of 1.6 %.(Chungath and Shorvon, 2008).  
In a population-based cohort study of 1,675,643 children born in Denmark between 1st
January 1977 and 31st December 2004, there were 232 deaths in 55,215 children with a 
history of febrile seizures. While the long-term mortality was not increased in children with 
febrile seizures, children with CFSs (but not SFSs) had a 80% increased risk of mortality in 
the first year (mortality rate ratio (MMR) 1.80 (95% CI 1.31, 2.4) and a 90% increased in 
the second year following a first febrile seizure (MMR 1.89 (95% CI 1.27, 2.7)) with the 
rate returning to that of the background population thereafter (Vestergaard et al., 2008).
1.7.2 Risk of subsequent epilepsy
There is much debate about the risk of the development of subsequent epilepsy in children 
with febrile seizures, particularly in light of the supposed risk of hippocampal sclerosis and 
temporal lobe epilepsy following a febrile seizure. In the NCCP one percent of children 
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with SFSs had developed epilepsy by the age of seven. In contrast, two percent of children 
with CFS, a family history of epilepsy or a pre-existing neurological deficit developed 
epilepsy, increasing to 10% if two or more risk factors were present (Nelson and Ellenberg, 
1978). In the Oakland study, about three percent of children with febrile seizures 
subsequently developed afebrile seizures (Van der Berg and Yerushalmy, 1969). In the UK 
National Cohort Study, nine of the 398 (2.26%) children with febrile seizures developed 
epilepsy, six of whom had CFSs (6.3% of those with CFSs) compared with only three
children with SFSs (1% of total) (Verity and Golding, 1991).
In the NGPSE, 12 of 208 (6%) had developed epilepsy after a median follow-up of 11.2 
years, with cumulative percentages of 1.4% (95% CI 0, 2.9) by two years, 3.3% (95% CI 
0.9. 5.7) by five years and 5.2% (95% CI 2.2, 8.3) by ten years. Having four or more febrile 
seizures was associated with a significantly increased risk of the development of 
subsequent epilepsy (OR 9.4 (95% CI 1.5, 5.7), p< 0.015) compared with the general 
population (MacDonald et al., 1999). In this thesis, we will examine the long-term risk of 
developing epilepsy in people with febrile seizures in the NGPSE cohort after 25 years 
follow-up.
In a prospective population-based cohort study of 1.54 million children born in Denmark 
between 1978 and 2002, 49,857 children were diagnosed with febrile seizures and 16,481 
people were diagnosed with epilepsy, of whom 2,149 (13%) had a history of febrile 
seizures. After 23 years follow-up, the cumulative incidence of epilepsy was 6.9% (95% CI 
6.5, 7.3) in those with a history of febrile seizures compared with 1.8% (95% CI 1.8, 1.9) in 
those without a history of febrile seizures. Overall children with febrile seizures had a six 
fold increased risk of developing epilepsy (rate ratio 5.98, 95% CI 5.71, 6.26) (Vestergaard 
et al., 2007).
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In a recent review on the morbidity and mortality of febrile seizures (Chungath and 
Shorvon, 2008) 16 studies were identified which looked at the risk of afebrile seizures 
following a febrile seizure with incidence ranging from 0.25% to 33%. Of the 4,160 
children with febrile seizures, 241 developed afebrile seizures giving a summated rate of 
5.8%. Twenty three studies were identified describing the risk of epilepsy after febrile 
seizures with the incidence ranging from 0.1 to 32% in hospital-based studies to a rate of 
two to seven percent in population-based studies. In total, 544 (2.5%) out of 21,901 
children with febrile seizures, developed epilepsy during the follow-up period. Not 
surprisingly the reported rate of subsequent epilepsy was higher the longer the period of 
follow-up, with studies with more than ten years follow-up reporting higher rates of 
epilepsy (4.5 to 7.5%) than the risk of 2 to 4% in studies of less than ten years follow-up
(Chungath and Shorvon, 2008).
Six studies were identified which examined the risk of developing epilepsy in people with a 
history of CFSs or FSE. Overall 73 out of 427 people (17.1%) developed epilepsy with 
reported incidences ranging from 2.1% to 32.1% (Chungath and Shorvon, 2008).
1.7.3 Conclusions
The risk of developing subsequent epilepsy is increased in children compared with the 
general population, particularly in the first few months following the febrile seizure. 
Overall the risk of epilepsy is approximately 1-2% for those with SFSs, 4 to 8% in those 
with CFSs and probably greater than ten percent in those with SFE.
In contrast, the associated mortality of febrile seizures is very low. Indeed there is no 
evidence of an increased mortality risk following a SFS or short CFS. The mortality rate in 
children with a prolonged CFS or SFE is probably less than 1.6% although the risk of 
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premature deaths appears to be slightly elevated in the first two years following the 
episode.  
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1.8 Status epilepticus
1.8.1 Introduction
Status epilepticus (SE) has been famously described as the “maximum development of 
epilepsy” (Clark and Prout, 1903/4) and is one of the most feared manifestations of 
epilepsy. 
The generally held contention that the underlying aetiology is the major determinant of 
outcome in SE is supported by a small study in which the effect of treatment on prognosis 
in 47 people with SE was examined. They found that the outcome was independent of the 
anaesthetic agent used or the extent of the EEG burst suppression achieved (Rossetti et al., 
2005). Similarly in a retrospective study from Serbia of 750 people with SE of whom 120 
(13%) died, the death was judged to be due to the underlying (or co-morbid) cause in 
65.8% and to a combination of the underlying disease and other aetiologies in a further 
22.5% (Sokic et al., 2009). 
Despite these studies, the role of aetiology and other factors such as seizure duration, level 
of consciousness, age and EEG on the prognosis of status epilepticus in terms of mortality 
and morbidity has not been examined in a systematic review. It is a contention of this thesis 
that only pooling the data from all the major studies of status epilepticus (both population-
and hospital-based) will allow an accurate appraisal of the relative contributions of the 
underlying cause and other factors independent of aetiology to outcomes measures in status 
epilepticus to be obtained.
75
75
1.8.2 Definition 
Any consideration of the prognosis of status epilepticus requires an examination of the 
definition. The current definition of status epilepticus derives from the proposals made at 
the first major meeting devoted to the subject of SE, the Xth Marseilles Colloquium, held in 
1962 and led by Henri Gastaut (Gastaut et al., 1967). At the meeting, a new and influential 
definition of SE was proposed - a condition characterised by an epileptic seizure, which is 
so frequently repeated or so prolonged as to create a fixed and lasting epileptic condition.  
A classification of status epilepticus was subsequently adopted which paralleled the newly 
formed International Classification of Seizure Type. The ILAE in its revision of the seizure 
type classification in 1981, revised the definition (in an addendum): The term status 
epilepticus” is used whenever a seizure persists for a sufficient length of time or is repeated 
frequently enough that recovery between attacks does not occur. These definitions of SE, 
excellent as they are, beg the question “how long should a seizure last before it is 
categorised as SE?”, and this lack of definition of a minimum time period has proved 
problematic from the point of view of clinical research (Shorvon, 1994) and epidemiology, 
and is the subject of continued debate. The definition of the minimum period of seizure 
activity before an episode is deemed to be considered status epilepticus clearly impacts on 
the overall prognosis. Gastaut himself suggested that 60 minutes duration was a reasonable 
minimum period to consider a seizure ‘enduring’ and this became the ILAE standard at the 
time. The suggested minimum time shortened to 30 minutes (Shorvon, 1994), then 20 
minutes (Bleck, 1991), to ten minutes (Treiman et al., 1998) and then to five minutes 
(Lowenstein, 1999). The five minute definition was based on the assumption that 
convulsive seizures lasting longer than five minutes were seldom self-terminating. Indeed 
based on their observations of 120 generalised tonic-clonic seizures (GTCSs) in 47 people,
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one group advocated the use of intravenous AEDs if a GTCS persisted longer than two
minutes (Theodore et al., 1994). Such a proposition does not seem to be in accord with 
common clinical experience, where many seizures lasting longer than five minutes are self-
terminating without therapy. Indeed this impression is supported by a study in which the 
time period used in the definition of SE was 30 minutes or more (for continuous seizures or 
intermittent seizures during which the person did not regain consciousness in between) was 
compared with prolonged seizure episodes lasting 10 to 29 minutes (DeLorenzo et al., 
1999). Almost all (93%) those with SE required anticonvulsant treatment to control and 
stop the seizures compared with 57% of the prolonged seizure group. Moreover the 
mortality for people with SE was 19% compared with 2.6% for the prolonged seizure group 
(p<0.001) and 0% for those whose seizures stopped spontaneously. The definitions with 
30-60 minute minimum durations are based on physiological criteria and the definitions 
with 5-10 minute minimum durations have been devised for an essentially operational 
reason – the highly important goal of encouraging the early application of therapy.
The issue of the minimum duration of status epilepticus was discussed at the London 
Colloquium of Status Epilepticus (April 2007) (Shorvon et al., 2007) where most, but not 
all, participants still favoured the 30 minute period. 
Another term frequently encountered in the literature is ‘refractory SE’. There is no 
universally agreed definition, and different studies have used different definitions. Three 
factors are commonly used to define ‘refractoriness’ in convulsive SE – the duration of the 
status, the number of ineffective therapies and the need for anaesthesia. All are arbitrary. 
Some authorities have defined SE to be refractory if it is resistant to sub-anaesthetic drug 
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therapy. The lack of agreement reflects the inherently unsatisfactory nature of the term, 
which is probably best avoided (Neligan and Shorvon, 2008).
1.8.3 The epidemiology of status epilepticus
To date there have been seven population-based studies of status epilepticus published from 
Richmond, Virginia (DeLorenzo et al., 1996), Rochester, Minnesota (Hesdorffer et al., 
1998a), Switzerland (Coeytaux et al., 2000; Jallon et al., 1999a), Hessen, Germany (Knake 
et al., 2001), California (Wu et al., 2002), Bologna, Italy (Vignatelli et al., 2003) and 
London (Chin et al., 2006). All but the Rochester study were prospective and conformed to 
the ILAE recommendations for epidemiological studies in epilepsy (1993) (ILAE 
Commission on Epidemiology and Prognosis, 1993). These studies give a minimum 
incidence of SE of 10-20/100,000. Under-ascertainment of cases is a major problem for all 
epidemiological studies of epilepsy and SE. The Richmond study gave a much higher 
estimated incidence of SE 0f 41-61/100,000. Evidence that the incidence of GCSE 
requiring hospitalisation may be decreasing is provided by the Californian study (Wu et al., 
2002). This study was carried out using a state-wide hospital database to identify all 
hospitalisations for generalised convulsive status epilepticus in California between 1991 
and 1998. Overall the incidence rate for GCSE was 6.2/100,000 population but this figure 
fell by 42% between the years 1991 and 1998 from 8.5 to 4.9/100,000. The incidence of SE 
was slightly higher in males in all studies except the study from Italy (Vignatelli et al., 
2003), which showed a slight female preponderance.
Race and ethnicity have been recognised as important factors; the Richmond study found 
that the incidence of SE was three times higher in the African-American population than in
the Caucasian population (DeLorenzo et al., 1996), a finding that was replicated in the 
78
78
Californian study (Wu et al., 2002). Age is a dominant factor, with SE incidence forming a 
U-shaped graph with peaks in the very young and the elderly.  
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Richmond 
Virginia USA  
Rochester, 
Minnesota, USA 
French speaking 
Switzerland 
Hessen, Germany Bologna, Italy California 
USA
London
UK 
Year 1989-1991 1965-1984 1997-1998 1997-1999 1999-2000 1991-1998 2002-4
Population 202,774 1,090,055 1,735,420 743,285 336,876 N/A 605230
Number of cases 166 199 172 150 44 19,491 226 total
176 first-ever 
episode of SE
Incidence of SE 
(per 100,000 per 
year)
41 (raw)
61 (adjusted)
18.3 (adjusted) 9.9 (raw)
10.3 (adjusted)
15.0 13.1 6.2 (4.9-8.5) 17-23 (adjusted)
12.5-14 (adjusted; 
first-ever episode)
Female: male 
ratio 
1:1.21 1:1.92 1:1.72 1:1.93 1:0.742 1:1.1 1:1.12
History of prior 
epilepsy
42% 46% 42.4% 33% 39% N/A 7%4
Case fatality 22% (3%)5 19% 7.6% 9.3% 39% 10.7% 3%
Inclusions/Exclu People aged < one  - Excluding people Only people aged Only people aged Only people with Only convulsive 
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sions month old 
excluded
with post anoxic 
encephalopathy 
> 18 years 
included
> 20 years 
included 
generalised 
convulsive SE 
included 
SE; only children 
<15yrs included 
Case 
ascertainment
Prospective
hospital record 
review
Retrospective 
review using 
record linkage 
system
Prospective
hospital record 
review
Prospective
hospital record 
review
Prospective.
Active 
surveillance of 
hospital 
admissions 
Prospective 
hospital discharge 
record review
Prospective active 
surveillance 
through A&E and 
hospital 
admissions
Table 7: Population-based studies of status epilepticus
(Data derived from:  DeLorenzo RJ et al 1996; Hesdorffer et al 1998; Coeytaux et al 2000; Knake et al 2001; Wu et al 2002; Vignatelli et al 2003; Chin et al 
2006)
FOOTNOTES 
1 = Raw data
2 = Adjusted ratio
3 = Adjusted figures, from the regions with the best case ascertainment (and least likely to selection bias 
4 = Excluding febrile seizures
5= 22% overall mortality, 3% mortality in children with SE
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Chapter 2: Aims
2.1 The aims of the Systematic Review of the Temporal Trends in 
Mortality in People with Epilepsy (Study 1) are:
1. To determine the pattern of change of mortality risk, relative to the general 
population, in people with epilepsy (as measured by Standardised Mortality Ratios 
(SMRs)) in the course of their epilepsy by means of longitudinal prospective cohort 
studies.
2. To determine whether there have been any changes in reported mortality rates for 
epilepsy over time
The analyses was subdivided according to source populations (population-based, hospital-
based and studies from institutions.
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2.2 The aims of this extension to the National General Practice Study of 
Epilepsy and Epileptic Seizures (NGPSE), a prospective 
community-based cohort study (Study 2) are:
1. To determine the long-term mortality rates for people with epilepsy and febrile 
seizures in this cohort, with particular reference to previously reported rates and 
epilepsy classification at initial assessment
2. To determine the long-term risk (22+ years) of the development of non-febrile 
seizures/epilepsy in people in the cohort with a history of childhood febrile seizures
3. To determine the long-term (22+ years) remission and terminal remission rates for 
people with epilepsy in the cohort
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2.3 The aims of the Seizure Patterns in Chronic Epilepsy Study (Study 
3) are:
1. To determine the pattern of remission and relapse of epilepsy in a cohort of people 
with refractory epilepsy, attending a tertiary referral centre
2. To determine whether any clinical or demographic features are predictive of seizure 
patterns
3. To use the data from this and other studies to develop a remission and relapse model 
of prognosis of epilepsy 
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2.4 The aims of the Impact of Medication Change in people with 
Chronic Epilepsy Study are:
1. To determine the seizure outcome at six to seven years follow-up in a cohort of 
people with drug-resistant epilepsy with AED treatment changes and to compare 
them with baseline seizure frequency (as measured by the average seizure frequency 
in the three months prior to AED initiation).
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2.5 The aims of the Systematic Review of the Prognosis of Status 
Epilepticus are: 
1. To determine the impact of aetiology on the prognosis of status epilepticus with 
particular reference to morbidity and mortality
2. To determine the impact of other factors (age, duration of SE, level of 
consciousness and EEG findings) on the prognosis of status epilepticus with 
particular reference to morbidity and mortality
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Chapter 3: The Systematic Review of the Temporal Trends 
in Mortality in people with epilepsy (Study 1)
3.1 Methods: Research strategy 
A search of PubMed and Medline for suitable articles was carried out.  Initially the terms 
“epilepsy” AND (“mortality” OR “premature death” OR “death” OR “fatality”), excluding 
animal studies, were searched and all papers written in English and French were reviewed. 
This identified 2505 articles and this was reduced by excluding papers whose primary focus 
was status epilepticus or sudden unexpected death in epilepsy (SUDEP). Titles and 
abstracts of all relevant articles were reviewed and the bibliographies of key papers were 
perused to identify other relevant studies. A further search of the literature was performed 
using the search terms “epilepsy” AND “mortality” AND “trends”.
87
87
3.2 Changes in SMR in people with epilepsy over the course of the 
condition
3.2.1 Population-based cohort studies
Eight population-based studies of mortality amongst people with epilepsy have been reported 
(Table 7). Three of these studies (Ding et al., 2006; Loiseau et al., 1999; Zielinski, 1974) have 
only short follow-up periods, so no conclusions about changes in mortality rates with duration 
of epilepsy can be drawn from these.  The oldest study, a prevalent cohort from Poland,
(Zielinski, 1974) had a follow-up of three years, the Gironde study looked at the SMR in 
people with epilepsy one year after diagnosis (Loiseau et al., 1999), and in the other, a 
prospective study of a predominantly prevalent cohort in rural China, the median follow-up 
was 25 months (Ding et al., 2006).
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Reference Country SMR Length of Follow-up Ages Comments
Zielinski (1974) Poland 1.8 3 years All Retrospective prevalent cohort
Hauser et al (1980) US 2.3 (1.9, 2.6) Mean 13 years (0 - 29 
years)
All Historic incident cohort (Rochester)
Cockerell et al1
(1994)
UK 3.0 (2.5, 3.7)*
2.5 (2.1, 
2.9)**
Median 6.9 years All Prospective incident cohort (NGPSE)
1984-1992
Olafsson et al (1998) Iceland 1.6 (1.2, 2.2) Mean 28 years All Historic incident cohort
Loiseau et al (1999) France 4.1 (2.5, 6.2) 1 year All Prospective, incident cohort
Lindsten et al. (2000) Sweden 2.5 (1.2, 3.2) Mean 7.9 years 17 years Prospective incident cohort (first 
seizure)
Lhatoo et al1. (2001) UK 2.6 (2.1, 3.0)*
2.1 (1.8, 
2.4)**
Median 11.8 years All NGPSE cohort 1984-1997
Camfield et al (2002) Canada 5.3 (2.3, 8.3) Median 13.9 years for 
survivors
< 17 years Historic incident cohort
Ding et al (2006) China 3.9 (3.8, 3.9) Median 25 months >2 years Prospective incident and prevalent 
cohort
Table 8: Population studies of mortality in people with epilepsy with Standardised Mortality Ratios (with 95% confidence intervals)
* Definite epilepsy, ** definite and possible epilepsy. 
1 Two papers reported mortality rates for the NGPSE cohort, after a median follow-up of 6.9 and 11.8 years respectively. 
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A Swedish study identified 107 people, newly diagnosed with unprovoked epileptic seizures 
between 1985 and 1987, and followed them until death or until 1996 (Lindsten et al., 2000).  
The overall SMR was significantly increased (2.5; 95% CI 1.2, 3.2).  In the first year the SMR 
was 7.3 (95% CI 4.4, 12.1) and in the second year it was 3.6 (95% CI 1.6, 8.1), following 
which the SMR decreased to a plateau level of between 1 and 2 for years 4-9 of follow-up 
(apart from year 4 at which the SMR rose slightly above 2 and year 6 at which it dropped 
below 1). In years 9 to 11, however, the SMR was 5.4 (95% CI 2.7, 11.2). 
In the NGPSE the incident cohort of 792 people with definite or possible epilepsy, 
identified between 1984 and 1987, was followed for 14 years. The initial mortality data was 
reported at a median follow-up of 6.9 years, when the SMR for people with definite 
epilepsy was 3.0 (95% CI 2.5, 3.7) and for those with definite or possible epilepsy was 2.5 
(95% CI 2.1, 2.9).  The SMR for those with definite or possible epilepsy combined was 
maximum at one year since diagnosis at 5.1 (95% CI 3.8, 6.5), decreasing to 2.5 (95% CI 
1.5, 3.9) at four years and 1.3 (95% CI 0.7, 2.0) at greater than five years (Cockerell et al., 
1994). 
At a median follow-up of 11.8 years the overall SMR (definite and possible epilepsy) was 
2.1 (95% CI 1.8, 2.4). The SMR decreased to 1.3 (95% CI 0.9, 1.7) at years 4 to 9 and was 
slightly higher at 1.6 (95% CI 1.1, 2.2) at years 9 to 14 years after diagnosis. This 
suggestion of a trend was more marked for those with definite epilepsy (n=564), for whom 
the SMR was significantly elevated at all points of follow-up (Lhatoo et al., 2001). It had
previously been shown in this cohort that people with epilepsy have a decreased life 
expectancy dependant on the severity of the epilepsy (Gaitatzis et al., 2004).  
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A Canadian study followed 692 children (up to 16 years old) who developed epilepsy 
between 1977 and 1985, for a median of 13.9 years (range 0-22.5 years) from the time of 
diagnosis (Camfield et al., 2002).  The SMR from 1980 to 1989 (corresponding to 0 to 12 
years since diagnosis) was 5.3 (95% CI 2.3, 8.3) and for 1990-1999 (5 to 22 years since 
diagnosis) was 8.8 (95% CI 4.2, 13.4). Twenty years after the onset of seizures 6.1% (95% 
CI 3.0, 9.2) of the cohort had died. 
In a retrospective Icelandic population-based study of 224 children and adults, the overall 
SMR after 30 years was 1.6 (95% CI 1.2, 2.2) (Olafsson et al., 1998). This risk was most 
marked in those with remote symptomatic epilepsy (SMR 2.3; 95% CI 1.4, 3.5) while there 
was no significantly increased risk in any age group for those with idiopathic epilepsy at 
any point during follow-up (overall SMR 1.3; 95% CI 0.8, 1.9).  The overall risk of 
mortality was only elevated for the first 14 years of follow-up, returning to baseline risk 
thereafter. The SMR was 3.0 (95% CI 1.5, 5.4) at 0 to 4 years follow-up, 2.1 (95% CI 1.0, 
3.9) at 5 to 9 years, 2.0 (95% CI 1.0, 3.8) at 10 to 14 years follow-up and between 0.7 and 
1.2 thereafter. 
In the Mayo Clinic Linkage study, a historical cohort of all residents in Rochester, 
Minnesota who had a first diagnosis of epilepsy between 1935 and 1974, the SMR for the 
total group after 29 years follow-up was 2.3 (95% CI 1.9, 2.6) (Hauser et al., 1980). The 
SMR was initially high at 3.8 (95% CI 2.8, 5.0) at 0 to 1 years follow-up, subsequently 
decreasing to 2.4 (95% CI 1.7, 3.3) at 2 to 4 years and SMR 2.0 (95% CI 1.4, 2.7) at 5 to 9 
years. The SMR was not significantly elevated at 10 to 14 years follow-up (SMR 1.4; 95% 
CI 0.8, 2.2), 15 to 19 years (SMR 1.4; 95% CI 0.7, 2.5) and 20 to 24 years (SMR 1.8; 95% 
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CI 0.7, 3.0) but was again significantly raised at 25 to 29 years follow-up. (SMR 3.9; 95% 
CI 1.8, 7.6) 
The SMRs by broad aetiological category for these studies are shown in Table 8.  The SMR 
is either not increased, or is slightly increased in people with idiopathic/cryptogenic 
epilepsy, is between 2.2 and 3.7 for those with symptomatic epilepsy, but is much higher in 
people with a congenital neurological deficit.  Most studies did not have comparable data 
for specific causes of death.
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Reference Idiopathic/Cryptogenic
SMR (95% CI).
Acute Symptomatic
SMR (95% CI).
Remote Symptomatic
SMR (95% CI).
Congenital Deficit
SMR (95% CI).
Hauser et al (1980)* 1.8 (1.4,2.3) 2.2 (1.8, 2.7) 11 (6.9, 16.4)
Olaffson et al (1998)** 1.3 (0.8, 1.9) N/A 2.3 (1.4, 2.5) N/A
Lhatoo et al (2001) 1.3 (0.9, 1.9) 3.0 (2.0, 4.3) 3.7 (2.9, 4.6) 25 (5.1, 73.1)
Lindsten et al (2000) 1.1 (0.5, 2.4) N/A 3.3 (2.4, 4.5) N/A
Camfield et al (2002)*** 1.51 (0.19, 2.83) N/A
Table 9: Population studies of mortality in people with epilepsy with Standardised mortality ratios (with 95% confidence intervals) for the 
major aetiological categories
N/A Not available
*Acute and remote symptomatic causes could not be differentiated
**14 of 42 with remote symptomatic seizures had learning disability or cerebral palsy
***Only SMRs for the whole cohort and for those without a severe neurological deficit 
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3.2.2 Hospital-based studies
The largest hospital-based study was a Swedish study which identified 9,061 people aged 
15 to 97 years who were admitted for inpatient care with a diagnosis of epilepsy between 
1980 and 1989 (people with both incident and prevalent epilepsy) (Nilsson et al., 1997).  
Four thousand and one people in the cohort died.  The overall SMR was 3.6 (95% CI 3.5, 
3.7), highest in young people but significantly elevated in all age groups.  The overall SMR 
was compared with that in people who died more than four years after entering the cohort 
and thus at least four years after onset of epilepsy.  The SMR in the group who died later 
was 3.1 (95% CI 3.0, 3.3), lower than the SMR of the whole cohort but within the same 
range. No comparison was made of the SMRs for the group who died less than or equal to 
four years after entering the cohort and those who died more than four years after entering 
the cohort.  
In a retrospective Scottish study of people attending epilepsy services between 1981 and 
2001, those with newly diagnosed epilepsy (N=890) had a 42% increased risk of premature 
mortality compared with the general population (SMR 1.42; 95% C.I 1.16, 1.72) (Mohanraj 
et al., 2006). People who did not respond to treatment had a greater increase in mortality 
(SMR 2.54; 95% CI 1.83, 3.44) while people in remission had no increased risk (SMR 
0.95; 95% CI 0.68, 1.29). 
In a Danish study (Henriksson et al., 1967) cited elsewhere, of 2,450 people with prevalent 
epilepsy aged 15 to 89 attending four epilepsy outpatient clinics from 1950 to 1963, and 
excluding those with acute symptomatic causes, the overall SMR for the cohort was 2.8, 
with males having a higher SMR (3.5) than females (2.0) (Shackleton et al., 2002).
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3.2.3 Studies from institutions
In a retrospective Dutch study, the mortality of all people attending an institution (both 
inpatients and outpatients) between 1953 and 1967 was investigated with a mean follow-up 
of 28 years (range 6 months to 41 years) (Shackleton et al., 1999).  The overall SMR for the 
cohort with incident epilepsy was 3.2 (95% C.I 2.9, 3.5). The SMR was significantly 
elevated soon after diagnosis (SMR 16; 95% CI 11, 20 in the first two years, decreasing 
thereafter to an SMR of approximately 7.0 for the next eight years. The SMR decreased 
further to 3.9 and subsequently plateaued at between 2.0 and 2.4 between 15 and 34 years. 
The SMR was no longer significantly elevated in the last years of follow-up (years 35-41: 
SMR 0.9; 95% CI 0.4, 1.4). 
Two studies carried out in institutions for people with mental disorders in the 1930s and 
40s were identified, one from the United States and the other from Sweden (Alstrom, 1942; 
Malzberg, 1934).  Both these studies comprised people with LD and prevalent epilepsy, 
(Shackleton et al., 2002) and both reported high SMRs; 8.0 (United States) and 8.7 
(Sweden). 
In a study from the Chalfont Centre for Epilepsy in the UK, deaths in 2,099 people with 
prevalent epilepsy who were admitted between 1931 and 1971 were investigated.  Between 
1951 and 1977 636 people died (both while at the centre and after discharge), giving an 
SMR of 3.0 (95% CI 2.8, 3.3) (White et al., 1979).  In another study from the Chalfont 
Centre, the death certificates of all patients who died between January 1980 and December 
1990 were examined; there were 113 deaths giving an SMR of 1.9 (95% CI 1.6, 2.3) 
(Klenerman et al., 1993). The deaths occurring in people still resident in the Chalfont 
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Centre in five year periods from 1896-1965 were also examined (O'Donoghue and Sander, 
1997).  During this period, there were 416 deaths, with an overall SMR of 2.34 (95% CI 
2.12, 2.56).  The SMR remained relatively stable at between 1 and 3 throughout most of the 
period of follow-up, with the lowest reported SMR (0.91) occurring during the earliest 
period of observation (1896-1900) and the highest occurring between 1916-1920 (4.41), 
which may in part be explained by the Spanish Flu pandemic preferentially affecting death 
rates in institutions. 
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3.3 Population-based mortality trends in people with epilepsy 
Mortality rates (age-adjusted mortality rates per million) per year from all causes in ten 
developed countries (Australia, Canada, England & Wales, France, Germany, Italy, Japan, 
The Netherlands, Spain and the United States) were studied between 1979 and 1997 to 
determine if there were any changing patterns in neurological deaths (Pritchard et al., 
2004). There were significant differences in the annual mortality rates between different 
countries, ranging from 6 per million in Japan to 24 per million in France but there was 
little variation in mortality rates year by year in each country. Males had a consistently 
higher mortality rate than females in all countries. 
The trends in annual mortality rates (and hospital admissions) in England and Wales 
between 1993 and 2000 were examined using ICD-9 coding for death certificates (Bruce et 
al., 2004). Epilepsy was mentioned on the death certificate in about 2,000 cases and listed 
as the underlying cause of death in approximately 800 cases each year. Overall there were 
15,990 death certificates where epilepsy was mentioned and 6,497 (40.6%) in which it was 
listed as the underlying cause of death. Age-standardised annual death rates for epilepsy 
varied little between 1993 and 2000. Deaths were higher in males for each year with a 
mean of 484 deaths attributable to epilepsy each year (compared with 332 in females).  
Males had higher annual mortality rates than females for all age groups.  In both males and 
females there was a sharp increase in mentions of epilepsy in the elderly. 
The mortality rates (per million person-years) of people with epilepsy between 1950 and 
1994 in England & Wales and the United States were analysed (O'Callaghan et al., 2000).  
Trends were broadly similar for both countries with mortality consistently higher in males, 
although mortality rates were higher in England and Wales than in the United States. The 
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mortality rate declined in both countries between birth and the age of ten, increasing 
sharply during teenage years and early adulthood. Rates fell gradually thereafter until the 
age of 70, when they increased, with the increase in mortality in those aged greater than 70 
years being more pronounced in England and Wales. There was evidence of significantly 
decreased mortality rates in successive birth cohorts born after 1950; this decrease occurred 
earlier among women (after 1905) but was more marked after 1950. Similarly the age 
distribution of those who died also changed between 1950 and 1994 with a two- to 
threefold decrease in mortality in young people, a decrease in young and middle-aged 
adults (with some differences between the countries) and a steep decrease in the elderly 
between 1950 and 1970 but an increase thereafter (O'Callaghan et al., 2000). There was 
little evidence of period effects.  Mortality was highest during the 1950s, decreased slightly 
until the 1970s and remained relatively stable thereafter in the United States, while 
increasing slightly in England/Wales after 1980 (O'Callaghan et al., 2000).
An earlier study (Massey and Schoenberg, 1985), which compared mortality rates in 33 
countries between 1967 and 1973 with the mortality rates for the same countries in the 
1950s (Goldberg and Kurland, 1962), found a significant decrease in mortality rates for 
most countries.
A summary of these findings is discussed on Page 207.
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Chapter 4: National General Practice Study of epilepsy
(NGPSE) (Study 2)
4.1 Methods
4.1.1 Study design 
4.1.1.1 Participants
The National General Practice Study of Epilepsy (NGPSE) is a prospective cohort study, 
the design and methodology of which has been previously reported (Hart et al., 1989).  In 
summary, people with newly diagnosed seizures (or possible seizures) were registered with 
the study between June 1984 and October 1987 by 275 general practitioners (GPs) across 
the UK, who were asked to notify to the study all people seen with newly suspected 
seizures apart from neonatal seizures.  
4.1.1.2 Classification
At six months, a diagnostic review panel (consisting of two neurologists and one paediatric 
neurologist) reviewed all 1,195 cases registered using all contemporaneous available 
information, including detailed eye-witness accounts of the episodes, clinical course and 
investigations (EEG, Neuro-imaging and the clinical assessment of their attending hospital 
physician).  The panel members designated people as having possible/probable epilepsy 
where they were undecided whether the episodes represented epileptic seizures or not, or in 
people in whom epilepsy was felt to be the likely diagnosis but that further clinical 
information was needed to confirm the diagnosis.  The panel classified 564 (47.2%) people 
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as having definite epilepsy, 228 (19.1%) as having possible epilepsy and 220 (18.4%) as 
having febrile seizures; the remainder (183, 15.3%) were either excluded (104 with a prior 
diagnosis of epilepsy or neonatal seizures), or classified as not having epilepsy (79). (Those
classified as not having epilepsy included those with a final diagnosis of syncope, non-
epileptic attacks, vascular events, night terrors, breath-holding attacks, vertigo and 
migraine.)  
Those classified as having definite epilepsy were subdivided broadly by aetiology into 
idiopathic/cryptogenic (no obvious cause identified [346]), acute symptomatic (seizures 
within three months of a defined risk factor [83]), remote symptomatic (seizures more than 
three months after a risk factor [119]), and seizures occurring in association with a 
neurological deficit presumed present at birth (16) (Annegers et al., 1979).  Those in whom 
no obvious cause was identified included people with idiopathic epilepsy (IGE) and 
cryptogenic epilepsy (people with focal onset epilepsy in whom no structural abnormality 
was identified). As the NGPSE is an observational study no additional investigations were 
carried out beyond that which was indicated clinically.  No further sub-analysis of those 
groups has been carried out in this thesis, an approach consistent with previous reports 
(Hart et al., 1989; Sander et al., 1990).
A new definition of acute symptomatic seizures has recently been proposed by the ILAE 
(Beghi et al., 2010) of a seizure occurring usually within seven days of an acute CNS insult.
Consequently those originally classified as having acute symptomatic seizures (N=83) have 
been reclassified in line with this definition and the SMRs for the acute and remote 
symptomatic groups recalculated.  Analyses using both the original and the new 
classifications are presented in the mortality section (4.2.1).
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The original classifications of definite epilepsy, possible/probable epilepsy and febrile 
seizures were maintained throughout the analysis in the thesis.
4.1.1.3 Initial follow-up
People with definite and possible epilepsy were initially followed up at 6 months after 
registration and then yearly thereafter.  Follow-up was by means of postal questionnaires 
completed by the person’s GP, detailing seizure frequency, seizure recurrence, seizure 
semiology, hospital follow-up and AED treatment.  Follow-up for the cohort was yearly up 
to 1997.  A further follow-up was performed in 2001 (unpublished) but was not completed 
due to changes in Data Protection Regulations. Children with febrile seizures were initially 
followed for two years after the close of recruitment with one further follow-up in 1998 
(MacDonald et al., 1999).
The results presented in the thesis represent the most complete attempted follow-up of the 
NGPSE cohort since the early years of the study.
4.1.1.4   Ethical approval
The NGPSE was originally approved by the local ethics committee of the National Hospital 
of Neurology and Neurosurgery and the Royal College of General Practitioners. In light of 
the changes to the data protection legislation in 2001, the NGPSE research group were 
informed that we would no longer be able to follow the cohort up without consent. When 
the decision to attempt a further follow-up of the NGPSE cohort was reached, it was 
therefore necessary made a new application to the National Research Ethics Committee. 
Ethics approval was obtained for the study in November 2007 (REC Reference: 
07/H0720/160), the application being subject to four further (one substantive) amendments 
with final ethical approval being granted in January 2009. 
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4.1.2 Data protection and the implications for the NGPSE  
When the NGPSE was set up, like all other observational epidemiological studies with no 
direct patient contact, individual patient consent was not necessary for registration with the 
study, with the issue of obtaining individual patient consent left to the discretion of the 
notifying general practitioners. Following the enactment of the Data Protection Act 1998 
and the Health & Social Care Act 2001 (www.legislation.gov.uk/ukpga/1998/29/contents; 
www.legislation.gov.uk/ukpga/2001/15/content), GPs would no longer be able to release 
identifiable patient information (necessary for the study) without direct patient consent to 
do so without being in breach of confidentiality and GMC guidance.  There is, however, a 
provision (Section 60 exemption of the Health & Social Care Act 2001) which allows for 
the disclosure of patient information without explicit consent, when it is impractical to 
obtain patient consent or when an important public interest is at stake, (as in the case of 
cancer registries which were one of the primary reasons for the provision of such an 
exemption). We believed that the necessity of obtaining patient consent for the release of 
information would inevitably result in a significant reduction in case ascertainment, and 
also that it was impractical to ask GPs to obtain patient consent; thus the only practical way 
for the study to continue was with Section 60 support. It was, however, recognised that 
such a request, if successful, would likely only be granted on a one-off basis and would 
therefore preclude any further follow-up of the cohort and the inevitable end of the study. 
4.1.2.1 PIAG and the NGPSE
Following the granting of ethical approval for the study, an application for Section 60 
exemption for the study was made to the Department of Health Patient Information 
Advisory Group (PIAG) in December 2007 with the application being considered at the 
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PIAG meeting in February 2008. This application was accompanied by a strong letter of 
support for the study by the UCLH Caldicott Guardian.  Prior to the PIAG meeting (which 
occur every two months) there was extensive communication (both via email and 
telephone) with the PIAG policy support management clarifying diverse aspects of the 
study and the necessity for such an application. The application for Section 60 exemption 
was considered at the PIAG meeting of the 5th February 2008 and was not successful. The 
primary reasons, as stated in the outcome letter, which the Group gave for not granting 
Section 60 exemption for the study were expressed as follows:
It is a principle of the Group that long term retention of identifiable information is only 
done with consent. Whereas members recognise that obtaining patient consent for 
historical studies can be difficult, the Group noted that you are intending to contact 
patient’s GPs and this is an ideal opportunity to ask them to publicise the study and to 
attempt to obtain consent. As this appears to be a reasonable alternative to Section 60 
support, members felt that it would be inappropriate to offer Section 60 support in this 
instance. However, if it can be shown that seeking consent via GPs is impracticable then 
PIAG would welcome evidence of this. 
Upon receipt of the decision letter, we informed the PIAG support management of our 
intention to appeal against this decision. There followed further intense communication 
between the NGPSE Research team and the PIAG Support Management culminating in a 
meeting with the head of the PIAG secretariat (with Professor Sander and Aidan Neligan) 
and a formal request to attend the next PIAG meeting on 14th April 2008. This was granted
and was attended by Professor Shorvon and Aidan Neligan. At the meeting the Group 
initially argued that permission to ask GPs whether the patient still had epilepsy or not 
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would be sufficient for the study. We argued that such a provision would both be 
inappropriate (in the cases of febrile seizures and possible epilepsy) and meaningless (as a 
diagnosis of epilepsy is subject to different interpretations by different clinicians). 
Ultimately we were granted leave to resubmit the application for consideration at the next 
meeting following clarification of several points of contention. It was agreed that the 
application would be for a one-time approval and that the study would end thereafter. The 
application was reconsidered at the PIAG meeting of the 25th June and the study was 
granted one-off Section 251 support (Section 60 of the Health and Social Care Act 2001 
was re-enacted under Section 251 of the NHS Act 2006) under the following conditions 
(with the questionnaire being amended accordingly [see Appendix]).
The first two questions in the questionnaire were changed to the following:
1) Has the patient had any seizures in the past five years? (this is the point at which 
patients are believed to be in long-term remission)
2) Has the patient taken any medication for epilepsy in the past five years?
If the answer to both of these questions was no then the GPs had permission to complete 
the questionnaire without patient consent on this single occasion. If, however, the answers 
to either of these questions was yes then patient consent would be required to complete the 
questionnaire. (The GPs could, however, answer the first two questions without patient 
consent and therefore return the questionnaire partially completed).  The rationale for such 
a decision was that if a patient had had seizures or was on medication for seizures in the 
previous five years, then the patient would clearly be aware of a diagnosis of epilepsy or 
seizures and would therefore be in a position to grant consent for inclusion in an epilepsy 
study.  These conditions were accepted and formal notification of the awarding of Section 
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251 support for the study was received at the end of August 2008 with an initial duration of 
one year. This approval was formally extended by another year in September 2009.
4.1.2.2 The Office of National Statistics (ONS) and the NGPSE
The whereabouts of all people in the NGPSE cohort was tracked by the Information Centre 
NHS (formerly the ONS and previously the NHS Central Registry). Given that the last 
attempted follow-up was over eight years previously, it was believed that a significant 
number of people may have moved. A request was made to be notified of the location of 
the current GP of each person in the study (Members and Posting application). Such a 
request required approvals from the ethics committee of the Central Register as well the 
Ethics and Confidentiality Committee of the National Information Governance Board for 
Health and Social Care (NIGB; formerly PIAG) which was formerly granted in March 
2009. 
The locations of GPs for all people in the study were given in April 2009, listed by area 
with the contact details for the Patient Data Management team for each area, to whom a 
request for the details of the GP practices could then be made. 
4.1.2.3 Research & Development Departments 
In order to carry out research in an individual Primary Care Trust (PCT) (i.e. sending the 
follow-up questionnaire to a GP practice in that area), approval from the PCT Research & 
Development Department (R&D department) is required. Applications to individual (& 
consortiums of) R&D departments started in late February 2009 continuing up to 
September 2009 with further applications made as required when the questionnaires were 
being sent out. There was initial confusion as to the exact number of PCTs for which 
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approval would be required as the list of areas supplied by the Information Centre NHS did 
not exactly correspond to the geographical areas of the PCTs (for example the area 
designated “East Riding” contained practices in East Riding PCT and Hull City PCT), 
necessitating more PCT approvals than originally anticipated based on the list of “PCTs” 
provided by the Central Register. In total approvals were required from120 PCTs 
(including seven in Scotland and three Health Authorities in Wales). In addition to 
obtaining approvals from several PCTs which, in the end, did not contain any people in the 
NGPSE cohort we were also required to obtain individual PCT approvals for one person in 
the study in several instances.  One PCT initially did not grant approval for the study but 
did so upon appeal.  
This process of applications to PCT R&D departments for approval was greatly facilitated 
by the fact that we were successful in getting the study adopted onto the National Institute 
for Health Research (NIHR) Comprehensive Research Network (CRN) and the Primary 
Care Research Network (PCRN) portfolios. This had the added bonus that the study was 
now eligible for Service Support Costs and therefore GP practices (in England) could be 
paid for participating in the study.
4.1.2.4 Scotland and the NGPSE 
In contrast to England & Wales, in Scotland there is no provision comparable to Section 
251 Support to allow long-term epidemiological cohort studies such as the NGPSE to 
proceed without consent. It was therefore anticipated that consent would be required from 
all people in the NGPSE cohort in Scotland. (The issue was discussed at length with the 
Privacy Advisory Committee (PAC) which confirmed this view). Accordingly separate 
106
106
research documents were drawn up for Scotland to reflect the different ethical situation. 
Given this requirement for consent from all people in the study in Scotland, it was our 
original intention to phone all practices to discuss and stress the importance of the study 
with each GP (in Scotland) prior to sending out the questionnaire. This was not possible as 
it was the contention of the PAC and the General Register Office that the study did not 
have the authorisation to have GP details. Therefore the questionnaires would need to be 
forwarded to GPs through the intermediary of the NHS Central Register (NHSCR) 
Scotland (who in turn sent the envelopes containing the questionnaires to the appropriate 
Practitioner Services Divisions Office who then forwarded the information to the relevant 
GPs).
4.1.3 Current follow-up
The current follow-up questionnaires were sent out between October 2009 and April 2010.
In some cases the questionnaire was sent out a second time when the original 
correspondence had been misplaced. Where possible, all practices from whom a response 
had not been received after three months, were contacted by telephone (initially via the 
practice manager) and the questionnaire completed over the phone with the GP in several 
instances. Such an approach was not possible in Scotland.
4.1.3.1 Mortality analysis
All people in the study were flagged at the UK NHS Information Centre who notified the 
study group of all deaths of people in the study and the death certificates were obtained 
where available, ensuring complete case ascertainment in the UK. This was made possible 
because the study had previously obtained Section 60 Support for the study in relation to 
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notification of deaths in the study as well as approval from the PAC, National Services 
Scotland and the General Register Office Scotland. 
The principal cause of death was obtained from the death certificates (which were available 
in all but three cases) and allocated ICD codes following deliberation by the study review 
panel.  Mortality data from the NGPSE cohort has previously been reported at a median of 
6.9 years from registration with a total of 161 observed deaths and 7,500 person-years of 
observation (Cockerell et al., 1994), and at a median of 11.8 years with 214 deaths and 
11,400 person-years (Lhatoo et al., 2001).
4.1.3.2   Mortality statistical analysis: statistical analysis
Expected numbers of deaths were estimated using age (5 or 10 year bands), sex and 
calendar year-specific death rates in England and Wales.  Data were obtained from the 
Registrar General’s mortality statistics (up to 1997), the CD 20th century mortality (1998) 
and the website of the Information Centre NHS (1999 onwards) 
(www.statistics.gov.uk/STATBASE; Office of National Statistics, 2003 Twentieth century 
mortality [CD-ROM]).  SMRs with 95% CIs were calculated (for the whole cohort and for 
those with definite epilepsy, possible epilepsy, febrile seizures and for subgroups of those 
with definite epilepsy) using the person-years method with SMRs and 95% CIs based on 
the Poisson distribution, and two-tailed significance tests.  SMRs for specific causes were 
also calculated for those with definite and possible epilepsy. 
SMRs were calculated at various follow-up intervals and for different age groups in the 
group with definite and possible epilepsy.  Analysis was carried out in Stata (version 10; 
Statacorp LP, Texas) with participants followed up from registration in the study until 
death or, if alive, to 30th April 2009.
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4.1.3.3 Febrile seizures statistical analysis 
The age-specific incidence rates reported in the British National Child Development Study 
cohort (Kurtz et al., 1998) were used to calculate the number of children with febrile 
seizures expected to develop epilepsy (with ages 24 to 30 years extrapolated from age 23 
years).  Standardised incidence rates (SIRs) with 95% CIs were calculated in five-year age 
bands using the person-years method with the SIRs and 95% CIs based on the Poisson 
distribution and two-tailed significance tests.
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4.2 Results
4.2.1. The long-term risk of mortality in people with epilepsy
Median follow-up was 22.8 years, and 19,144 person-years of follow-up in those with 
definite or probable epilepsy or febrile seizures was achieved.  There were 301 deaths in the
cohort.  Thorough re-examination of all the source data files held by the NGPSE research 
group (all previous completed follow-up questionnaires, death certificates) resulted in some 
minor changes in demographic data and allocation of cause of death.
The overall SMR was increased for those with definite epilepsy (SMR 2.55) and those with 
possible epilepsy (SMR 1.57) (Table 10). 
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Table 10: All-cause mortality for Whole Cohort and Specific Subgroups
Obs=observed, Exp=expected
Group Number 
at risk
Number of deaths
Males Females Total
Obs Exp Obs Exp Obs Exp SMR 95% CI p
Definite 
epilepsy
564 122 50.7 103 37.6 225 88.2 2.55 2.24 to 2.91 <0.001
Possible 
epilepsy
228 33 17.9 42 29.9 75 47.8 1.57 1.25 to 1.97 <0.001
Subtotal 792 155 68.5 145 67.5 300 136.0 2.21 1.97 to 2.47 <0.001
Not 
epilepsy
79 10 5.5 15 12.6 25 18.0 1.39 0.93 to 2.05 0.072
Febrile 
seizures
220 1 2.1 0 0.9 1 3.0 0.34 0.05 to 2.39 0.950
Total 1091 166 76.1 160 80.9 326 157.0 2.08 1.86 to 2.31 <0.001
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One person with a history of febrile seizures (three febrile seizures as a child with no 
further seizures) died by suicide.  
Mortality within different age groups is summarised in Figure 1.  
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Figure 1: All cause mortality by age-group during follow-up in the combined group with 
definite and possible epilepsy, people with definite epilepsy, and the subgroup with 
idiopathic epilepsy
Mortality ratios were significantly raised for all age groups in those with definite epilepsy 
and the combined groups of definite and possible epilepsy. For people with definite 
epilepsy, the overall SMR for the different aetiologies (idiopathic/cryptogenic, acute and 
remote symptomatic and congenital deficit) were significantly elevated in all four groups 
(Table 11).  
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Cause Number 
at risk
Number of deaths
Obs Exp SMR 95% CI
Idiopathic/cryptogenic 346 80 48.4 1.66 1.33 to 2.06
Remote symptomatic 119 98 26.2 3.73 3.06 to 4.55
Remote symptomatic 
(Revised 2010)
142 112 30.5 3.68 3.05 to 4.42
Acute symptomatic 83 43 13.4 3.20 2.38 to 4.32
Acute symptomatic 
(Revised 2010)
60 29 9.19 3.16 2.19 to 4.54
Congenital deficit 16 4 0.2 18.64 6.99 to 49.65
Table 11: All-cause mortality in people with definite epilepsy according to aetiology
Obs.=observed, Exp.=expected
The SMR remained elevated for people with acute symptomatic seizures who had survived 
the first year (SMR 2.5, 95% CI 1.7 to 3.5).  Mortality over time for people with definite 
epilepsy, definite and possible epilepsy and people with idiopathic epilepsy is summarised 
in Figure 2.
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Figure 2: Mortality by years of follow-up from index seizure in the combined group with 
definite and possible epilepsy, people with definite epilepsy, and the subgroup with 
idiopathic epilepsy
Current cause-specific SMRs and those previously reported for the first seven and fourteen 
years are listed in Table 12.  
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Up to 7 years follow-up Up to 14 years follow-up Total follow-up (up to 25 years)
O E SMR 95% CI O E SMR 95% CI O E SMR 95% CI
Definite & possible epilepsy 
(N=792)
Malignant neoplasms 47 13.5 3.5 2.5,4.6 56 21.3 2.6 1.9,3.4 86 33.3 2.6 2.1,3.2
Malignant neoplasms 
excluding brain
33 13.3 2.5 1.7,3.5 39 20.7 1.9 1.3,2.6 67 32.5 2.1 1.6,2.6
Neoplasms of lung 10 3.3 3.0 1.4,5.5 14 5.1 2.7 1.5,4.6 21 7.7 2.7 1.8,4.2
IHD 16 15.6 1.0 0.5,1.7 25 23.4 1.1 0.7,1.6 47 31.3 1.5 1.1,2.0
CVD 28 7.5 3.7 2.4,5.4 35 11.1 3.2 2.2,4.4 43 15.1 2.9 2.1,3.9
Pneumonia 25 3.5 7.2 4.6,10.7 39 6.6 5.9 4.1,8.0 60 9.2 6.6 5.1,8.4
Definite epilepsy (N=564)
Malignant neoplasms 43 8.9 4.8 3.4,6.5 50 14.3 3.5 2.6,4.6 75 22.7 3.3 2.6,4.1
Malignant neoplasms 
excluding brain
30 8.8 3.4 2.3,4.9 34 13.9 2.4 1.7,3.4 57 22.1 2.6 2.0,3.3
115
115
Neoplasms of lung 10 2.3 4.3 2.0,7.9 12 3.6 3.3 1.7,5.8 18 5.5 3.3 2.1,5.2
IHD 10 9.9 1.0 0.4,1.9 16 15.1 1.1 0.6,1.7 30 20.9 1.4 1.0,2.1
CVD 19 5.0 4.4 2.6,6.8 24 6.5 3.7 2.3,5.5 29 9.3 3.1 2.2,4.5
Pneumonia 18 1.9 9.6 5.6,15.1 27 3.7 7.3 4.8,10.6 44 5.6 7.9 5.8,10.6
Idiopathic/cryptogenic 
epilepsy (N=346)
Malignant neoplasms 8 3.9 2.0 0.8,4.0 9 7.0 1.3 0.6,2.5 23 13.0 1.8 1.2,2.7
Malignant neoplasms 
excluding brain
5 3.8 1.3 0.4,3.0 6 6.8 0.9 0.3,1.9 18 12.7 1.4 0.9,2.3
Neoplasms of lung 0 1.0 0 0.0,3.6 1 1.8 0.6 0.0,3.2 4 3.1 1.3 0.5,3.5
IHD 1 3.9 0.3 0.0,1.4 4 6.7 0.6 0.1,1.5 15 11.0 1.4 0.8,2.3
CVD 1 1.5 0.6 0.0,3.6 3 2.7 1.1 0.2,3.3 6 4.8 1.2 0.6,2.8
Pneumonia 6 0.6 10.1 3.6,21.8 8 1.5 5.4 2.3,10.7 20 3.0 6.7 4.3,10.4
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Table 12: Cause-specific SMRs in the combined group with definite and possible epilepsy, people with definite epilepsy, and the 
subgroup with idiopathic epilepsy.  Not all causes of death are included in the table. 
*Up to 7 years follow-up and up to 14 years follow-up taken from Cockerell et al., 1994 and Lhatoo et al., 2001.
IHD; ischaemic heart disease: CVD cerebrovascular disease
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The 5 year SMRs for the major causes of mortality for those with definite or possible 
epilepsy are listed in Table 13.
SMRs with 95% Confidence Intervals
Malignant 
neoplasms
Malignant 
neoplasms 
excluding 
brain
Neoplasms 
of lung 
IHD CVD Pneumonia
Years 
0-5
4.44 (3.3, 
6.0)
3.11 (2.2, 
4.4)
4.69 (2.7, 
8.3)
1.35 (0.8, 
2.2)
4.21 
(2.8, 6.3)
10.23 (6.9, 
15.1)
Years 
5-10
1.43 (0.8, 
2.6)
1.35 (0.7, 
2.5)
1.11 (0.3, 
4.4)
1.13 (0.6, 
2.2)
2.50 
(1.3, 4.8)
3.22 (1.6, 
6.4)
Years 
10-15
1.90 (1.1, 
3.4)
1.46 (0.8, 
2.8)
2.14 (0.7, 
6.6)
1.79 
(0.96, 3.3)
2.28 
(1.0, 5.1)
4.51 (2.5, 
8.1)
Years 
15-20
1.81 (0.98, 
3.4)
1.67 (0.9, 
3.2)
1.67 (0.4, 
6.7)
1.35 (0.6, 
3.2)
1.04 
(0.3, 4.1)
8.32 (4.3, 
16.0)
Years 
20-25
2.19 (1.1, 
4.4)
2.25 (1.1, 
4.5)
2.55 (0.6, 
10.2)
3.34 (1.6, 
7.0)
1.67 
(0.4, 6.7)
9.88 (4.7, 
20.7)
Table 13: Selected causes of death (with SMRs and 95% Confidence Intervals) for 
people with definite or possible epilepsy
There were only seven epilepsy-related deaths in the cohort, three from status 
epilepticus, three from accidents and drowning, and one from possible SUDEP (Lhatoo 
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et al., 1999).  Epilepsy was listed as a contributory factor in 11 deaths.  One further 
person in the cohort died in March 2009 (apparently as a result of murder), but as this 
death is still being officially investigated and has therefore not been formally notified to 
the study group by means of the death certificate, it is not included in this analysis.
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4.2.2 Follow-up of seizure outcome
Follow-up was commenced in October 2009 and was completed at the end of July 2010. 
As of October 2009, of the 1,012 people registered in the initial cohort, 304 were known 
to have died. An additional two people had previously indicated that they did not wish 
to participate further in the study and so further follow-up information was not 
attempted.
Consequently information was sought from the ONS on the GP details of 704 people in 
the study, which subsequently supplied us with the details of the local health authority 
of the GPs whereabouts for 659 people in the study. Of the 45 people on whom no 
further information was available, it was known that nine had previously emigrated.
The local health authorities provided us with the current GP details for 612 people, with 
a further nine people not having a registered GP. In Scotland, we did not have the 
authority, because of issues with consent and confidentiality, to access the GP details 
for the 38 people in the study resident there. Follow-up questionnaires were therefore 
sent out directly to GP practices on 612 people in England (607) and Wales (5). In 
Scotland, questionnaires on 38 people were forwarded to GPs through the intermediary 
of the NHS Central Register (NHSCR) Scotland (who in turn sent the envelopes 
containing the questionnaires to the appropriate Practitioner Services Divisions Office 
who in turn forwarded the information to the relevant GPs). We were subsequently 
informed that a further 21 people were no longer registered with the indicated GP 
practice and no further information on their current whereabouts was available.
In total follow-up information was potentially available on 629 people in the cohort. 
Two people refused consent to participate further in the study while seven GPs (11 
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people) refused outright to help with the study, returning the questionnaires 
unanswered. One person died after signing the consent form while one further person 
immigrated (to Sweden) during the follow-up period. In addition, we received two
signed consent forms from two people (one in England, one in Scotland) without 
receiving the completed questionnaire from their GP. 
By the end of July 2010, 552 responses (partial or complete) had been received, of 
which 540 (91.4% of the potential number) concerned people in England, 10 (26.3%) 
people in Scotland and 3 (60%) people in Wales.  The basic data is summarised in 
Table 14. 
Thorough re-examination of all the source data files held by the NGPSE research group 
(all previous completed follow-up questionnaires) resulted in some minor changes in 
demographic data and seizure frequency.
Febrile seizures Definite 
epilepsy
Possible 
epilepsy
Total 220 564 228
Still alive 219 334 152
Follow-up information 181 (82.6%) 253 (75.4%) 119 (78.3%)
Seizure free in the last 5 years 175 (96.7%) 201 (80.6%) 103 (86.6%)
Seizure free and off AEDs 172 (95.0%) 145 (58.3%) 90 (75.6%)
Table 14 Basic follow-up data from the NGPSE cohort 2009-10
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4.2.3 The long-term prognosis of people with febrile seizures
Of the original 220 children (60.5% male) with febrile seizures originally registered 
with the study, 219 were still alive in October 2009. Of these 219, follow-up 
information was obtained in 2009-10 on 181 (82.6%), with a mean follow-up for the 
whole cohort of 21.6 (SD 6.0) years (median follow-up 24 years, range 0.6 to 25.9 
years).  In 189 (86%), the index febrile seizure was the first seizure while 26 (11.8%)
had a previous single febrile seizure and five (2.3%) had two prior febrile seizures. Over 
two thirds (148; 67.3%) had no further seizures after the index febrile seizure while 57 
(25.9%) had 1-5 further seizures during follow-up, four had 6-10 further seizures, one 
had 11-15 further seizures and nine (4.1%) had 20 or more seizures and in one the 
number of seizures was not known.
Five years after the index febrile seizure 212 people (96.4%) were still being followed. 
Of these, 144 (67.9%) had had no further seizures during those five years while 58 
(27.4%) had 1-5 seizures in that time. Three had 6-10 seizures, one had 11-15 seizures 
and six had more than 20 seizures. 
After ten years, follow-up was achieved in 211 (95.9%). Of these 201 (95.3%) had had 
no seizures in the preceding five years while four had had 1-5 epileptic seizures and the 
remaining six had many (> 20) seizures.
Of the 181 (82.6%) with follow-up after more than 20 years, 175 (96.7%) were seizure 
free in the preceding five years while 171 (94.5%) were seizure free and off AEDs.  In 
those who had any seizure recurrence, the mean time to recurrence from index seizure 
was 1.1 years (SD 2.1 years, median 0.6 years, range one day to 16 years).  
For children in whom the index febrile seizure was not the first seizure, the risk of 
recurrence of febrile seizures was slightly higher (HR 1.76, 95% CI 0.98, 3.2) (Figure 3)
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Figure 3: Cumulative risk of febrile seizure recurrence in relation to the index seizure
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Figure 4: Time to develop epilepsy in people with febrile seizures
In total 17 (7.7%) had afebrile seizures of whom 14 (6.4%) had two or more afebrile 
seizures (epilepsy) (summarised in Table 15). The mean time to second afebrile seizure 
was 5.7 (SD 4.3) years (median 4.4 years; range 1.0-16.9 years) (figure 4).  In the 14 
people who developed epilepsy, long-term follow-up was achieved in 13 (92.9%). At 20 
years after the index febrile seizure, the estimated percentage who had developed 
epilepsy was 6.7% (95% CI 4, 11%).
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Follow-up 2009-2010 N Epilepsy syndromes
Seizure-free, 5 years off AEDs 5 CPE (3), probable CPE (1), SPE (1).
Seizure-free for 5 years, taking AEDs 2 IGE (1), CPE (1)
Seizure free less than 5 years, off AEDs 1 Probable CPE (1)
Ongoing seizures, taking AEDs 5 Nocturnal generalised seizures* (1), 
IGE (2 – one JME), SPE (2)
Last follow-up 1997
Active epilepsy, off AEDs 1 IGE (JAE)
Table 15:  Outcome of people with febrile seizures who developed epilepsy (N=14)
Information on epilepsy syndrome based on limited information in people with few 
seizures.  
*insufficient information to allow syndromic classification
Legend: CPE=cryptogenic partial epilepsy, SPE=symptomatic partial epilepsy, 
IGE=idiopathic generalised epilepsy, JME=juvenile myoclonic epilepsy, JAE=juvenile 
absence epilepsy
Overall the risk of developing epilepsy in the cohort was almost ten times that of the 
general population (Standardised Incidence Rate [SIR] 9.7, 95% CI 5.7, 16.4). The SIR 
for epilepsy in the cohort in the 0-5 year age group was 14.2 (95% CI 5.9, 34.2) and
16.3 (95% CI 7.3, 36.2) in the 5-10 year age group. The SIR was 7.2 (95% CI 1.8, 28.7) 
in the 10-15 year age group and was no longer significant in the 15-20 year age group 
(SIR 4.5, 95% CI 0.6, 32.0).
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4.2.4 The long-term prognosis of people with epilepsy 
In the original cohort 792 were classified as having definite (n=564) or possible (n=228) 
epileptic seizures, of whom 486 (334 (59.2%) with definite epilepsy) were still alive in 
October 2009 when the current follow-up was commenced. In 263 (46.6%) of those 
with definite epilepsy and 113 (49.6%) of those with possible epilepsy, the index 
seizure was the first seizure. In total, long-term follow-up information was available in 
372 (76.3%); 253 (75.4%) of those with definite epilepsy who were still alive and 119 
(78.3%) of those with possible epilepsy. The mean duration of follow-up was 15.9 years 
(SD 8.9; median 16.6 years, range 0 to 25.9 years) for those with definite epilepsy and 
16.9 years (SD 8.6; median 22.5 years, range 11 days to 25.8yrs) for those with possible 
epilepsy. At last follow-up, 201 (80.6%) of those with definite epilepsy and 103 
(86.6%) of those with possible had been seizure free in the previous five years with 145 
(72.4% of those with definite epilepsy) and 90 (87.4% of those with possible epilepsy) 
off AEDs.
Follow-up information is summarised in Table 16.
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Definite Epilepsy (N=564) Possible Epilepsy (N=228)
Male 293 (52.0%) 95 (41.7%)
No seizures before Index 
Seizure (IS)
263 (46.6%) 113 (49.6%)
1-5 seizures before IS 233 (41.3%) 78 (34.2%)
6-10 seizures before IS 43 (7.6%) 26 (11.4%)
>10 seizures before IS 24 (4.4%) 1 unknown 11 (4.8%) 
Number of seizures during total follow-up
No further seizures after IS 205 (36.3%) 115 (50.4%)
1-5 further seizures 171 (30.3%) 54 (23.7%)
6-10 further seizures 39 (6.9%) 12 (5.3%)
11-15 further seizures 14 (2.5%) 8 (3.5%)
>15 further seizures 132 (23.4%). 3 unknown 39 (17.1%)
Follow-up at 5 years1 N= 459 N=193
No seizures in past 5 years 176 (38.3%) 104 (53.9%)
1-5 seizures 145 (31.6%) 46 (23.8%)
6-10 seizures 34 (7.4%) 13 (6.7%)
11-15 seizures 11 (2.4%) 5 (2.6%)
>15 seizures 91 (19.8%) 25 (13.0%)
Follow-up at 10 years2 N=414 N=175
No seizures in past 5 years 275 (66.4%) 128 (73.1%)
1-5 seizures 67 (16.2%) 26 (14.9%)
6-10 seizures 18 (4.3%) 4 (2.3%)
11-15 seizures 3 (0.7%) 1 (0.6%)
>15 seizures 50 (12.1%) 15 (8.6%)
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Table 16: Seizure outcomes in those with definite and possible epilepsy
1Seizure outcome unknown in two people with definite epilepsy
2Seizure outcome unknown in one person with definite and one person with possible 
epilepsy
Estimation of seizure frequency in the first ten years was possible because GPs were 
sent yearly follow-up questionnaires up to 1997 allowing accurate estimation of seizure 
frequency during this time. The current follow-up represents one of only two further 
follow-ups undertaken after this point (the other was in 2001). Consequently the data 
were insufficient in some cases to accurate estimate seizure frequency beyond ten years 
and this was therefore not attempted. 
In those classified as having definite epilepsy who had long term follow-up, 48 (19.1%) 
had seizures in the last five years of whom 45 (93.7%) were on AEDs. The index 
seizure was the first seizure in 17 (35.6%). Of the 48, the aetiological classification (at 6 
months) was idiopathic/cryptogenic in 37 (77.8%); acute symptomatic seizures in three, 
remote symptomatic seizures in three and five had congenital deficits. Similarly for 
those classified as having possible epilepsy, 16 (13.4%) had seizures in the last five
years of whom all but one remained on AEDs. The index seizure was the first seizure in 
eight (50%).
Seizure outcome in people for whom the index seizure was the first seizure is shown in 
Table 17.
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Complete Follow-
up (%)
Incomplete 
Follow-up
Died 
Definite Epilepsy 
(N=263)
114 (43.3%) 35 (13.3%) 114 (43.3%)
Single Seizure 43 (37.7%) 12 (34.3%) 65 (57.0%)
Further Seizures 71 (62.3%) 23 (65.7%) 49 (43/0%)
Mean follow-up 
(years) (SD)
24.1 (0.91) 13.2 (3.3) 6.3 (6.5)
Possible Epilepsy
(N=113)
60 (53.1%) 13 (11.5%) 40 (35.4%)
Single Seizure 33 (55%) 9 (69.2%) 28 (70%)
Further Seizures 27 (45%) 4 (30.8%) 12 (30%)
Mean follow-up 
(years) (SD)
24.1 (0.97) 13.2 (2.4) 6.0 (5.8)
Table 17: Seizure outcomes in people in whom the index seizure was the first seizure
*These results are discussed in conjunction with a previous published report (Hart et al., 
1990) on page 211.
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4.2.4.1 Survival analysis of time to first seizure and Cox regression model
The probabilities of relapse after the index seizure for those with definite, possible and 
febrile seizures are shown in Figure 5. 
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Figure 5: Kaplan-Meier analysis of probability of remaining seizure free after index 
seizure for those with definite, possible and febrile seizures
The risk of relapse is highest in the first five years with the probability of remaining 
seizure free appearing relatively stable 10 to 15 years after the index seizure for all 
seizure groups
The log-rank test was used to check the difference in the probability of relapse in those 
with definite and possible epilepsy (χ2=19.3, df=1, p<0.001).  People classified as 
having possible epilepsy were less likely to relapse than those with definite epilepsy 
(HR 0.63, 95% CI 0.51, 0.78). 
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In people with definite and possible epilepsy the only factor found to be associated with 
an increased risk of seizure recurrence was having seizures prior to the index seizure in 
the Cox regression model. For those in whom the index seizure was the first seizure, the 
risk of seizure recurrence was significantly lower than those who had seizures before 
the index seizure (HR = 0.65, 95% CI 0.54, 0.78, p<0.001). Neither age, gender nor 
seizure type significantly affected the probability of seizure recurrence.  
The proportions of those with definite and possible epilepsy who attained five year 
seizure freedom in the first ten years with subsequent relapse rates are shown in Table 
18.
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Complete 
FU
Incomplete 
FU
Died Total (%)
Definite Epilepsy N=252 N=82 N=230 N=564
SF 0-5 yrs then 
relapse 5-10 yrs
8 (5 in TR, 1 
SF)
(N=96)
5
(N=26)
4 (3 in TR, 1 
SF)
(N=54)
14 (8.1%)
(N=176)
SF 0-10 yrs then 
relapse thereafter
11 (5 in TR, 
3 SF )
(N=88)1
0
(N=21)
2 (1 SF)
(N=35)3
13 (9.0%)
(N=144)
SF 5-10 yrs then 
relapse thereafter2
11 (3 in TR, 
4 SF)
(N=84)
1
(N=22)
4 (2 SF)
(N=63)
16 (9.5%)
(N=169)
Possible Epilepsy N=119 N=33 N=76 N=228
SF 0-5 yrs then 
relapse 5-10 yrs
9 (8 in TR)
(N=68)
2 (TR)
(N=18)
2 (1 SF)
(N=18)
12 (11.7%)
(N=104)
SF 0-10 yrs 2 (1 SF)
(N=59)
0
(N=16)
0
(N=16)
2 (2.2%)
(N=91)
SF 5-10 yrs then 
relapse thereafter
2 (1 TR)
(N=28)
0
(N=8)
1 (SF)4
(N=5)
2 (7.1%)
(N=41)
Table 18: Proportion of people with definite and possible epilepsy who attain at least 
five year seizure freedom in the first ten years of follow-up
Legend: FU=Follow-up, TR=Terminal Remission (five or more years seizure free up to 
the end of follow-up), SF=Seizure Freedom (one or more years seizure free but less 
than five years seizure freedom at last follow-up)
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1Calculated from the 96 people SF in the 1st five years minus the eight people who had a 
recurrence in the next five years
2Refers to people not seizure free in the first five years but who were seizure free in the 
second five years of follow-up
315 of those who were seizure free at 0-5 years died before ten years of follow-up.
4Died within five years of last seizure
Only a small proportion of those who attained at least five years of continuous seizure 
freedom in the first ten years subsequently relapsed during follow-up (30/252 (11.9%) 
of those with definite epilepsy; 13/119 (10.9%) of those with possible epilepsy) of 
whom 13 (43.3%) of those with definite and nine (69.2%) with possible epilepsy had 
become seizure-free again and were in terminal remission (seizure-free for at least five 
years on or off AEDs) at last follow-up.
Seventy seven (30.6%) of those with definite epilepsy and 57 (47.9%) with possible 
epilepsy entered and remained in terminal remission after the index seizure while a 
further 73 (29.0%) of those with definite and 26 (21.8%) with possible epilepsy entered 
five year terminal remission within the first five years of the index seizure.  Another 38 
(15.0%) of those with definite and 11 (7.2%) with possible epilepsy entered terminal 
remission for the first time after more than ten years of follow-up.
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4.2.4.2 The impact of aetiology on prognosis in definite epilepsy
In those classified as having definite epilepsy, presumed aetiology affects the 
probability of seizure recurrence (p<0.001) (Table 19). Compared with those with 
idiopathic/cryptogenic epilepsy, people with remote symptomatic epilepsy had no 
difference in the probability of seizure relapse (HR 1.16, 95% CI 0.89, 1.51). In contrast 
people with acute symptomatic epilepsy were less likely to relapse (HR 0.43 0; 95% CI 
0.30, 0.64) while those with epilepsy associated with a congenital deficit were more 
likely to relapse (HR 2.07, 95% CI 1.21, 3.56) (Figure 6).
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Idiopathic/Cryptogenic
(%) (N=346)
Remote 
Symptomatic
(%) (N=119)
Acute 
Symptomatic
(%) (N=83)
Congenital 
Deficit
(%) (N=16)
Alive 262 (75.7%) 21 (17.6%) 40 (48.2%) 11 (68.8%)
Complete 
Follow-up
193 (73.7%) 14 (66.7%) 34 (85%) 11 (100%)
Seizures in 
last 5 yrs
36 (18.7%), 35 (97.2%) 
on AEDs1
3 (21.4%), all 
on AEDs2
3 (8.8%), all 
on AEDs
5 (45.5%), 4 
on AEDs
SF < 5 yrs 14 (38.9%), 13 on AEDs 2 1 1
SF in last 5 
yrs, on 
AEDs
47 (24.4%) 5 (35.7%) 4 (11.7%) 1
SF in last 5 
yrs, off 
AEDs
110 (57.0%) 6 (42.9%) 27 (79.4%) 5 (45.5%)
Table 19: Seizure outcome in those classified as having definite epilepsy by aetiology
1Date of last seizure unknown in 12
2Date of last seizure unknown in one
135
135
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
P
ro
ba
bi
lit
y 
of
 r
e
m
ai
ni
ng
 s
e
iz
u
re
 fr
e
e
16 2 1 1 1 1Congenital
81 41 35 28 26 21Acute symptomatic
118 20 13 5 5 4Remote symptomatic
344 117 101 74 59 47Idiopathic/cryptogenic
Number at risk
0 5 10 15 20 25
analysis time
Idiopathic/cryptogenic Remote symptomatic
Acute symptomatic Congenital
Figure 6: Kaplan-Meier analysis of probability of remaining seizure free after index 
seizure in those with definite epilepsy stratified by aetiological grouping
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In people with idiopathic/cryptogenic epilepsy, 47 were seizure free in the last five
years but remained on AEDs. Of these eight had not had any further seizures since the 
index seizure (although all had seizures prior to the index seizure), 18 (38.3%) had been
seizure free for over 20 years and eight were seizure free for at least 15 years with all 
but two of the remainder seizure free more than ten years.
In those with remote symptomatic epilepsy, five were seizure free, on AEDs, in the last 
five years. Of these two had had no further seizures since the index seizure (both had 
seizures prior to the index seizure), while another two were seizure free more than 20 
years.  Four people with acute symptomatic seizures were seizure free on AEDs. Of 
these one only ever had one seizure (index seizure) while the remaining three were 
seizure free for more than twenty years at last follow-up.
One person with seizures as a result of a congenital deficit remained on AEDs despite 
being seizure free more than twenty four years. Of the 16 people with possible epilepsy 
with seizures in the last five years, at least three were seizure free for at least one year at 
the end of follow-up.
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Chapter 5: The Study of Seizure Patterns in people with             
chronic epilepsy (Study 3)
5.1 Methods
5.1.1 Participants:
Participants, who all gave informed consent, were recruited sequentially from two 
specialist epilepsy clinics at the National Hospital for Neurology and Neurosurgery 
between March 2008 and March 2010.  Those eligible for inclusion had a history of 
established refractory epilepsy, defined as active epilepsy (seizures in the past two
years) at least five years after onset and had been treated with at least two AEDs during 
that time. People in whom an alternative diagnosis or a diagnosis of non-epileptic 
seizures was considered, or who had had epilepsy surgery, were excluded.  Data were 
collected in all cases by the completion of a short questionnaire by the participants, 
including a one-to-one interview to identify periods of remission (if any) as well as to 
ascertain seizure frequency in the previous year, and by a review of medical notes. 
5.1.2 Seizure patterns:  
Seizure patterns were determined. These were adapted from those previously described 
in a primary care study (Goodridge and Shorvon, 1983). Remission was defined as the 
presence of a period of at least two years during which no seizures occurred. All 
participants had active epilepsy at the time of inclusion in the study, and could be 
categorised into two groups according to seizure pattern: 
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 continuous seizure pattern - no period of remission had occurred since the onset 
of the epilepsy 
 an intermittent pattern - at least one period of remission had occurred since the 
onset of the epilepsy 
In addition we identified a number of people who were in late terminal remission (two 
or more years seizure free at the time of enrolment) but who had had a previous 
continuous pattern. 
Factors (age, age of onset, gender, seizure type, epilepsy syndrome, current and total 
number of AEDs, seizure frequency in the past year, aetiology, history of SE, Vagus 
Nerve Stimulator implantation) which were potential determinants of the different 
seizure patterns in people with refractory epilepsy, were investigated. 
5.1.3 Seizure and syndrome classification: 
The age of onset of seizures, the time since the last seizure (in days) and the 
predominant seizure type experienced by the individual were recorded. Seizures were 
classified according to the 1981 seizure classification (ILAE, 1981) (simple partial 
seizures, complex partial seizures or primary generalised and secondary generalised 
seizures) although a new classification for epileptic seizures and syndromes has recently 
been proposed (Berg et al., 2010). The epilepsies were classified as cryptogenic partial 
epilepsy, symptomatic partial epilepsy, idiopathic generalised epilepsy (IGE) or 
unclassified whether partial or generalised.  Seizure frequency was classified into three 
categories: no seizures, 12 seizures or fewer, or more than 12 seizures in the previous 
year. 
The information was entered into a secure anonymised database.
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5.1.4 Ethical approval: 
The study was approved by the Joint Research Ethics Committee of the National 
Hospital for Neurology and Neurosurgery and the UCL Institute of Neurology. (REC 
reference 07/H0716/99)
5.1.5 Statistical analysis: 
Analysis was carried using STATA version 10 and SPSS v17. Categorical data was 
compared using the Chi-Squared test or, where appropriate, the Fisher’s Exact Test.  
The number of current AEDs taken and total AEDs ever taken were grouped for 
analysis.  Normally distributed data were analysed using Student’s t-tests, while non-
normally distributed data were analysed using the Mann-Whitney test.  All p-values 
were 2-sided.
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5.2 Results
We included 290 people, of whom 169 (58%) were female in the study. The mean age 
was 41.0 (SD 12.3) years, with a mean age of onset of seizures of 14.9 (SD 10.3, 
median 13) years. 
Seventy percent (204) of the participants had had a continuous pattern of seizures over 
the time of follow up (i.e. had had no periods of remission of 2-years or more) and 86 
(30%) had an intermittent pattern (i.e. with at least one previous period of remission). In 
these two groups, the demographics and clinical features (Table 20), the seizures types 
(Table 21) and seizure frequencies (Table 22) are shown.
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Table 20: Basic demographics and epilepsy features
Legend: Vagus Nerve Stimulation (VNS), Status Epilepticus (SE), Cerebrovascular 
Disease (CVD).
Continuous Pattern 
(N=204)
Intermittent Pattern 
(N=86)
Total number of AEDs ever 
taken
Mean 8.1, SD 4.1, 
median 8 (range 2-21)
Mean 6.6, SD 3.3, 
median 6 (range 2-16)
Number of current AEDs Mean 2.4, SD 1.0, 
median 2 (range 0-5)
Mean 2.2, SD 0.8,
median 2 (range 1-4)
Female 120 (58.8%) 49 (57.0%)
Age in years Mean 40.5, SD 12.4
Median 39.5 (range 16-75)
Mean 42.2, SD 12.2
Median 39 (range 24-69)
Age of first seizure (years) Mean 15.6, SD 11.0
Median 14 (range 0.5-68)
Mean 13.3, SD 8.3
Median 13 (range 0.5-39)
Duration of epilepsy (years) Mean 24.9, SD 13.4, 
Median 23.5, 
(range 5-65)
Mean 28.9, SD 13.6 
Median  28.5 (range 5-60)
Normal Imaging 127 (62.6%) 56 (65.9%)
History of SE 45 (22.1%) 16 (18.6%)
Learning Disability 10 (4.9%) 2 (2.3%)
VNS 13 (6.4%) 1 (1.2%)
Hippocampal Sclerosis 25 (12.3%) 13 (15.1%)
Cortical dysplasia 13 (6.4%) 3 (3.5%)
CVD 26 (12.7%) 7 (8.1%)
Multifocal pattern on EEG 30 (14.7%) 9 (10.5%)
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Continuous Pattern 
(N=204)
Intermittent Pattern 
(N=86)
Seizure type
Simple partial seizures 19 (9.3%) 3 (3.5%)  
Complex partial seizures 112 (54.9%) 43 (50%) 
Secondary generalised seizures 38 (18.6%) 19 (22.1%) 
Generalised seizures* 35 (17.2%) 21 (24.4%) 
Syndrome
IGE 32 (15.7%) 18 (20.9%) 
CPE 92 (45.1%) 39 (45.3%) 
SPE 74 (36.3%) 23 (26.7%) 
Unclassified 6 (2.9%) 6 (7.0%) 
Table 21: Frequency of the predominant seizure type and epileptic syndromes in seizure 
patterns
*Primary generalised seizures or generalised not determined if focal or generalised in 
onset
Legend: Idiopathic Generalised Epilepsy (IGE) Cryptogenic Partial Epilepsy (CPE), 
Symptomatic Partial Epilepsy (SPE)
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Seizure Pattern No seizures in last 
year (%)
≤ 12 seizures in 
last year (%)
> 12 seizures in 
last year (%)
Continuous 5 (2.5%) 45 (22.1%) 154 (75.5%)
Intermittent 6 (7%) 37 (43.0%) 43 (50.0%)
Table 22: Seizure frequency in the previous 12 months in people with continuous and 
intermittent seizures patterns
Neither current age (p=0.26) nor age of onset (p=0.22) was significantly different 
between those with continuous and intermittent seizure patterns. The total number of 
AEDs ever taken was significantly different between the two groups, being higher in the 
continuous group than in the intermittent (chi squared = 11.2, df = 3, p=0.01). (Duration 
of epilepsy differed between the two groups (see table 1), but as this was not an 
independent variable, it was not included in this analysis). People with a continuous 
pattern also had more seizures in the past year than those in the intermittent group (Chi 
squared = 18.5, df = 2, p<0.001) (Table 21). 
In those who had a continuous pattern of seizures, 81% (166) had never experienced 
even a six-month period of seizure freedom.
In the intermittent pattern group, the majority (81.4%) had had only one period of 
remission. For 29 people (33.7%) in the intermittent group, the first (or only) remission 
started within the first five years after seizure onset (early remission). Comparing those 
with early and late remissions (starting after 5 years duration), there was no difference 
in seizure severity, total or current number of AEDs, age or age of onset.  
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A further 32 people who were in late terminal remission (who had a history of 
continuous seizures for at least five years and who then entered terminal remission 
(seizure free for two or more years at the time of the study)) were identified. These 
people did not meet the inclusion criteria and were excluded from the comparative 
analysis. The median number of AEDs tried was 6 (IQR 4.5, 8; range 2 to 11) and the 
median number of current AEDs was 2 (range 0 to 3).
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Chapter 6: The Study of the Impact of Medication change 
in People with Chronic Epilepsy (Study 4)
6.1. Methods
The methodology of the study of the study has been previously described (Luciano and 
Shorvon, 2007). People were retrospectively identified who had chronic uncontrolled 
epilepsy and who were commenced on a new AED (265 drug changes in 155 people) 
during a 24-month period (01/01/2002 – 31/12/2003). All had to fulfil the following 
criteria: (1) have active epilepsy (defined as at least one seizure a month in the previous 
three months) (2) a history of epilepsy for at least five years (3) age 16 years or older at 
the time of inclusion (4) a minimum follow-up in clinic of 12 months after the drug 
change. (5) a response to treatment that was easily quantifiable.  They were excluded if 
there was a suspicion of non-epileptic seizures, a history of poor drug adherence or poor 
outpatient attendance.
The seizure frequency in the three months prior to starting on the first new AED was 
recorded and was used as the baseline seizure frequency for comparison throughout 
follow-up.  Follow-up in this cohort was previously reported up to the end of June 2005. 
Follow-up is now extended follow up to the end of December 2009 or time of death. 
Those who subsequently underwent epilepsy surgery (excluding Vagus Nerve 
Stimulators (VNS) implantation) were followed up to the time of surgery. 
The primary endpoint was the response to the addition of the new AED compared with 
the baseline seizure frequency recorded. Response was categorised into three groups: 1) 
Seizure free (for one year or more at last follow-up 2) 50-99% reduction in seizure 
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frequency compared with baseline seizure frequency and 3) less than 50% reduction in 
seizure frequency. 
In the previous analysis, three factors (duration of epilepsy, number of previous AEDs 
tried and epilepsy syndrome) were found to be predictive of subsequent seizure 
freedom. This analysis was repeated using the duration of epilepsy, the syndrome and 
the number of previous AEDs at the time of the first drug change to predict seizure 
outcome at the end of follow-up. Other factors such as age, age of onset, seizure type, 
sex or number of concomitant AEDs were also analysed to determine if they influenced 
seizure prognosis. In contrast, the drug added was previously not found to influence 
seizure outcome. 
Analysis was carried out using STATA version 10 and SPSS version 17. Categorical 
data was compared using the Chi-Squared test or, where appropriate, the Fisher’s Exact 
Test.  Seizure outcomes at the end of the initial and later follow-up periods were 
compared using the Stuart-Maxwell test. Kaplan-Meier analysis was used to estimate 
time to seizure recurrence in those who became seizure free (for one year or more). 
Time to event was defined as the duration from the date of first seizure freedom to the 
date of seizure relapse or to the date of the last clinic visit if seizure relapse had not 
occurred.  
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6.2 Results
Of the original 155 registered in the study, further follow-up data was available on 139 
(90%), of whom 67 (48 %) had a greater than 50% reduction in seizure frequency at 
follow-up in 2009.
Two people (1.4%) died and five people (3.6%) underwent epilepsy surgery during the 
follow-period.  Complete follow-up to 31st December 2009 was achieved in 118 (85%). 
The mean follow up was 6.7 (SD 1.1, median 6.9) years. In total 448 drugs changes 
(Table 23) were made (468 in the original cohort of 155) of which 228 (50.9%) were 
drug switches. In addition, 12 people had a VNS implanted.
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Drug Number of changes (n=448)
Levetiracetam 
Clobazam
Pregabalin
Topiramate
Zonisamide
Lamotrigine
Sodium Valproate
Carbamazepine
Oxcarbazepine
Phenytoin
Lacosamide
Tiagabine 
Gabapentin
Acetazolamide
Clonazepam
Phenobarbital
Primidone
Lorazepam
Midazolam 
Rufinamide
Vigabatrin
106
51
50
41
38
23
22
19
19
19
17
15
10
7
3
2
2
1
1
1
1
Table 23: List of drug changes (AEDs started) in the 139 people with extended follow-
up
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The drug with the highest proportion of positive responses was Carbamazepine (47%) 
followed by Levetiracetam (45%) but there were no statistically differences in response 
rates.
The treatment responses are summarised in Table 24.
Seizure Outcome1 Total n (%) (N=448)
Less than 50% Reduction in Seizure 
Frequency
336 (75%)
50-99% Reduction in Seizure Frequency 74 (17%)
Seizure Freedom 37 (8%) (AED changes in 33 people )2
Table 24: Seizure outcome following individual medication changes in the 139 people 
with prolonged follow-up. 
1Seizure outcome unknown in one person following one additional medication change. 
2Four people who had at least one year seizure freedom on one AED (one person having 
separate periods of seizure freedom), attained a further period of seizure freedom on 
addition of a further AED (the original AED being discontinued because of relapse or 
side-effects) 
Seizure outcome at the end of the original follow-up was strongly predictive of outcome 
at the end of the later follow-up (Stuart-Maxwell p=0.03). In particular, 64% of those 
who were seizure-free at the end of the original follow-up were seizure-free at last 
follow-up. Similarly 69% of those with less than 50% improvement remained so at last 
follow-up. Outcomes are summarised in Table 25. 
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Outcome in 2004 Outcome in 2009 N
Seizure free (N=25) Seizure free 16
>50% improvement 8
<50% improvement 1
>50% improvement (N=26) Seizure free 3
>50% improvement 13
<50% improvement 10
<50% improvement (N=88) Seizure free 7
>50% improvement 20
<50% improvement 61
Table 25: Seizure outcomes in 2004 and 2009 in the cohort of 139 people
In contrast, the epilepsy syndrome (Chi squared = 5.69, df = 4, p=0.2) and the duration 
of epilepsy (< or ≥ 10 years) (chi squared = 0.05, df = 2, p=0.97) were no longer 
predictive of seizure outcome while the number of previous AEDs tried at study entry 
(< or ≥ 5 AEDs) was of borderline statistical significance (chi squared = 5.9, df = 2, 
p=0.052).
Seven of those seizure-free at last follow-up had five or more previous drug failures,
and two of these had tried more than six previous AEDs (the number of previous AED 
trials was unknown in one). 
As in the previous analysis age, age of onset, gender or seizure type, were not 
associated with seizure outcome. In contrast the number of concomitant AEDs (0, 1 or 2 
or more concomitant AEDs) was associated with seizure prognosis (Chi-squared = 10.5, 
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df=4, p=0.033), with those taking two or more AEDs less likely to attain seizure 
freedom.
VNS was implanted in 12 people with severe refractory epilepsy as evidenced by a 
mean duration of epilepsy of 30.7 (SD 13.0, median 30.5) years, a median of 13.5 
AEDs tried (range 10 to 16) and two concomitant AEDs (range 1 to 4). VNS 
implantation resulted in a greater than 50% reduction in seizure frequency in one while 
another person reported some symptomatic improvement (seizures less severe and 
shorter in duration) without a significant reduction in seizure frequency.  
Two people died during the study; one had a greater than 50% reduction in seizures up 
to the time of death. The other person continued to have severe refractory epilepsy 
without improvement up to the time of death, despite an initial improvement in seizure 
control. Twenty five people were seizure free at the end of the previous follow-up in 
2004. Of these, 16 (64%) were seizure free at the end of the current follow-up; 11 
(69%) of these remained seizure free throughout, with the remaining five people 
relapsing and subsequently re-entered remission. (One person had three separate periods 
of at least one year of seizure freedom).
In addition to the 35 people seizure free at the start or the end of the current follow-up, 
there were an additional 13 people (9.4%) who had a significant period of seizure 
freedom of at least six months (range 6 to 10 months - three people) or one or more 
years (range 1 to 3.75 years - ten people) during the follow-up period but who were not 
seizure free at either end-point.. Consequently 45 (32%) people in the cohort had at 
least one year of seizure freedom during follow-up; 33 (73.3%) occurred in the context 
of a clear medication change. Two of this group (plus one other person without any 
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significant period of seizure freedom) had complete cessation of their generalised 
seizures as a result of a medication change but had a recurrence of myoclonus. In total 
20 had remained seizure free up to the end of follow-up after entering remission with a 
mean period of seizure freedom of 4.9 (SD 2.09) years. 
Time to relapse in those who had a period of seizure-freedom is shown in Figure 7.  
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Figure 7: Kaplan-Meier analysis of the probability of remaining seizure free
Of the 45 people who achieved at least one year of seizure freedom during the course of 
follow-up, 25 (55.6%) subsequently relapsed. Comparing those who remained seizure 
free (n=20) with those who eventually relapsed (n=25) neither epilepsy syndrome 
(p=0.33) nor the number of previous AEDs (< or ≥ 5 AEDs, p=0.37) were predictive of 
subsequent relapse. In contrast, those who had a duration of epilepsy of ≥ 10 years and 
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became seizure free were less likely to relapse (43.3%) than those with an epilepsy 
duration of < 10 years (83.3%) (p=0.02) (Figure 8).
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Figure 8: Kaplan-Meier analysis of the probability of remaining seizure free comparing 
the effect of epilepsy duration 
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Chapter 7: The Systematic Review of the Prognosis of 
Convulsive Status Epilepticus (Study 5)
7.1 Methods: search criteria 
To carry out this review, I searched Medline and PubMed for all papers published from 
January 1st 1990 up to December 31st 2009 with the terms “status epilepticus” combined with 
the terms “outcome”, “mortality”, “morbidity”, “fatality”, “prognosis”, “coma”, “death” and 
“incidence”, “prevalence” and “epidemiology”. Only papers written in English and French 
were reviewed. From an initial 3,043 articles identified, all but 529 articles were excluded on 
the basis of the title and abstract. 
A further search of Medline and PubMed was carried out for all papers published from 
January 1st 1990 up to December 31st 2009 with the terms “status epilepticus” combined with 
the terms “mortality”, “death”, “duration” “EEG”, “outcome”,  “morbidity”, “prognosis”, 
“coma”, “cognition ”.and “intellectual decline”.  Only papers written in English and French 
were reviewed. From an initial 3,311 articles identified, all but 437 articles were excluded on 
the basis of the title and abstract.
Exclusion criteria included case reports, review articles, commentaries, treatment protocols 
and studies with fewer than 30 people. Papers specifically concerned with non-convulsive SE 
were excluded but papers where figures for convulsive and non-convulsive SE were given 
were considered. Inevitably a distinction between convulsive and non-convulsive SE was not 
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always made in some series and these papers are included. Both prospective and retrospective 
population- and hospital-based series were included. The search identified seven population-
based studies with the remainder of the studies cited being hospital-based. The reference lists 
of the identified articles were then examined for additional relevant studies. Common causes 
of SE were taken to be causes listed in at least one of the population-based studies of SE 
which had an incidence of greater than one percent.. The major studies of convulsive SE in 
the developing world are also reviewed in order to identify the predominant aetiologies of 
convulsive SE, although no attempt is made to analyse prognosis by aetiology, as is done for 
studies from the developed world.
Status epilepticus was defined according to the ILAE guidelines for epidemiologic studies on 
epilepsy as a single seizure of at least 30 minutes duration or a series of epileptic seizures 
during which function is not regained between ictal events in a period of at least 30 minutes
(Commission on Epidemiology and Prognosis ILAE, 1993). This definition was adapted by 
the vast majority of studies reviewed, when a definition was given.
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7.2. Major aetiologies in status epilepticus
In examining the seven population-based studies of SE (Table 26, Page 157), 11 major causes 
(plus cryptogenic/idiopathic) were identified, with the relative frequencies for each cause 
shown in Table 25.
The comparative figures for each cause, taken from several studies looking at the incidence, 
aetiology and prognosis of SE from Africa, Trinidad, India and more recently China, are 
shown in table 26. All of these studies were case series, not epidemiologically based, and 
although the range of aetiologies was very different from those in Western Europe and the 
US, it was not possible to derive any figures of frequency. Thus, although it seems likely that 
frequency is higher in the developing world primarily because of the high rate of infection, 
there are no figures to confirm this.
The prognosis of SE, in relation to each specific aetiology or, where appropriate, two 
aetiologies together, is reviewed here.
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Richmond2 Rochester Switzerland3 Hessen California Bologna London8
Low AEDs 21% (P)/34% (A) 1% 8.1%4 8.7% 3.9% - 0.5%
CNS Infections 52% (P)/5% (A) 8.5% - 0% 0.6% - 10.2%
Febrile - 8% 14.9%5 0% 2.5% - 32%
CVA 10% (P)/22% (A) 19.1% 30.5%6 66.7%1 12.4% 41% 0.5%
Alcohol 13% (A) - - 8.7% 8.1% 7% 0%
Trauma 3% (A) 4.5% - 7.3% 0.4% 10% 1.5%
CNS Tumours 7% (A) - - 12% 1.8% 5% -
Metabolic disturbance 5% (P)/15% (A) 3.5% - 8.7% 8.7% 24%7 3%
Degenerative brain disease/CNS 
anomalies
38% (P)/25% (A) 5.5% - 26.7% 13.3% 10% 32%
Medication induced/overdose 2% (P)/3% (A) 2% - 10.7% - - 1%
Anoxia/Hypoxia 5% (A) (anoxia)
5% (P)/13% (A) (hypoxia)
10% Excluded - 8% 9.1% 0.5%
Cryptogenic 5% (P)/3% (A) 13.5% 8.7% 8.7% - 11% 7%
158
158
Table 26: Major Aetiologies of Status Epilepticus1
A = adults;   P = paediatric
1 Some studies only give percentages for some aetiologies
2 In the Richmond study, aetiologies were given separately for the paediatric and adult populations
3In the EPISTAR study, aetiologies were given separately for people with and without a history of epilepsy
4 Percentage of the total cohort. (Low AEDs was the cause of SE in 18.9% of people with epilepsy)
5 People with prior history of epilepsy only
6 People with no prior history of epilepsy only
7 Combination of systematic metabolic disorders and postanoxic encephalopathy
8 Paediatric population
.
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Nigeria Trinidad Brazil Tunisia India Senegal Thailand Iran Congo Kenya Ethiopia China 
Study design R R P R P R R R R R R R/P
Duration 10 
years
18 
months
1989-
1993
1990-
1997
1994-
1996
1988-
1998
1981-
2000
1999-
2004
1998-
2003
2002-
2003
1997-
2007
1996-
2007
Number 41 41 111 139 85 697 32 135 607 3883 119 220
History of 
seizures
- - 59.4% 10% 20% 9.9% 75% 37% 14.5% 30.8% 38.7% 50%
Aetiology
Febrile seizures - 5% 5.4% 41% - 8.6% 0% 51.1% -
AED non 
compliance
- 18.9% 
(31.8%)
10% 20% 9.9% 9.4% 28.2% 3.8% 5.9% 17.6% 15.5%
CNS Infections 41.5% 15%2 10.8% 18.7% 28% 67% 65.6% 7.4% 74.5%1 8.0%4 36.1% 32.7%
Metabolic 34.1% 10.8% 10.1% 11% 4.3% 0% 2.9% - 13.4% 11.4%6
Stroke 14.6% 9.9% 5.8% 15% 8% 0% 0% - 12.6% 10.90%
Progressive 
Symptomatic
9.8% - 2.% 7% - 1.2% 3.1% 0% - = 10.9% -
Remote 
Symptomatic
- 51% - 6% 7% - 0% 0% - - - -
Idiopathic - 29% 25.3% 6% 19% - 18.8% 8.9% - 16.8% 7.7%5
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Mortality 100% 0% 19.8% 15.8% 10.50% 24.8% 6.3% 12.6% 26.5% 15.2% 20.2% 15.9%
Morbidity - 4.9% - 36% 13.6% 56.3% 
(66.7% 
severe 
n.d.)
27.3% 2.9% 11.9% 3.4% N/A
Inclusion 
Criteria
All 
ages 
(post-
Mortem 
Study)
All ages 
(51% 
less than 
10)
All 
ages
Study 
in 
infants 
(mean 
age 11 
months)
All  
ages 
(mean 
age 33)
All 
ages 
(61% 
aged 
less 
than 
10)
Paed 
study 
(mean 
age 
6.5yrs)
Paed. 
Study
Paed. 
study
Paed. 
Study
Children 
aged 
<13 
years 
excluded 
All 
ages 
(12% 
aged 
<16)
R=Retrospective, P=Prospective.  Paed.=Paediatric, n.d=neurological deficit
1=In this study, 568 cases (93.6%) were associated with fever, the common identified cause was malaria (68.5%) (Cerebral or otherwise). Sepsis was 
responsible for 9.5% of cases.
2=15% of causes listed as acute symptomatic
3=Confirmed (155) or probable cases (233) of CSE4=The primary causes of CSE in the study were infectious: malaria without febrile convulsions (FC) 29.4%, 
malaria with FC 23.7%, FC secondary to other infection 3.6% and acute bacterial meningitis 8%
5=The number of CNS tumours and developmental malformations combined
6=The number of toxic, hypoxia and metabolic cases combined
Table 27: Studies of Status Epilepticus in the developing world
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7.3 Frequency and prognosis of different aetiologies
7.3.1 Stroke and status epilepticus 
In epidemiological studies stroke has been shown to be a significant cause of SE in the 
elderly particularly in those with no prior history of seizures (table 26).  In the 
California study (Wu et al., 2002), acute stroke accounted for only 1.6% of cases but 
was associated with the second highest mortality rate (25.6%). In a review of 193 
people with refractory SE, stroke was the underlying cause in 20% (Claassen et al., 
2002).
In a population-based study from Germany (Knake et al., 2006), the long-term mortality 
rate in people with a first episode of cerebrovascular-related SE was 57% compared 
with 48% in people with acute stroke without SE. Multivariate analysis showed that, 
after six months, people with SE had twice the risk of death compared with people with 
stroke but without SE (hazard ratio of 2.12, 95% CI 1.04, 4.32, p=0.039). 
In a comprehensive study of the frequency of SE and stroke, 3,205 people with first 
time strokes over an 8-year period were reviewed (Rumbach et al., 2000). Of these, 159 
had first time post-stroke seizures and SE was diagnosed in 31 people, with SE being 
the presenting symptom of epilepsy in 17 (SE occurring within 14 days of the stroke in 
seven). In four people stroke began with SE, and in the remaining ten people SE 
developed after one or more seizures.  After a follow-up of 47 months, 15 people had 
died, with five deaths directly related to SE. Additional seizures occurred in eight of the 
initial SE cases and in all 14 people in whom SE was not the first post-stroke 
manifestation of epilepsy.. The study concluded that SE in stroke has a poor prognosis 
162
162
but that initial SE as a first epileptic symptom of epilepsy was not predictive of
developing subsequent seizures (Rumbach et al., 2000). 
A smaller study looked at stroke as a remote symptomatic cause of SE in a cohort of 
people with post-stroke first time seizures. Of 1,174 people with stroke, 180 had 
seizures. Of these 180, 17 (9%) developed SE. The risk of developing SE was higher in 
those with greater disability (Rankin scale > 3, odds ratio 4.36). Recurrent SE occurred 
in five people, all of whom had a first episode of SE within seven days post-stroke. 
Early onset SE was associated with a higher risk of recurrence of SE (p=0.003) and 
higher mortality (p=0.04) (Velioglu et al., 2001).  
Examination of the US Nationwide Inpatient Sample over an eight year period 
identified 718,531 hospitalisations of people with acute ischaemic stroke (AIS) of 
whom generalised convulsive SE (GCSE) developed in 1,415 (0.2%) (Bateman et al., 
2007). Of 102,763 who were admitted with intra-cranial haemorrhage (ICH), GCSE 
developed in 266 (0.3%). In-hospital mortality was significantly higher in those with 
GCSE as well as AIS or ICH, particularly if analysis was restricted to people with 
length of stay greater than one day. (AIS: 28.4% vs 9.2%, p<0.01; ICH: 30.1% vs 
24.3%, p=0.03). Other markers of morbidity such as pneumonia, the need for 
mechanical ventilation, tracheotomy and length of stay greater than seven days were all 
statistically associated with concomitant SE. In this study, no attempt at defining SE 
was made.  In the Northern Manhattan Stroke Study (NOMASS), of 904 people with 
stroke, 37 (4.1%) patients developed early seizures. SE occurred in ten people, 1.1% of 
the entire cohort of stroke patients and 27% of all patients with post stroke epileptic 
seizures (Labovitz et al., 2001).
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A cohort of 83 people with SE and stroke (44 with acute and 39 with remote stroke) and
159 people with acute stroke only (controls) were prospectively followed (Waterhouse 
et al., 1998). People with an acute stroke and SE had a mortality of 39%, almost three-
times as high as in those with acute stroke only (14%) or those with SE and remote 
stroke (5%), (p<0.001). In addition there was almost an 8-fold difference in mortality 
between the acute stroke and SE group and the remote stroke and SE group. This 
difference was not accounted for by age, sex or radiographic lesion size. Logistic 
regression analysis demonstrated a statistically significant synergistic effect of 
combined injuries of cerebral vascular ischaemia and SE (Waterhouse et al., 1998).   
SE occurring after stroke is associated with a higher functional disability, and poor 
functional disability was the only identified predictor of SE in one study (Velioglu et 
al., 2001). This study found that early-onset SE (within the first seven days after stroke) 
was associated with a higher risk of further episodes of SE and higher mortality rate 
than those with late onset SE (Velioglu et al., 2001). Stroke severity and mortality were 
also found to be higher in people with early-onset SE in other studies (Rumbach et al., 
2000; Afsar et al., 2003).  
In a series from Turkey (Afsar et al., 2003), 121 people admitted to a single centre with 
SE over a three-year period were identified. The aetiology of the SE was stroke in 30 
(24.8%). Most people (22 (73%)) had non-convulsive SE. Two-thirds were defined as 
early-onset (occurring with two weeks) and only ischaemic stroke was associated with 
late-onset SE. Overall mortality was 43.3%, and disability (as defined by NIHSS 
scores) in the early-onset group was significantly associated with increased mortality 
(p=0.02). This mortality figure is similar to that found for stroke-related SE (26.3%) by 
others (Towne et al., 1994). In a retrospective study of 107 episodes of SE in China, 
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cerebrovascular disease was the most common aetiology (27%) and was the strongest 
predictor of poor outcome following SE with an odds ratio of 5.57 (95% CI 1.45, 21.41, 
p=0.001) (Hui et al., 2003).
In a large study on mortality rates in SE, based on hospital coding and without clear 
definitions made, cerebrovascular disease was a predictor of in-hospital mortality with 
an odds ratio of 2.08 (95% CI 1.13, 3.82) and a mortality rate of 22% (p<0.0001) and 
was also a predictor for the need for mechanical ventilation (p<0.0001; Koubeissi and 
Alshekhlee, 2007).
7.3.2 Alcohol, substance abuse and drug-induced status epilepticus 
Alcohol abuse (intoxication or withdrawal) has been found to be a common cause of SE 
in many population-based and hospital-based studies, with a reported range of 8.1 to 
25% of SE caused alcohol, although alcohol was not reported to be a major cause in 
some studies (such as the Minnesota (Hesdorffer et al., 1998a) and EPISTAR (Coeytaux
et al., 2000) studies. Alcohol-related SE is generally associated with a favourable 
outcome with most studies reporting a mortality rate of 0 to 10% (9.6% in the California 
study (Wu et al., 2002).
In an examination of the records of 249 adults with GCSE admitted to a single centre 
over a 12 year period, 27 people (10.8%) in whom alcohol abuse was the only 
identifiable precipitating cause were identified (Alldredge and Lowenstein, 1993). In 12 
(44%), SE was the first presentation of alcohol-related seizures. At the time of 
discharge, 22 (81.5%) had returned to baseline although time to gross recovery of 
mental status was more than 12 hours in 24 of the 27. Four people (14.8%) had new 
neurological deficits at the time of discharge; significant gait instability (one), moderate 
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short-term memory deficits (one), and more diffuse cognitive dysfunction (two). The 
only death occurred in a 60 year old in whom the SE continued despite four hours of 
treatment (Alldredge and Lowenstein, 1993).
  
Drug toxicity or abuse is generally a more common cause of SE in hospital-based 
studies than in population-based studies, and the rate also varies markedly in different 
locations, with reported rates of 2 to 14% of cases. Cocaine (43%) and theophylline 
(21%) were the most commonly implicated drugs in the San Francisco study. Ten 
(71%) of those with drug toxicity as a cause for SE had a favourable outcome. The 
mean duration of SE however, was markedly different in the four (29%) with a poor 
outcome (severe neurological deficit or death; 1.9 hours) compared with people with 
favourable outcome (32.5 hours; Lowenstein and Alldredge, 1993).  In a study of 
medically ill patients in ICU who developed SE approximately one month after 
admission, theophylline toxicity was found to be a primary or contributing cause in 25% 
and was associated with an overall mortality rate of 61% (Delanty et al., 2001).  In 
another study drug toxicity-related cases of SE had a case fatality of 16.8% (Towne et 
al., 1994). 
7.3.3 Status epilepticus and antiepileptic drug reduction or withdrawal or low 
antiepileptic drug levels 
In people with a prior diagnosis of epilepsy, non-compliance with AEDs is often cited 
as the most common cause of SE (DeLorenzo et al., 1996). This may be the case in 
adults, but is not so in children. In the NLSTEPSS (Chin et al., 2006), only one case of 
convulsive SE was attributable to low antiepileptic drug concentrations, although low 
serum levels of AEDs were the cause in 21% of SE in children in the Richmond study 
(DeLorenzo et al., 1996).
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In older hospital-based series, ‘non-therapeutic’ anticonvulsant blood levels at the time 
of presentation was reported as the cause of SE in 3.9 to 34% of episodes of SE but with 
a low associated mortality (Shorvon, 1994).
The San Francisco Hospital Study found that 25% of episodes of SE were related to 
withdrawal of AEDs, with 90% of people having a good outcome (defined as 
unchanged from baseline, or mild neurologic deficits that allowed independent living) 
such that the authors conclude “... that patients with a history of epilepsy who develop 
SE because of anti-convulsant drug withdrawal or break-through seizures can be 
expected to respond well to acute anticonvulsants” (Lowenstein and Alldredge, 1993). 
This is a conclusion which has been widely confirmed.
Several studies have looked at the different aetiologies of SE and the subsequent risk of 
developing SE refractory to standard first line treatments. In a study of 83 episodes of 
SE, low levels of AEDs were the primary cause of the SE in 27.7% of the non-
refractory cases but no refractory cases (p <0.001), allowing the authors to conclude 
that “SE caused by insufficient levels of AEDs is usually not refractory” (Holtkamp et 
al., 2005). Similarly low AED levels or a recent change in medication was found in 
31% of people presenting in SE in 78% of whom the SE was non-refractory (Mayer et 
al., 2002). In a study looking at the use of propofol in 31 episodes of treatment resistant 
SE in 27 people, five people had SE secondary to AED withdrawal, all of whom had a 
good outcome (Rossetti et al., 2004). Low levels are often taken as a surrogate measure 
of poor compliance or drug reduction, but this is not always the case. 
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7.3.4 Severe acute cerebral anoxia/hypoxia and status epilepticus 
Anoxia, usually after cardiac arrest in adults, can result in deep coma with myoclonic 
jerking, and this is assumed by some authorities, but not all, to be a form of ‘SE’ 
(Shorvon, 1994). This dichotomy of opinion is evident by the fact that post-anoxic SE 
cases were excluded from the EPISTAR study (Coeytaux et al., 2000).  In the 
population-based studies, anoxia is the cause in 8 to 13% of people with SE, with an 
associated mortality typically in the range of 60-80% although a mortality of 100% was 
reported in the Bologna study (four people) (Vignatelli et al., 2003). In this study the 
30-day case fatality rates were calculated with (39%) and without (33%) the post-anoxic
patients.  
In a study of 166 post-anoxic survivors of cardiac arrest treated with hypothermia, post-
anoxic SE was present in 24% with a mortality rate of 80% compared with the overall 
mortality rate of 71% (p<0.001). Post-anoxic SE was associated with a higher mortality 
regardless of the type of acute cardiac rhythm or hypothermia treatment (Rossetti et al., 
2007).
In a large study of mortality in convulsive SE hypoxia-ischaemic brain injury-associated 
SE was the strongest predictor of mortality with an odds ratio of 9.85 (95% CI 6.63, 
14.6) and a mortality rate of 69% and was a significant risk factor for the need for 
mechanical ventilation (p<0.0001) (Koubeissi and Alshekhlee, 2007). In an earlier 
study anoxia induced SE was responsible for 11.9% of all deaths with a mortality rate of 
60% and was associated with the highest odds ratio for mortality (OR 8.2, p<0.0001)
(Towne et al., 1994). 
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In a study examining the outcomes of 114 people following cardiopulmonary 
resuscitation 50 (44%) had seizures or myoclonus. SE occurred in 36 (32%), of whom 
10 (9%) had SE other than Myoclonic (MSE), only one of whom was alive at six
months. Nineteen people (17%) had MSE, three (16%) of whom were alive at discharge 
and none alive at six months. Seven (6%) had status myoclonus other than MSE, none 
of whom were alive at discharge. When the subgroups with SE were considered 
individually, only MSE was associated with a significantly poorer survival (p<0.01)
(Krumholz et al., 1988).
It is clear that people with MSE following cardiopulmonary resuscitation have a poorer 
prognosis than those without myoclonus. In a series of 50 people with myoclonus 
following resuscitation 45 (90%) died within two weeks while the remainder remained 
in a permanent vegetative state (Thomke et al., 2005). Similarly in a series of 107 
consecutive comatose patients after cardiac arrest, 40 had MSE. All patients with MSE 
died whereas 20 of the 67 people without MSE regained consciousness (Wijdicks and 
Young, 1994).
In the AAN practice parameter of the prediction of outcome of comatose patients 
following cardiopulmonary resuscitation, MSE within the first 24 hours following 
primary circulatory arrest was recognised as a predictor of poor outcome (Wijdicks et 
al. 2006).
7.3.5 CNS infections, encephalitis and status epilepticus
Acute CNS infections and encephalitis are important causes of SE particularly in 
children, typically accounting for about 1-12% of all episodes of SE in various series 
from the developed world, and are a more common cause of SE in children than in 
adults. In the California study, acute CNS infection was the cause of SE in 0.6% of 
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cases with a median age of 42 years and a mortality rate of 32.6% (Wu et al., 2002). In 
the NLSTEPSS (Chin et al., 2006) 11 children (6%) with SE had acute bacterial 
meningitis and seven (4%) a viral CNS infection. Moreover three of the seven children 
who died had acute bacterial meningitis. The mortality rate for CNS infections in a large 
in-hospital study of SE was three percent (Koubeissi et al., 2007).
In a retrospective study of all admissions to a paediatric ICU in Montréal over a ten-
year period, there were 147 admissions with SE of which 20 (13.6%) were due to 
bacterial meningitis and 20 (13.6%) due to encephalitis; both were associated with high 
morbidity and mortality (Lacroix et al., 1994). CNS infections were the cause of SE in 
10.6% of cases in another study and were associated with a 71.4% mortality rate 
(OR=13.88, p=0.014) (Sagduyu et al., 1998). CNS infections causing SE were found to 
be predictive of a poor outcome in a study from Hong Kong (adjusted OR 30.27, 
p=0.003) (Hui et al., 2003). 
The refractory nature of the SE induced by encephalitis and its rather poor outcome has 
been demonstrated in several hospital-based studies. In a review of 22 episodes of 
treatment resistant SE in children, presumed or agent-identified encephalitis was the 
underlying aetiology in ten children, four of whom died, five developed seizures and 
one returned to baseline (Sahin et al., 2001). Encephalitis was the cause of 22% of 
episodes of treatment resistant SE compared with only 4.3% of non treatment resistant 
SE (p <0.18) (Holtkamp et al., 2005). In a case series of 17 episodes of treatment 
resistant SE in children, treated with a continuous midazolam, four had viral 
encephalitis, one of whom died, two developed moderate to severe encephalopathy and 
one made a full recovery (Yaffe and Lowenstein, 1993).
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In a review of all episodes of SE presumed to be caused by encephalitis in the paediatric 
intensive care unit over a four year period, 46 children with SE and encephalitis were 
identified. Of these 20 (43.4%) developed treatment resistant SE with a 30% mortality 
rate. Of the survivors, all but one developed subsequent epilepsy and/or neurological 
deficits, and none returned to baseline. For those with treatment responsive SE, four 
died, 16 developed epilepsy or had a neurological deficit and only six returned to 
baseline (Lin et al., 2008). 
Population-based studies tend to show a rather more favourable outcome, with a lower 
frequency of treatment resistant SE. For instance, in the California Encephalitis Project 
(CEP) which is an ongoing project aimed at determining the cause of encephalitis, 
people identified with encephalitis were subdivided into three categories: refractory SE 
(defined as SE requiring anaesthetic coma for management (Group I); Non-refractory 
SE (Group II); and people without seizures (Group III). Four percent had refractory SE, 
40% non-refractory SE and 56% no seizures. People with refractory SE associated with 
encephalitis tended to be younger (median age 10 years) and had a poorer outcome with 
28% dying within two years and 56% neurologically impaired or undergoing 
rehabilitation (Glaser et al., 2008).
In a study of the clinical characteristics and factors of post-encephalic epilepsy in 44 
children from Taiwan, SE occurring as the first seizure (p<0.05) and herpes simplex 
encephalitis (p<0.01) were associated with a poor prognosis and an increased risk of 
developing intractable epilepsy (Chen et al., 2007). It should also be noted that there are 
two reports in the literature of people presenting with acute encephalitis associated with 
refractory, repetitive partial seizures (Saito et al., 2007).
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7.3.6 Cerebral Tumour and status epilepticus 
Brain tumours are an uncommon cause of SE, representing two to five percent of 
episodes of SE in most studies although they were responsible for 12% of episodes of 
SE in the Hessen study (Knake et al., 2001). The associated mortality rates are 0 to 
36%. 
One study has specifically looked at the clinical implications of SE in people with 
neoplasms (Cavaliere et al., 2006). Thirty five people were retrospectively identified 
with cerebral neoplasms and SE. Of these, 25 (71.4%) had a primary brain tumour, the 
most common of which was a high-grade glioma (11) followed by low-grade glioma 
(6). Ten people had systemic tumours with presumed or identified cerebral metastases. 
Fifteen (43%) had a prior history of seizures and 20 (57%) were on AEDs at the time of 
SE. SE occurred at the time of diagnosis in ten (29%), during tumour progression (23%) 
or while the tumour was stable (23%). Only one episode of SE occurred in a person 
during a confirmed period of tumour regression. At thirty days eight (23%) people had 
died with four dying during the hospitalisation for SE. The only statistically significant 
factor in predicting 30-day mortality was tumour histology (three people [27%] with 
primary brain tumours died compared with five people (50%) with systemic tumours 
(p=0.01). All episodes of SE were controlled. In further follow-up, age was associated 
with higher mortality (five people (71%) older than 70 years and 15 people (54%) less 
than 70 years died at a median of 44 and 154 days respectively, p=0.049) (Cavaliere et 
al., 2006).   
7.3.7 Trauma and status epilepticus 
Trauma is also an uncommon cause of SE, typically accounting for between 0 and 10% 
of episodes of SE in the major studies with an associated mortality of up to 20%. SE as 
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a result of head trauma was associated with 0% mortality in one large in-hospital study
(Koiubeissi et al., 2007). In a series of 94 people with moderate to severe traumatic 
brain injury who underwent continuous EEG, seizures were detected in 21 (22%), 
manifesting in six as focal motor twitching or atypical myoclonus and as non-
convulsive SE in two. All people with SE died, two as a result of sepsis following 
control of SE, three died as a result of progressive neurological deterioration and the 
final person died as a result of respiratory arrest following discharge (Vespa et al., 
1999).
In a study to compare the risk of mortality and subsequent unprovoked seizures, 262 
people with acute symptomatic seizures and 148 people with a first unprovoked seizure 
(all due to a static brain injury) were identified in Rochester. Traumatic brain injury 
(TBI) was the cause of provoked seizure in 91 (34.7%) with 91 (34.7%) being due to 
acute stroke and 80 (30.5%) due to acute CNS infection. Of the 148 people with a first 
unprovoked seizure, 37 (25%) had a previous history of TBI, 101 (69.2%) had a 
previous stroke and 10 (6.8%) had a previous CNS infection. Ten (11%) people with 
acute TBI had SE which was significantly less than that seen with acute stroke (36.3%) 
and acute CNS infections (58.8%). Similarly those with a history of TBI with a first 
unprovoked seizure were less likely to present with SE (16.2%) than those with a 
history of stroke (22.8%) or CNS infection (90%). The 30 day mortality was 11% in 
those with acute symptomatic seizure due to TBI while the ten year mortality was 
similar in those with acute symptomatic and unprovoked seizures with a history of TBI 
(Hesdorffer et al., 2009).
7.3.8 Metabolic disorders and status epilepticus 
Metabolic disorders are the cause of SE in two to 15% of episodes of SE in reported 
series with an associated mortality rate of up to 31% (Towne et al., 1994). Acute 
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metabolic disturbance (electrolyte imbalance, hypoglycaemia, hypocalcaemia or 
hypomagnesaemia) was the aetiology of SE in approximately three percent of children 
in NLSTEPSS (Chin et al., 2006). In the San Francisco Study, four percent of episodes 
of SE were due to metabolic causes, half of which failed to respond to first-line 
treatments. Metabolic causes were associated with poor outcome (severe neurologic 
deficit requiring full supportive care or death) in 65% (Lowenstein and Alldredge, 
1993). 
Acute metabolic causes were the aetiology of SE in 11.5% with a mortality rate of 31% 
in one early study (Towne et al., 1994). Acute metabolic causes, although relatively rare 
as a cause of SE were responsible for a high proportion of treatment resistant SE with 
reported rates of 20% (Claassen et al., 2002), 22% (Mayer, 2002) and 26% in various 
series and a corresponding mortality rate of 25% in one study (Rossetti, et al. 2004).
Indeed people with metabolic disorders presenting with SE were significantly more 
likely to require mechanical ventilation (p<0.0001) than people with SE due to other 
causes with a three-fold increase in mortality for those requiring mechanical ventilation 
compared with those who did not (7.43% vs 2.22%, odds ratio 2.79) (Koubeissi et al., 
2007).
7.3.9 Cryptogenic status epilepticus
Despite investigations, the aetiology of SE remains undetermined in many cases. In the 
Richmond study (DeLorenzo et al., 1996), approximately five percent of episodes of SE 
were classified as idiopathic with a mortality rate of 22%. In the Rochester study 
(Hesdorffer et al., 1998) 17.5% of episodes of SE were classified as 
idiopathic/cryptogenic, while the aetiology of SE was unknown in 13 (8.7%) one of 
whom died in the Hessen study (Knake et al., 2001). In the NLSTEPSS (Chin et al., 
2006), 21 (11.9%) were classified as idiopathic or cryptogenic with 0% mortality, while 
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in the San Francisco study (Lowenstein and Alldredge, 1993) the cause of SE was 
unknown in eight (5.2%); five (62.5%) had a good outcome. In a Dutch paediatric study 
the aetiology of SE was unknown in 110 (31.8%), 100 (91%) of whom had a good 
outcome, seven (6.3%) had associated morbidity and four died (Scholtes et al., 1994). In 
another study 14.2% of episodes of SE were classified as idiopathic with an associated 
mortality rate of 19.4% (Towne et al., 1994). The cause of SE was unknown in seven 
(8.4%) episodes of SE in a German study none of whom developed treatment resistant 
SE (p=0.017) (Holtkamp et al., 2005).
In a retrospective review of all people with idiopathic/cryptogenic seizures in Rochester 
over a 30 year period, 291 people with a first brief unprovoked seizure and 16 people 
with SE were identified. There were five deaths (all aged greater than 65) in those with 
SE. Compared with people with seizures, the adjusted relative risk for death in those 
with SE was 2.4 over ten years. This risk was more marked among those aged greater 
than 65 years (RR=5.1, 95% CI 1.6, 15.7) and for those with SE who later developed 
epilepsy (5/16, 31.3%) (RR=6.3, 95% CI 1.5, 26.0). The SMR for SE was 2.6 (95% CI 
0.8, 5.3) (Logroscino et al., 2008).
Auto-antibodies (VGKC-complex Abs,LGi1 and CASPR2-Abs, anti-NMDA Receptor 
Abs, GABAA Receptor Abs and Glycine Receptors Abs among others) have been 
increasingly recognised in the past few years as a potential cause of seizures and in 
particular encephalitis (Granerod et al., 2010; Dalmau et al., 2011; Vincent et al., 2011a; 
Vincent et al., 2011b). Autoimmune mediated encephalitis is more commonly 
associated with seizures than other causes of encephalitis (Granerod et al., 2010) with 
anti-NMDA receptor encephalitis (Dalmau et al., 2008; Irani et al., 2010) and LGi1 
antibody limbic encephalitis (Irani et al., 2011) particularly associated with seizures. 
Autoimmune–mediated status epilepticus is, however, rare (Tan et al., 2010) even in the 
175
175
context of confirmed autoimmune mediated encephalitis with seizures. In a series of 
100 people with anti-NMDA receptor encephalitis, 78% developed seizures during the 
course of the condition while eight people developed status epilepticus (which was 
refractory in six) (Dalmau et al., 2008). Nevertheless when status epilepticus does 
develop with autoimmune-mediated encephalitis, it is likely to be refractory to standard 
AED therapy and general anaesthesia.  The possibility of an autoimmune-mediated 
aetiology of status epilepticus is important to consider, particularly in the setting of 
super-refractory status epilepticus (status epilepticus that continues or recurs 24 hours or 
more after the onset of anaesthetic therapy) (Shorvon and Ferlisi, 2011) as treatment 
with immunosuppression can sometimes result in a good outcome (Neligan et al., 
2011c).  
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7.4 Other prognostic factors in SE
Other factors such as seizure duration, EEG findings, patients’ level of consciousness 
and age, are thought to influence prognosis in SE independent of aetiology. The 
evidence for the impact of these four factors on the prognosis of SE is now discussed.
7.4.1. The duration of status epilepticus and its relation to outcome: 
It has been recognised since the 1970s that the longer the SE continues, the more 
difficult it is to control and the worse the outcome (Aicardi and Chervie, 1970). Any 
consideration of the impact of SE duration on prognosis needs to take into account the 
timing of initiation of treatment. It is well recognised that the longer the delay in 
initiating treatment inevitably the longer the duration of SE is likely to be. In a 
comparison of a group with prolonged seizures lasting 10 to 29 minutes versus a group 
with SE (defined as seizures for more than 30 minutes), 42% of seizures in the 
prolonged seizure group stopped spontaneously with 0% mortality while 58% of 
seizures were treated, with a 5.8% mortality rate (P<0.01). In contrast, only seven 
percent of episodes of SE stopped without treatment with no differences in mortality in 
the treated (19%) and untreated groups (18%) (DeLorenzo et al., 1999). Experimental 
studies have shown that as SE progresses, there are rapid changes to GABAergic 
receptor function, excessive NMDA receptor mediated transmission, mitochondrial 
changes and receptor trafficking (Chen and Wasterlain, 2006; Kapur and MacDonald, 
1997; Shorvon et al., 2007) and these changes may be part of the reason for the 
increasingly resistant nature of the SE. The recognition of this point has lead to earlier
and more aggressive treatment (and indeed a proposed change to the definition of SE) 
with an operational definition of SE of seizures lasting for more than five minutes being 
proposed (Lowenstein 1999). Such an aggressive approach to treatment is reflected in 
the two large clinical trails in SE. In the Veterans Affairs Cooperative Trial (Treiman et 
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al., 1998) SE was defined as continuous seizure activity or two or more generalised 
seizures, without full recovery of consciousness between seizures of more than ten
minutes duration. Similarly in the San Francisco study comparing out of hospital 
treatment of SE with lorazepam, diazepam and placebo, SE was defined as continuous 
or repeated seizure activity for more than five minutes without recovery of 
consciousness (Alldredge et al., 2001).
A representative early study (Towne et al.,1994) reported that a seizure duration of 
more than one hour was associated with a mortality rate of 32% compared with a 
mortality rate of 2.7% for seizure duration of less than one hour, a finding which 
remained statistically significant (p=0.0033) on multivariate analysis. Similarly a SE 
duration of more than one hour was associated with increased mortality (39.4% vs 3%, 
OR 2.41, p<0.0003, univariate analysis) (Sagduyu et al., 1998). Others have made 
similar observations (Gulati et al., 2005). Treatment delay, defined as initiation of AED 
treatment 30 minutes after the onset of SE (and therefore seizure duration of one hour or 
more) is associated with poorer outcome on multivariate analysis (OR 3.51, p=0.04) 
(Hui et al., 2003).
In a prospective study of 645 people with SE comparing mortality in people with 
continuous and intermittent SE, adults but not children, with continuous SE had a 
significantly higher mortality than those with intermittent SE (31.4% vs 19.6, p<0.001) 
with a relative risk of mortality of 1.79 (p<0.04). After examining the role of ictal time 
versus SE duration and adjusting for age, aetiology and SE duration on multivariate 
analysis, however, ictal time was no longer predictive of mortality (P<0.60). In contrast,
SE duration remained a highly significant predictor of mortality (P<0.001) indicating 
that it is SE duration rather than the duration that the person is actively seizing that is 
the primary determinant of mortality (Waterhouse et al., 1999).
The impact of SE duration and prognosis is summarised in Table 28.
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Authors Country Number of cases Duration (for poor 
outcome)1
Study Design
Towne et al. 
(1994)
USA 253 > 1 hour 
32% mortality 
< 1 hour
2.7% mortality
OR 17.9
Retrospective
All aged > 16 
years
Eriksson and 
Koivikko (1997)
Finland 65 > 2 hours
68.8% morbidity2
< 2 hours 
32.7% morbidity
P< 0.025
Retrospective
Paediatric 
study
Sagduyu et al
(1998)
Turkey 66 > 1 hour
39.4% mortality
< 1 hour
3% mortality
OR 2.41 
P< 0.003
Retrospective
All ages 
(range 6-77 
years)
Gulati et al
(2005)
India 30 > 45 minutes
100% mortality
< 45 minutes 
9.5% mortality
P< 0.001
Retrospective
Paediatric 
Study
Dislane et al.
(2009)
USA 119 > 10 hours
OR 4.3 (95% CI 
1.21, 15.3)
P=0.0242
>  24 hours
OR 1.8 (95% CI 
0.74, 4.36)
P=0.19 (NS)
Retrospective
Adult 
population 
(range 24- 96 
years)
Table 28: Duration and Status Epilepticus
1Poor outcome: morbidity and mortality. 2No reported deaths
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As was suggested by the classic French study of febrile SE in children in 1970 (Aicardi 
and Chervie, 1970), very long duration of SE is also associated with the development of 
neurological deficits, perhaps largely due to brain swelling, vascular effects or the 
underlying aetiology. More recent studies have shown that where new neurological 
signs develop due to SE, these appear after four hours of persistent SE (Drislane et al, 
2009). In a review of 119 people with SE with a median duration of 48 hours, a duration 
of less than ten hours was associated with a better outcome (Proportion of people with a 
good outcome was 69% compared with 31% in people with a longer duration, p<0.05) 
Once the aetiology of epilepsy, coma at presentation and generalised SE were corrected 
for on multivariate analysis, however, duration was no longer a significant predictor of 
outcome (Drislane et al., 2009).
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7.4.2 EEG and prognosis of SE:
While the EEG is an important tool in the diagnosis and management of SE, its role in 
terms of predicting prognosis is less established. Most attention has been paid to the 
presence of periodic epileptiform discharges (PEDs; or periodic lateralised epileptiform 
discharges - PLEDs). The association between PLED/PEDs and outcome however, does 
not seem to be strong, and furthermore PLEDs and PEDs are more likely to occur in 
certain aetiologies with poor prognosis (not least acute anoxic cerebral damage). One 
study found that if PEDs were present at any time during or after SE, outcome tended to 
be worse (44% of the 18 patients with PEDs on at least one EEG vs 19% of the 32 
without PEDs had a poor outcome) (Nei et al., 1999). There were no substantial 
differences in aetiologies between those with and without PEDs and structural lesions 
were not more associated with PEDs. The PEDs occurred at any time during and after 
SE and timing did not correlate with outcome. No other EEG characteristics (lateralised 
vs bilateral symmetric ictal EEG, discrete vs continuous ictal activity and post-ictal 
focal slowing) correlated with outcome and no predictable EEG sequence changes were 
found during SE. Another group found that the presence of burst suppression, ASIDs 
(After SE Ictal Discharges) and, less so, PLEDs were significantly associated with 
morbidity and mortality after controlling for aetiology on multivariate analysis (Jaitly et 
al., 1997). Others however have found that the outcome of SE was more related to age 
and aetiology than to any specific ictal EEG pattern (Garzon et al., 2001). In another 
study the presence of PLEDs was significantly associated with refractory SE compared 
with non-refractory SE on multivariate analysis (42% vs 10%, p=0.004) and the authors 
concluded that this reflected the longer duration of SE in these people (Mayer et al., 
2002).  In a study of 70 people prospectively followed, ictal discharges on EEG one
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hour post termination of SE (found in 15 of the 38 with seizure recurrence) were 
predictive of seizure recurrence within 24 hours (Kalita et al., 2006).
Author Number of Cases EEG features
during/after SE 
Study  Design Prognosis
Jaitly et al 
(1997)
N=180 Burst 
suppression
ASIDs
PLEDs
Normal
Prospective 
Study 78% Poor 
Outcome1
(59% mortality)
OR 7.56
P<0.00005
53% Poor 
Outcome
(41% mortality)
OR 2.41
P<0.022
53% Poor 
Outcome
(40% mortality)
OR 2.14
P<0.045
0% Poor 
Outcome
P<0.0008
Nei et al.
(1999)
N=50 PEDs Retrospective
Study
44% Poor 
Outcome in those 
with PEDs
19% Poor 
Outcome in those 
without PEDs
P=0.053
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Garzon et al.
(2001)
N=55
(62 episodes of 
SE)
IES
MES
CID
PEDs (PLEDs 
and PBEDs)
Prospective 
Study 
No pattern 
independent of 
aetiology was 
predictive of 
poor outcome
Mayer et al.
(2002)
N=74
(83 episodes of 
SE)
PLEDs Retrospective 
Cohort Study
42% developed 
RSE compared 
with 10% of 
those without 
PEDs 
P<0.004
Kalita et al.
(2006)
N=70 1-hour EEG 
abnormality
Prospective 
Study
Predictive of 
seizure 
recurrence within 
24 hours
Lambrechtsen 
and Buchhalter
(2008)
N=154 Electrographic 
seizures without 
clinical 
manifestations
Focal discharges
Retrospective 
Paediatric Study
31.7% in those 
with RSE vs 
13.8% with ASE
P<0.027
38.3% in those 
with RSE vs 
17% with ASE
P<0.003
Table 29: The EEG and the prognosis of Status Epilepticus
Glossary: ASE, aborted SE; ASIDs, after SE ictal discharges; CID, continuous ictal 
discharges; MES, merging EEG seizures; PEDs, periodic epileptiform discharges; 
PBEDs, periodic bilateral epileptiform discharges; PLEDs, periodic lateralised 
epileptiform discharges; RSE, refractory SE
1Poor Outcome: death or dependency at 30 days post SE on multivariate analysis 
controlling for aetiology.
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7.4.3 GCS on admission: 
It is perhaps not surprising that a lower level of consciousness associated with SE at 
admission is a risk factor for poor prognosis. This reflects the severity of the SE and 
also of damage due to the underlying cause. This factor has been the subject of a 
number of investigations. One study found that when a patient presented with stupor or 
coma, there was higher mortality, more SE refractory to therapy, longer median hospital 
and a lower chance of return to baseline (Rossetti et al., 2006). Similarly another study 
demonstrated that the median Glasgow Coma Scale (GCS) score of people with 
treatment resistant SE was 6 compared with a median GCS of 7 for people with non-
refractory SE (p=0.02), and that refractory SE was associated with reduced GCS at 
discharge compared with non-refractory SE (54% vs 28%, p=0.02), increased median 
ICU stay (7.5 days vs 1 day, p<0.001), increased median hospital stay (32.5 vs 11 days, 
p<0.001) and increased mortality (23% vs 14%; but this was not significant) on 
multivariate analysis (Mayer et al., 2002). The need for ventilation in SE (a marker of a 
decreased level of consciousness) has been shown to be associated with a higher 
mortality rate by others (44.4% vs 12.5%, OR= 1.575, p=0.004 (Towne et al., 1994);
Koubeissi and Alshekhlee, 2007).
Studies of level of consciousness and SE are shown in Table 30.
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Reference Number Marker of 
Consciousness
Mortality P-value
Sagduyu et al. 
1998
66 Need for ventilation
(N=18)
44.4% (N=8) OR 1.58
(95% CI 1.03, 
2.41)
Mayer et al. 
2002*
74 (83 
episodes)
Median GCS score 
on admission
6 RSE (N=26)
7 Non-RSE (N=57)
23% (N=6)
14% (N=8)
P=0.02
NS
Rossetti et al. 
2006
96 Alert (N=4)
Somnolent/Confused 
(N=20)
Stuporous (N=28)
Comatose (N=44)
0%
5% (N=1)
14.3% (N=4)
22.7% (N=10)
OR 3.03
(95% CI 1.05, 
11.3)
P=0.04**
Koubeissi and 
Alshekhlee 
2007
11,580 Respiratory failure 
necessitating 
intubation
(N=2,784)
7.4% (N=202) OR 2.79
(95% CI 
2.18, 3.59)
P<0.0001
Table 30: Level of consciousness and Status Epilepticus
*Refractory SE (RSE) was defined as SE lasting >1 hour and failure of 2 AEDs. Lower 
GCS score was significantly associated with RSE but not increased mortality
**Increased mortality associated with decreased level of consciousness
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7.4.4 Age: 
7.4.4.1 Status epilepticus in children: 
The range of aetiologies of status varies considerably with age, and perhaps largely for 
this reason age is a major determinant of prognosis. The extent to which age per se 
renders an individual more or less susceptible to adverse outcomes is less clear, but it is 
frequently stated that SE in very young children has less risk than SE in older children 
or adults. For instance, in an old study of 193 children with SE (mean age five years), 
causes were classified as idiopathic in 46, febrile in 46, acute symptomatic in 45 and 
progressive neurologic in 11. All seven deaths occurred in the progressive neurologic 
group and of the 186 survivors, new neurologic deficits were found in 17 (9.1%). 
Fifteen of the 17 sequelae occurred in children with acute or progressive neurologic 
deficits.  Of the 125 surviving children with no previous history of seizures, 30% 
subsequently had a further unprovoked seizure (Maytal et al., 1989).
Febrile illness, with or without infection, is a predominant cause of SE in young 
children, accounting for 32% of all episodes of SE in the NLSTEPSS (Chin et al., 
2006).
A review of the published literature over the last 15 years found that febrile SE was 
noted to have a low mortality (14 out of 876 people with febrile SE; 1.6 %) and this has 
fallen significantly from the early 1970s probably due to early and aggressive treatment 
of status epilepticus (Chungath and Shorvon, 2008). A cohort of 180 children aged one 
to ten years with febrile SE followed prospectively over ten years, were compared with 
244 children with their first febrile seizure. There were no deaths and no cases of 
cognitive impairment (Shinnar et al., 2001).
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In population studies, the occurrence of SE in children does not seem to be associated 
with poorer overall mortality or prognosis. In the Dutch study of 494 children with 
newly diagnosed epilepsy, followed prospectively for five years, SE occurred in 47 
(9.5%) but neither terminal remission nor mortality was significantly worse in the 
children with SE (Stroink et al., 2007). Similarly in a cohort of 150 children followed 
over 33 to 36 years, 41 (27%) had an episode of SE of whom 22 (56%) had two or more 
episodes. The occurrence of SE did not alter the mortality rates and had only a modest 
impact on the probability of attaining remission (Eriksson and Koivikko 1997). In a 
study of 65 children from Finland permanent neurological sequelae secondary to SE 
occurred in 15% and were associated with SE duration of greater than two hours. There 
were no SE related deaths (Sillanpaa and Shinnar 2002).  
Other studies from around the world have given varying mortality figures of SE in 
children: Japan (234 children; 19.2% poor outcome and 4% mortality (Maegaki et al., 
2005));  Iran (135 children, mortality 12.6%, morbidity 27.3% (Asadi-Pooya and 
Poordast, 2005)); Korea (189 children, mortality 3%, morbidity 33% (Kang et al., 
2005)); India  (30 people, mortality 30% (Gulati et al., 2005)); Turkey (83 children, 
mortality 7.2% (Karasalihoglu et al., 2003)); Thailand (32 children, mortality 6.3%, 
morbidity 56.3% (Visudtibhan et al., 2006)); Kenya (388 children, 15.2% mortality, 
11.9% morbidity (Sadarangani et al., 2008)) and Hong Kong (37 children, mortality 
11%, morbidity 27% (Kwong et al., 2004)).
Other factors also have an impact on the relationship between age and outcome, and 
these were explored in a retrospective study of SE in 154 children (Lambrechtsen and 
Buchhalter, 2008). Sixty (39%) had treatment resistant SE which was significantly 
associated with: a family history of seizures, higher seizure frequency, higher number of 
maintenance AEDs, non-convulsive SE and focal or electrographic seizures on initial 
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EEG. Predictors for poor outcome in both children with treatment-responsive and 
treatment –resistant SE were long seizure duration (p<0.001), acute symptomatic 
aetiology (p=0.04) (which included causes such as acute metabolic disorders (32.5%), 
encephalitis (25%), acute brain trauma (12.5%), stroke (12.5%), hypoxia-ischaemic 
encephalopathy (10%)and AED non-compliance (9%)), non-convulsive SE (p=0.001) 
and age at admission < 5 years at admission (p=0.05) (Lambrechtsen and Buchhalter, 
2008). 
Other studies (Maytal et al., 1989) have suggested that if SE fails to respond to initial 
therapy, the prognosis is poor with high mortality and morbidity. In a study of the 
outcome of treatment resistant SE in 22 children, the mortality rate was 32% and 
subsequent seizures occurred in 53% of survivors. Prognosis was largely related to 
aetiology, with the worst prognosis in the acute symptomatic group where out of eight 
children, three died and five developed a neurological deficit or seizures with none 
returning to baseline (all presumed or confirmed encephalitis). Other causes associated 
with a poor outcome were CNS lymphoproliferative disease, brainstem neoplasm, 
Alpers disease, MCAD disease and previous haemorrhage (Sahin et al., 2001).
7.4.4.2 Status epilepticus in adults
The outcome of SE in adults is poorer than in children and is particularly bad in those 
over 60 years of age as demonstrated in the Richmond study where children had a mean 
mortality rate of three percent, young adults (aged 15-59) a 13% mortality rate and 
people aged over 60 years a 38% mortality rate (DeLorenzo et al., 1996). The major 
reason seems again to be the underlying aetiology, with most episodes of convulsive SE 
in the elderly due to acute stroke or anoxic brain damage. This has been confirmed in 
various studies. The mortality rate of SE in the elderly was found to be 30% (342 
patients) (Claassen et al., 2002) and 29% with an odds ratio of death of 5.41 at age over 
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65 years compared with people aged less than 65 years (Rossetti et al., 2006). Age over 
45 years at the time of SE was significantly associated with mortality (77.7% vs 12.2%; 
OR=2.88, p<0.011) (Sagduya et al., 1998). In an older study the mortality rate was 
found to increase with age with a mortality rate of 12.5% in people aged 16 to 30 years, 
15.2% in people aged 30 to 60 years and a mortality rate of 32.3% in people aged over 
60 years with SE (Towne et al., 1994).  
In a multiple logistic regression analysis of mortality in SE in a study of 83 people with 
SE, increased age was found to be predictive of death in SE (mean age of people who 
died was 78 years vs 59 years with a good functional outcome; Odds Ratio 1.1, p=0.02)
(Claassen et al., 2002). Similarly mortality rates in SE were shown to increase with 
increasing age in a large in-hospital series with mortality rates of 0.7% for those aged 
ten years or younger, 1.3% (ages 11-20), 1.2% (ages 21-30), 2.1% (ages 31-40), 2.6% ( 
ages 41-50), 5.1% (ages 51-60), 6.8% (ages 61-70), 8.1% (ages 71-80) and 10.2% for 
those aged over 80 years (Koubeissi and Alshekhlee, 2007).  
Studies of age and status epilepticus are shown in Table 31.
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Reference Country Number of Cases Mortality/Morbidity Study Design
Maytal et al. 
1989
USA 193 3.6%  (N=7) mortality
8.8% (N=17) morbidity
Paediatric
Prospective/
Retrospective
Scholtes et al.
1994
Holland 346 11.0% (N=38) 
mortality
13.0% (N=45)
morbidity
All aged ≥ 15 
Retrospective
Towne et al. 
1994*
USA 253 23.3% (N=60)
12.5% 16-30 years
15.2% 30-60 years
32.3% >60 years
All aged ≥ 16
Retrospective
DeLorenzo et al. 
1996
USA 166 22% mortality overall
3% (children)
38% (age >60)
All aged > 1 
month
Prospective 
Eriksson & 
Koivikko
1997
Finland 65 0% mortality
15% (neurological 
morbidity)
23% (de novo epilepsy)
Paediatric
Retrospective
Mean follow-up 
3.6 years
Sillanpaa & 
Shinnar 2002**
Finland 41 17% (N=7) Paediatric
Prospective study 
of 150 children 
with epilepsy over 
23-26 years
Rossetti et al. 
2006
USA 96 15.6% (N=15)
Mortality
Age ≥ 65 
OR 5.41 (1.3, 25.5)
P=0.02
Retrospective
All aged ≥16
1st episode of SE
Stroink et al. 
2007
Holland 47 4.3% (N=2) Paediatric 
Prospective 5 
follow-up 
Koubeissi & 
Alshekhlee 2007
USA 11,580 3.45% (N=399)
0.67% Age ≤ 10
10.15% Age > 80
All ages
Retrospective
Table 31: Age and Status Epilepticus
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*Age significant predictor of mortality on multivariate analysis (P=0.0155)
**No significant difference in mortality in children with (N=41) and without SE 
(N=109)
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7.5 Outcome measures in status epilepticus
In discussing the prognosis of SE, the outcome measures which are usually considered 
are mortality and three measures of morbidity (functional deficit, neuro-cognitive deficit 
and the risk of ongoing epilepsy). Each of these outcomes following SE, based on the 
literature, are now discussed.
7.4.1 Mortality and status epilepticus
The studies mentioned earlier were concerned largely with mortality. Formal measures 
of mortality after SE can take several forms. The most commonly employed is the case 
fatality (CF), the proportion of people in the cohort dying, and the 30 day mortality rate 
is taken as standard (Logroscino et al., 2005). CF was 19% in the Minnesota study 
(Hesdorffer et al., 1998) and 22% in the Richmond study (DeLorenzo et al., 1996), 
while the CF figure for the EPISTAR study (Coeytaux et al., 2000) was 7.6% (with the 
exclusion of post-anoxic patients) and 9.3% in the Hessen study (Knake et al., 2001). 
By contrast the 30 day CF for the Bologna study was 33% (Vignatelli et al., 2003) 
(excluding post-anoxic patients) while the 30 day CF in another study from a different 
area in Italy (Lugo di Romagna) (Vignatelli et al., 2005) was only seven percent. The 
authors emphasised the impact of treatment and different regional treatment protocols in 
the acute management of SE for the disparity in the CF rates between the two studies 
(Vignatelli et al., 2008). As noted, the outcome and mortality rates for paediatric SE are 
better than for adults. In a recent review of the outcome of paediatric convulsive SE the 
short-term mortality was between 2.7 and 5.5% (Raspall-Chaure et al., 2006). While the 
30-day CF overall in the California study (Wu et al., 2002) was 10.7%, the childhood 
CF associated with GCSE was only 1.4%, the lowest reported to date. 
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One group looked at the short-term mortality (1997) and long-term mortality (2002) in a 
cohort of 201 people with a first episode of afebrile SE identified between 1965 and 
1984 in Rochester. The CF within the first 30 days was 19% (38 deaths) with 34 (89%)
deaths occurring in people with acute symptomatic SE (anoxic encephalopathy 38%, 
cerebrovascular disease 21%) while four (11%) occurred in people with unprovoked 
SE. Age over 65 years was associated with a relative risk of short-term mortality of 18.4 
(Logroscino et al., 1997). At ten years, the cumulative mortality among 30-day 
survivors was 43% with an SMR at ten years of 2.8 (95% CI, 2.1, 3.5). The SMR 
however, was not increased for those with cryptogenic/idiopathic SE (SMR=1.1; 95%
CI 0.5, 2.3). The long-term risk for mortality was increased for SE at least 24 hours in 
duration vs SE of less than two hours (RR=2.3; 95% CI 1.1, 5.1), acute symptomatic 
aetiology vs idiopathic/cryptogenic (RR=2.2, 95% CI 1.0, 5.1) and myoclonic vs 
generalised convulsive SE (RR=4.0; 95% CI 1.3, 13). Based on these findings it was 
suggested that SE alone does not modify long-term mortality (Logroscino et al., 2002).
7.4.2 Morbidity - neurological deficit and status epilepticus
In the study from San Francisco of 154 people with SE (Lowenstein and Alldredge, 
1993), 15 (9.7%) had severe neurological deficits requiring long-term hospitalisation or 
full supportive care. In the Dutch study of 346 children, 45 (13%) had resultant 
morbidity (15 (33.3%) had cognitive deterioration, 13 (28.9%) had paresis, three had 
impairment of consciousness, two had aphasia and one had ataxia). The sequelae 
however, were felt to be directly attributable to the SE in only 27% (the deficits were 
due to the underlying cause in 53% of children, with the main contributing factor 
undetermined in the remaining 20%) (Scholtes et al., 1994). 
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In children morbidity following SE remains low in the absence of acute symptomatic or 
progressive cause with less than 15% developing new neurological deficits as a result of 
SE (Raspall-Chaure et al., 2006). In an older study neurological deficits occurred in 17 
(9.1%) of survivors of SE of whom 15 had acute or progressive insults and only two of 
the 137 with other causes sustained any new deficits (p<0.001) (Maytal et al., 1989). 
Others have reported morbidity rates following SE of 15% (Eriksson and Koivikko, 
1997) and 15.4% (Maegaki et al., 2005). One study, in contrast to the overall trend, 
found significant morbidity in children three months after an episode of SE with 79% of 
children being abnormal neurologically and 34% demonstrating neuro-developmental 
deterioration at follow-up with predictors being aetiology (non-idiopathic or non-
febrile), SE at twelve months or younger and abnormal neuro-imaging (Barnard and 
Wirrell, 1999).
Morbidity rates were retrospectively examined in the Rochester cohort (Cascino et al., 
1998).  In the 146 people surviving 30 days (20.6% mortality) (Logroscino et al., 1997) 
morbidity attributable to SE was noted in five people (3.4%) including three with 
hemiparesis and encephalopathy, one with LD and one with aphasia. All morbidity 
occurred in people with either acute symptomatic (four) or remote symptomatic (one)
aetiologies.  The authors concluded that morbidity related to SE was uncommon and 
related to the underlying cause (Cascino et al., 1998).
Morbidity and mortality rates appear to be higher in people who develop treatment 
resistant SE. People with non treatment resistant SE and morbidity were more likely to 
return to baseline (50%) compared with people with treatment resistant SE and resultant 
morbidity (31%) (p=0.04). Over half (54%) of people with treatment resistant SE had 
functional deterioration compared with 28% of people with treatment responsive SE 
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(p=0.02) (Rossetti et al., 2005). In children treatment resistant SE is similarly associated 
with higher morbidity. None of the seven children with morbidity in a series of 22 
children with treatment resistant SE returned to normal (Sahin et al., 2001) while in
another study the number of children who returned to baseline was significantly less in 
children with treatment resistant SE than in children with treatment responsive SE 
(66.6% vs 82.9%; p=0.05) and they had a higher risk of developing a new deficit 
(71.4% vs 55.1%; p=0.0001) (Lambrechtsen and Buchhalter, 2008).
7.4.3 Morbidity – neuro-cognitive sequelae of status epilepticus
The question as to whether or not seizures and in particular SE are risk factors for 
cognitive dysfunction has been debated for many years. In an early review of the 
literature of studies of cognitive impairment in relationship to SE, nineteen studies were 
analysed and the following conclusions were drawn: most studies involved children, did 
not use any type of formal psychological assessment and were retrospective.  The older 
studies tended to report greater losses in cognitive abilities after SE than more recent 
studies. The authors concluded that almost every study attributed at least some negative 
effects to SE per se (Dodrill and Wilensky, 1990). Certainly it is common clinical 
experience to see that memory and other cognitive functions are impaired immediately 
after an episode of severe SE, but these may often improve over ensuing months. 
Formal studies, in the literature are sparse. Most have found no evidence of persistent 
cognitive deficits (Adachi et al., 2005; Dodrill and Wilensky, 1990; Dunn, 1988; 
Ellenberg et al., 1986; Ellenberg and Nelson, 1978).
In the UK national cohort study 37 children with a history of prolonged seizures were 
prospectively followed up (19 had lengthy febrile seizures and 18 had SE). of the 35 
survivors, 33 underwent intellectual evaluations, which were normal in 23 and abnormal 
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in ten. Eight of these children, however, had preceding developmental or neurological 
abnormality, implying that the cognitive outcome is more determined by the underlying 
cause (Verity et al., 1993). There is an anecdotal report in the literature of a young 
woman with progressive cognitive and neurological deficits during a parietal lobe SE, 
who had complete normalisation of cognitive and neurological function one year after 
seizure remission (Van Paesschen et al., 2007). 
7.4.4 Morbidity - the risk of epilepsy after status epilepticus
There is a great deal of unequivocal experimental evidence in animal models of SE 
showing that an episode of SE will lead to continuing epilepsy, and it seems likely that 
a similar risk occurs in humans. As in other aspects of prognosis, however, it is difficult 
to differentiate the risk of ongoing epilepsy following SE itself from that of the 
underlying condition. 
In the review of outcome of paediatric SE, the risk of subsequent epilepsy following an 
episode of SE ranged from 13 to 74% (Raspall-Chaure et al., 2006). In a British cohort 
study 14 (82%) children developed afebrile seizures after SE compared with only four
(21%) children with prolonged febrile seizures. Over one third (36%) of children with 
no history of seizures developed epilepsy following SE and 25% developed refractory 
epilepsy with 50% having recurrent SE (Barnard and Wirrell 1990). During a mean 
follow-up of 3.6 years, 23% of children developed epilepsy following SE in a Finnish 
study (Eriksson and Koivikko 1997) while 30% (37) had subsequent unprovoked 
seizures in an earlier paediatric study (Maytal et al., 1989). In a prospective study of 95 
children followed up for a mean of 29 months from the time of a first episode of SE, the 
overall risk of recurrence of SE was 17% (16 children), with SE recurring primarily in 
neurologically abnormal children (88% (14), p<0.001) and in all five children with 
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multiple episodes (p<0.001) (Shinnar et al., 1992).  The risk of developing epilepsy 
following a single seizure was 44% (Shinnar et al., 1996) implying that SE by itself 
does not significantly add to the risk of subsequent epilepsy in children.
One study investigated the impact of SE in the development of subsequent epilepsy. At 
ten years follow-up, the risk of unprovoked seizure was 41% for people with acute 
symptomatic SE compared with 13% for people with a single acute symptomatic 
seizure without SE. After controlling for cause of acute symptomatic seizure, age and 
sex, acute symptomatic SE was associated with a 3.3-fold increase in risk for a first 
unprovoked seizure compared with those with acute symptomatic seizure only. 
Moreover the risk of a subsequent unprovoked seizure was increased 18.8-fold 
following SE with anoxic encephalopathy, 7.1-fold for structural causes of SE and 3.6-
fold with metabolic SE. This study provides support to the belief that SE in adults is a 
significant factor in the development of subsequent epilepsy (Hesdorffer et al., 1998b).
The risk of epilepsy following SE in children and adults seems also determined by the 
severity of the episode of SE. In one study, symptomatic epilepsy developed more often 
in those with treatment resistant SE (87.5%) than in people with treatment responsive 
SE (22.2%; p<0.05) (Holtkamp et al., 2005).  This trend is also seen in children where 
in one study of treatment resistant SE all surviving children developed intractable
epilepsy (Sahin et al., 2001) while in another study the risk of subsequent epilepsy was 
significantly higher for those with treatment resistant SE (30.6% vs 16%; p=0.004) 
(Lambrechtsen and Buchhalter 2008). 
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Chapter 8: Discussion
In the discussion several of the studies are discussed together, where applicable, in 
relation to different prognostic themes: epilepsy and mortality (studies 1 and 2), seizure 
prognosis of people with chronic epilepsy (studies 3 and 4) and a prognostic model of 
epilepsy (studies 2-4). The prognosis of febrile seizures (study 2) and the prognosis of 
status epilepticus (study 5) are discussed separately.
8.1 Epilepsy and mortality (Studies 1&2)
An attempt was made to address two issues with regard to the risk of premature 
mortality in people with epilepsy 1) how SMRs change during the course of the 
condition, with particular reference to the long-term mortality data from the NGPSE,
and 2) how reported mortality rates have changed over time. 
8.1.1 SMRs (Study 1)
SMRs compare the mortality rates in people with epilepsy with that of the population 
from which they derive and hence give some indication of the premature mortality 
experienced by them. As previously discussed (Section 1.6.1, Page 55), direct 
comparison of SMRs derived from different populations is problematic, particularly 
between populations of different age groups with many studies having an over-
representation of young people. This results in proportionally higher SMRs due to the 
lower expected death rate in children and young adults (Camfield et al., 2002). Indeed it 
has been suggested that these potential differences may even invalidate direct 
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comparison of SMRs derived from distinct populations (Logroscino and Hesdorffer, 
2005).
In examining reported SMRs in prevalent cohorts, it needs to be emphasised that 
prevalence studies generally under-represent people with milder forms of epilepsy 
whilst simultaneously missing some people who may have died previously for whatever 
reason.  It is clear, therefore, that results from incident cohorts provide a more accurate 
picture. Indeed, so great are the potential inaccuracies of prevalence studies that these 
cannot be considered useful and they are not considered further. Currently, there are few 
incident cohorts available for comparison. 
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8.1.2 The long-term risk of premature mortality – evidence from the NGPSE 
(Study 2)
There have been few population-based studies of mortality in people with epilepsy with 
more than ten years follow-up.  This analysis extends follow-up of the NGPSE 
considerably, increasing mean follow-up to over 18 years and the person-years by two-
thirds, from the last analysis (Lhatoo et al., 2001).  Overall there were no major 
differences from the previous analyses; extra follow-up has, however, increased the 
precision of the estimates and narrowed the CIs. 
This analysis is in line with previous reports arising from the NGPSE cohort using 
information available at the time of the initial (6 month) classification by a review 
panel.  The designation of some cases as possible/probable epilepsy had the advantage 
at the time of allowing the inclusion in the study of some cases which would otherwise 
have been excluded due to a lack of a definitive diagnosis of epilepsy.  It was also in 
line with the original study design which was intended to be over-inclusive to allow 
GPs to refer people who they considered might have a diagnosis of possible epilepsy.
A pragmatic decision was taken at the time that changing diagnostic categories 
according to information acquired later in the follow-up period was not a sound 
approach to the analysis of longitudinal data. This is standard epidemiological practice 
in line with other longitudinal prospective cohort studies. No attempt has been made to 
re-assess the aetiology of epilepsy in those classified as having idiopathic/cryptogenic 
epilepsy or to re-evaluate the original diagnostic categories, in part because such 
reclassification would be incomplete (in people with a short course of active epilepsy in 
whom no further investigations would have been carried out or in people who died early 
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in the course of their epilepsy) and therefore subject to bias.  Similarly no analysis with 
regard to co-morbidities was possible due to incomplete data, in particular as specific 
inquiry into co-morbidities was not permitted in later follow-up due to recently 
introduced legal restrictions.  Consequently all people remain in the same categories in 
which they were classified at six months after the index seizure.  Because of the 
diagnostic uncertainty in those categorised as having possible/probable epilepsy, we 
have continued to present separate SMRs for those with definite and probable/possible 
epilepsy.  The overall SMR for those with possible/probable epilepsy was significantly 
elevated but less so than in those with definite epilepsy.
Mortality was elevated overall for all aetiological subgroups of people classified as 
having definite epilepsy.  It is well recognised that people with remote symptomatic 
epilepsy or epilepsy associated with a congenital deficit have higher SMRs and indeed 
remote symptomatic aetiology is the major determinant of mortality in children 
(Camfield et al., 2002).  Some studies, however, have not reported an increased SMR in 
people with idiopathic or cryptogenic epilepsy (Lindsten et al., 2000; Olafsson et al., 
1998) although one study did (Hauser et al., 1980).  The SMR of those with idiopathic 
/cryptogenic epilepsy in our cohort was significantly elevated for the last ten years of 
follow-up, which was not seen previously (Cockerell et al., 1994; Lhatoo et al., 2001).
Mortality was most marked in the younger age groups (aged less than 60 years) for 
those with definite and possible epilepsy as seen previously (Lhatoo et al., 2001).  The 
cohort included 83 people with acute symptomatic seizures with an overall SMR of 3.2 
(95% CI 2.4, 4.3) which has been relatively constant throughout follow-up.  A recent 
study reported that people with acute symptomatic seizures were nine times more likely 
to die within the first thirty days than those with a first unprovoked seizure.  In contrast 
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there was no difference in mortality at ten years in those who survived 30 days when 
adjusted for age and aetiology (Hesdorffer et al., 2009).  In our study, the SMR 
remained significantly elevated (2.5, 95% CI 1.7, 3.5) in those who survived the first 
year.  
The study records of all 83 people originally classified as having acute symptomatic 
seizures were re-examined and re-classified according to the new definition of acute 
symptomatic seizures (a seizure occurring usually within seven days of an acute CNS 
insult (Beghi et al., 2010)). Sixty people remained classified as having acute 
symptomatic seizures.  It was found, however, that changing the timing of the seizure 
from within three months to within one week of the precipitating cause in our 
classification did not make any difference to the overall mortality with the reported 
SMRs being virtually identical (Table 11, Page 111).  
The overall SMRs for those with definite and possible seizures remained significantly 
raised throughout follow-up.  There is a weak suggestion that there is a late increase 
(20-25 years) in the SMR. While this late increase is not significant in the NGPSE, 
premature mortality in the cohort does not appear to be decreasing.  To investigate this 
possible late increase in mortality, the study records of the people who died in the last 
10 years of follow-up were examined.  Of these 71% people were seizure free for the 
previous five years at last follow-up and 39% were off AEDs.  The fact that the majority 
of those who died remained on AEDs raises the possibility that some died as a result of 
AED non-compliance which has been suggested to increase risk of premature mortality 
(Faught et al., 2008) in people with previously well controlled seizures.  This is, 
however, unlikely to be the explanation in the majority of our cases as the trend of an 
increasing proportion of the cohort being in terminal remission has continued with 
longer follow-up (Cockerell et al., 1997; Neligan et al., 2010b).
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It has been suggested that AEDs are possibly associated with an increased risk of cancer 
(Olsen et al., 1989; Nilsson et al., 1997; Lamminpaa et al., 2002; Singh et al., 2007) 
although others have not found any definitive evidence for such an association (White et 
al., 1979; Adelow et al., 2006).  We found, however, that cancer-related deaths were 
highest in the first five years (and therefore possibly the cause of seizures) and again in 
the final years of follow-up.  The reason for the modest increase in later years is 
unclear, but the possibilities include the prolonged use of AEDs or common genetic 
predispositions; these hypotheses have not yet been tested. 
Another possible explanation for the higher mortality rates in people with epilepsy is the 
interplay between epilepsy and socio-economic status. It has been shown that the 
incidence of epilepsy appears to increase with socio-economic deprivation (Heaney et 
al., 2002). Similarly it has been suggested that socio-economic deprivation is associated 
with a lower life-expectancy even in developed countries with universal access to health 
care. (De Vogli et al., 2005). Lower economic status may lead to poor treatment access 
and disparities in health care as a result of rural isolation, ethnicity and lack of public 
and physician knowledge of modern approaches to epilepsy care and this may lead to an 
increased risk of premature mortality (Theodore et al., 2006).
At this stage, any explanation of why there is a possible late increase in mortality in 
people with a history of seizures (or why there is no decrease in mortality despite an 
increasing proportion of people who are seizure free) can only be speculative.  It does, 
however, raise the possibility that a predisposition to seizures (with or without clearly 
identified aetiology) may be but one manifestation of a polygenic phenotype with other 
associated conditions which may also predispose to premature mortality.  This may, in
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part, explain why we did not find a significant difference in the mortality in people with 
acute symptomatic compared with those with remote symptomatic seizures. 
The suggestion of a persistently elevated risk of premature mortality throughout follow-
up raises a dilemma when counselling people with epilepsy as to what they should be 
told of an increased risk of premature death irrespective of seizure control.
In the NGPSE, the causes of death were based on those listed on the death certificate 
which also included other conditions or co-morbidities which were believed to have 
contributed to, but which were not the primary cause of, death.  No other clinical or 
para-clinical information about the circumstances in which the death occurred was used.  
Only in a small number of cases where there was doubt about the primary cause or 
circumstances of the death was a post-mortem performed which was at the discretion of 
the local coroner.  Despite the well documented problems of the use of death certificates 
in people with epilepsy (Bell et al., 2004), death certificates form the basis for mortality 
data in population studies and were the source of cause-specific mortality in the two 
other long-term population-based studies in people with epilepsy (Hauser et al., 1980; 
Rafnsson et al., 2001).
One might expect a decrease in SMR with prolonged follow-up in a cohort of people 
largely seizure free, yet we and others have not seen this (Hauser et al., 1980).  We thus 
looked at specific causes of death to identify possible reasons for this. The most 
common causes of death for those with definite or possible epilepsy, as recorded in the 
death certificates, were cancers (including lung cancer), cerebrovascular disease, 
pneumonia and ischaemic heart disease.  Pneumonia was common with a significantly 
increased SMR in the group with definite and possible epilepsy at all points of follow-
up (Table 13, Page 116) and appearing to increase at 15-20 and 20-25 years follow-up.  
204
204
Pneumonia has long been recognised as a common cause of premature mortality in 
people with epilepsy (Munson, 1910) and this has been replicated in other, more recent, 
studies (Hauser et al., 1980; Lindsten et al., 2000; Nilsson et al., 1997); the reason for 
this increase is currently unclear.  Intuitive suggestions that this may be associated with 
aspiration as a result of seizures have not been tested and this would not, in any case, 
apply to people in remission.  In some cases, pneumonia with fever and administration 
of antibiotic therapy could have precipitated a seizure contributing to mortality with 
only pneumonia recorded on the death certificate.  Similarly it has been shown that 
generalised tonic-clonic seizures can lead to neurogenic pulmonary oedema with 
symptoms resembling pneumonia (Baumann et al., 2007) with the result that the 
primary cause of death could be mistakenly recorded as pneumonia instead of epilepsy.  
Another possible explanation for the high prevalence of pneumonia is the recently 
postulated theory that inflammatory mechanisms are involved in the pathogenesis of 
epilepsy with the result that chronic epilepsy may lead to relative suppression of the 
immune system with a subsequent increased risk of infections such as pneumonia 
(Vezzani and Granata, 2005; Najjar et al., 2008; Bauer et al., 2009).  None of the above
possible theories, however, explains why pneumonia continues to feature so 
predominantly in the later stages of follow-up when the majority of people have entered 
terminal remission.
The SMR for cerebrovascular disease was significantly elevated for the first fifteen 
years of follow-up but not thereafter.  As expected, the SMRs for all cancers and for 
cancers excluding brain tumours were significantly elevated in the first five years, 
decreasing thereafter but were both again significantly elevated at 20-25 years follow-
up.  The SMR for lung cancer was significantly elevated only during the first five years 
although numbers were inevitably smaller. The SMR was significantly elevated for 
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ischaemic heart disease (SMR 3.34, 95% CI 1.6, 7.0) for the first time at 20-25 years, 
although the confidence intervals are wide.  This was also associated with an increased 
SMR in a hospital-based study (Nilsson et al., 1997) and in population-based study but 
only for those aged < 65 years old (Annegers et al., 1984).
8.1.3 Temporal trends in mortality (Study 1)
As we have confirmed, the risk of premature mortality is significantly higher than that 
of the general population in the initial one to two years following seizure onset and this 
risk decreases thereafter with the SMR often falling to rates comparable with those of 
the general population (Cockerell et al., 1994; Hauser et al., 1980; Loiseau et al., 1999; 
Neligan et al., 2010a). Much of this initial risk is related to the underlying aetiology and 
seizure type as seen in the Gironde study (Loiseau et al., 1999) and the Canadian 
paediatric study (Camfield et al., 2002). 
There is a suggestion, however, from several studies and possibly in the current 
investigation of the NGPSE that there is a subsequent increase in mortality ratio after 
more prolonged follow-up: 10 years (Camfield et al., 2002; Lhatoo et al., 2001; 
Lindsten et al., 2000) or later (Hauser et al., 1980). In contrast, no such late increase in 
mortality was observed in the Icelandic study (Olafsson et al., 1998).  This temporal 
mortality trend primarily appears to be significant only among people with symptomatic 
epilepsy although, as shown above, the SMR for people with idiopathic/cryptogenic 
epilepsy in the NGPSE was significantly elevated for the first time during the last ten 
years of follow-up (Section 4.2.4; Neligan et al., 2011a). 
If such a late increase in mortality risk does occur, it raises the question as to why this 
should occur. The persistent increase in observed SMR noted in the NGPSE cohort 
occurs despite the fact that 71% of those who died were in terminal remission at time of 
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death (see above), similar to that found in another study (Annegers et al., 1979).  This is 
further strengthened by the finding that, at the most recent follow-up conducted, over 
80% of people in the cohort were in 5-year terminal remission, of whom 60% were off 
AEDs for five or more years (Section 4.2.4; Neligan et al., 2010b). In a previous time-
dependent analysis of the cohort, seizure recurrence and antiepileptic drug treatment did 
not seem to affect mortality (Lhatoo et al., 2001).
Whether or not the risk of premature mortality is preventable ultimately depends on 
what is driving this higher mortality rate. If, as has been suggested by some (but not all 
(Camfield et al., 2002)) of the childhood epilepsy studies (Sillanpaa et al., 2010), 
ongoing seizures (and therefore epilepsy-related causes) are the primary cause of death, 
then rendering people with severe epilepsy seizure-free either by surgery (Bell et al., 
2010; Sperling et al., 1999) or by medication in people with remote symptomatic 
epilepsy (Strauss et al., 2003) will reduce the mortality. Indeed, it has been suggested in 
one study that people rendered seizure free do not have an increased mortality rate 
(Mohanraj et al., 2006). 
Patient education regarding the risk of drowning, the importance of AED compliance 
(AED non-compliance may be associated with increased mortality (Fraught et al., 
2008)) and a discussion on the possibility of SUDEP (Morton et al., 2006) may further 
modify the mortality risk. If, on the other hand, the long-term mortality is primarily due 
to non-epilepsy related causes as suggested by our recent results and others (Lhatoo and 
Sander, 2005), then modifying the long-term mortality risk may not be possible until a 
better understanding of the patho-physiology of mortality in epilepsy is obtained. 
Highlighting to health-care professionals that people with a history of epilepsy are at 
higher risk of dying from unrelated causes such as pneumonia, may help modify this 
risk.
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8.1.4 Changing mortality rates over time (Study 1)
Mortality rates are usually age standardised and are typically expressed as the number 
of deaths/100,000/year.  They enable us to give an indication of how death in people 
with epilepsy varies over time.
Population-wide studies are largely based on death certificate data (O'Callaghan et al., 
2000; Pritchard et al., 2004; Massey et al., 1985; Goldacre et al., 2010; Goldacre et al., 
2003; Bruce et al., 2004). It is well recognised that mortality statistics based on death 
certificates significantly underestimate mortality rates in people with epilepsy (Bell et 
al., 2004; Bruce et al., 2004), but such deficiencies should not bias interpretation of 
secular trends unless there is evidence that the degree of under-reporting varies over 
time (O'Callaghan et al., 2000).
The study comparing epilepsy mortality rates (per million patient-years) in the United 
States and England and Wales demonstrates a significant birth cohort effect with 
progressively lower mortality rates in children and young people, which is likely to be 
as a result of improved perinatal care (O'Callaghan et al., 2000). This is supported by 
evidence from population studies, which suggest that the incidence of epilepsy is 
decreasing in children (Sander, 1993; Kurtz et al., 1998; Sillanpaa et al., 2006). The 
apparent decrease in mortality rates shown in the study comparing rates in 33 countries 
about 20 years apart (Massey and Schoenberg, 1985) may represent an age-specific 
effect, with the decreased mortality rates reflecting the decreasing mortality rate in 
children mirrored by the falling incidence of epilepsy in children.  There are also 
methodological differences between the two studies. In contrast there is no evidence 
that the mortality rates from epilepsy have decreased since the 1970s (Bruce et al., 
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2004; Goldacre et al., 2010; Hauser et al., 1980; O'Callaghan et al., 2000; Pritchard et 
al., 2004).
Most of the population-based studies provide mortality rates in people with epilepsy up 
to the 1990s and so do not include many people taking the new AEDs. One study 
(Goldacre et al., 2010) does, however, examine mortality in England between 1996 and 
2006 with no significant change in mortality rates in people with epilepsy during this 
time. The impact of the new AEDs in reducing mortality is, therefore, unclear and 
further studies are needed. Over the last decade, certifying physicians have been 
encouraged to mention epilepsy and, where appropriate, SUDEP on death certificates, 
following the finding that previously epilepsy was frequently not included even in death 
certificates of people who had active epilepsy (Hanna et al., 2002). If this 
encouragement was heeded one would expect that the number of deaths attributed to 
epilepsy would have increased.  This does not appear to be the case (Goldacre et al., 
2010), suggesting the possibility that the actual number of deaths may have fallen 
although no firm data are available to support this idea.
Further prospective incident cohort studies with long-term follow-up are urgently 
needed to confirm that people with epilepsy have a persistently elevated risk of 
premature death despite good seizure control, and more importantly to try to explain 
such a finding in order that this risk can be modified if possible. 
Similarly more general population studies examining mortality rates attributable over 
the past twenty years are needed to determine if the large increase in the number of 
treatment options has impacted on mortality rates. 
209
209
8.2 The long-term prognosis of people with epilepsy (Study 2)
Long-term follow-up studies are important in determining the course and prognosis for 
people with epilepsy. The significance and inference that can be drawn from the 
findings from such studies are influenced by the cohort size, study population 
(paediatric or adult), setting (hospital- or population-based) and methodology 
(retrospective or prospective).
The NGPSE is the largest prospective long-term study of people with epilepsy in 
existence with a mean duration of follow-up of 15.9 and 16.9 years for those with 
definite and possible epilepsy respectively. Few other studies have examined the 
prognosis for people with epilepsy with a follow-up period greater than ten years and 
the majority of these studies have been in paediatric cohorts (Annegers et al., 1979; 
Okuma et al., 1981; Brorson and Wranne 1987; Oka et al., 1989; Wakamoto et al., 
2000; Lindsten et al., 2001; Sillanpaa and Schmidt 2006; Geerts et al., 2010).  Findings 
of other long-term studies are shown in Table 6 (Page 44). 
Overall the reported rates of people in terminal remission in these studies range from 
approximately 60-80% with the lower ranges generally in studies with shorter follow-up 
(< 15 years) and all were in paediatric populations. The figures from the NGPSE 
represent the highest proportion of people in terminal remission reported to date (80.6% 
in those with definite epilepsy and 86.6% in those with possible epilepsy), in part 
influenced by the long period of follow-up attained in this study.
In examining the two other population-based cohorts with prolonged follow-up from 
Rochester and Finland, it is evident that the number of people entering terminal 
remission continues to increase with longer follow-up. In the Rochester cohort 61% of 
the cohort was in TR at 10 years and 70% at 20 years (Annegers et al., 1979). In the 
Finnish study the proportion in TR increased with longer follow-up: 15% in TR at five
years, 48% at ten years, 52% at 15 years, 56% at 20 years, 60% at 30 years, 62% at 35 
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years and 70% at 40 years follow-up. Overall 81% of this cohort had achieved a seizure 
free period of at least five years with or without subsequent relapse (Sillanpaa et al., 
1998; Sillanpaa 2000; Sillanpaa and Schmidt, 2006). Such findings are similar to those 
in the NGPSE. In the previous analysis 96% of those with definite and possible seizures 
had achieved a one year remission, 93% a three year remission and 71% (67% from the 
1st seizure) by nine years follow-up (Cockerell et al., 1997). Many (82.3%) were in TR 
(64% in TR and off AEDs) after a further 15 years of follow-up (median follow-up 24.1 
years). Indeed this trend of a higher proportion attaining TR appears to be continuing, as
one third (21/63) of those with seizures in the last five years had experienced at least 
one year of seizure freedom at the end of follow-up. It is therefore probable that a 
proportion of these will remain seizure free with further follow-up.
Overall 164 people (44.2%) in the cohort (96 classified as having definite epilepsy and 
68 with possible epilepsy) with long-term follow-up entered early remission (five years 
or more seizure freedom from the index seizure) with 30 (18.3%) subsequently 
relapsing.  A further 161 people (43.4%) (122 with definite and 39 with possible . 
epilepsy) became seizure free for five years or more after having had further seizures
(late remission), with 13 (8.1%) subsequently relapsing, giving a total of 43 people who 
attained five years or more seizure freedom and subsequently relapsed (Table 18, Page 
130).  In comparison in the Finnish paediatric cohort, 45 (31%) entered 5-year TR 
within the first year with 22 (48.9%) subsequently relapsing while 26 (36.1%) of the 72 
who attained 5-year TR late subsequently relapsed (Sillanpaa et al., 2006). 
The lower rates of relapse in those with early and late remission and proportions with a 
relapse-remitting pattern of seizures in the NGPSE cohort (11.6% with 48% re-entering 
TR) compared with the Finnish cohort (33% with 58% re-entering TR) may, in part be 
explained by the different age profile of the cohorts. In the Rochester study, which like 
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the NGPSE cohort included paediatric and adult populations, approximately 75% of the 
cohort had attained five year of seizure freedom with 70% in TR at the end of follow-
up.
The higher rates of TR seen in the NGPSE compared with the other cohorts may, in part 
be explained by the inclusion of people with single seizures (unlike the Finnish and 
Rochester cohorts) who would be expected to have a lower risk of seizure recurrence 
than people with two or more seizures (Berg et al., 1991; Hauser et al., 1998). Similarly 
the inclusion of people with acute symptomatic seizures is likely to have favourably 
influenced the overall outcome. In a study comparing outcomes in people with a single 
unprovoked seizure and a first acute symptomatic seizure (stratified by aetiology), the 
risk of a subsequent unprovoked seizure was significantly higher at ten years follow-up 
in people in the first unprovoked seizure group (64.8%; 95% CI: 55.1, 74.4) compared 
with people in the acute symptomatic seizure group (18.7%; 95% CI: 13.7, 25.4, 
p<0.001) (Hesdorffer et al., 2009).
For people with an initial single seizure, 37.7% (95% CI 95% 29, 47) with a definite 
epileptic seizure had no further seizures at a median follow-up of 24 years. 
In a previous report from the NGPSE cohort, the recurrence rate after a seizure for all 
people with definite epilepsy (n=564) was 78% (95% CI: 74, 81) at three years. This 
figure was lower, however, (recurrence rate 56% (95% CI: 51, 60)) at three years when 
the analysis was confined to people in whom the index seizure was also the first seizure 
(n=252) (Hart et al., 1990); these people are those designated as presenting with a single 
seizure in the current analysis. In most cases where the index seizure was not the first 
seizure, the previous seizures were focal. Consequently the figure of 37.7% of people 
prospectively followed after a single seizure, who remain seizure free at 24 years, 
indicates that only an additional six percent of people had a first relapse (recurrence rate 
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62% compared with 56% at three years) in the 21 intervening years of follow-up. This 
emphasises the finding that the risk of relapse following a single seizure is highest in 
the initial two to three years after the seizure with relatively few relapsing thereafter.
A meta-analysis of the recurrence rate after a single seizure in prospective studies found 
a median recurrence rate of 40%, but all of these studies had a follow-up of less than 
five years (Berg and Shinnar, 1991). Retrospective cohort studies of people with single 
seizures typically report higher recurrence rates. The Rochester cohort reported a 
recurrence rate of 48% at three years and 56% by five years (Annegers et al., 1986). In a 
prospective study from Sweden of 107 people aged ≥17 years with a single unprovoked 
seizure, the recurrence rate was 58% at ten years with nobody having a reported first 
recurrence after 750 days (Lindsten et al., 2001b). As with the Swedish study results 
from the NGPSE suggest that the risk of recurrence after a single seizure plateaus after 
10 to 15 years follow-up.
In this analysis the only factors found to influence the long-term risk of seizure 
recurrence were aetiology and seizures before the index seizure. A higher frequency of 
seizures, before or after the initiation of treatment, appears to be predictive of long-term 
seizure outcome (MacDonald et al., 2000; Sillanpaa and Schmidt, 2009). Similarly 
aetiology appears to be an important determinant of long-term prognosis, a finding in 
keeping with other studies (Annegers et al., 1979; Brorson and Wranne, 1987; Sillanpaa 
and Schmidt, 2009; Geerts et al., 2010). In particular children with seizures associated 
with a congenital deficit had the worst prognosis even though over half were in TR at 
last follow-up. In contrast, people classified as having acute symptomatic seizures have 
the best prognosis with less than one in ten still having seizures at the end of follow-up. 
Interestingly this good prognosis with regard to seizure control was not seen in the 
mortality analysis with people with acute symptomatic seizures having a comparable 
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SMR to those with remote symptomatic seizures even with the exclusion of those who 
died within the first year of follow-up (See Section 4.1). People classified as having 
idiopathic/cryptogenic epilepsy had a slightly better prognosis than people classified as 
having remote symptomatic epilepsy in the early years of follow-up (Cockerell et al., 
1997) but this difference seems to have disappeared with longer follow-up. 
One of the major limitations of the NGPSE is the aetiological classification used in 
people with definite epilepsy. Such a classification was based purely on the presumed 
temporal cause of the seizures. In particular no distinction was made between people 
with IGE and cryptogenic partial epilepsy. In saying that, it must be recognised that the 
NGPSE started several years before the ILAE published the classification of epilepsy
syndromes (ILAE, 1989). Only 33.6% of people in the NGPSE cohort could be 
confidently classified into specific epilepsy syndromic categories when subsequently 
analysed (Manford et al., 1992). Consequently the latest findings from the NGPSE, 
while indicating an excellent prognosis for the majority of people with epilepsy and 
especially for people with an initial provoked seizure, can provide little information on 
the prognosis for people with specific epileptic syndromes.
The finding that an increasing proportion of people become seizure free with longer 
follow-up is encouraging. This study suggests that approximately 80% of people with 
epilepsy will achieve TR challenges the often cited statistic that 30-40% of people with 
epilepsy will ultimately have refractory epilepsy (Kwan and Brodie, 2000). Despite its 
limitations, the long-term follow-up data from the NGPSE cohort provides important 
information necessary for counselling people about the prognosis of epilepsy.
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In summary further long-term prospective general population-based studies are 
necessary to replicate this finding. Future studies need to be rigorous in stratifying 
people both by aetiology and epilepsy syndrome. This in turn may allow clinicians to 
give people with specific aetiological and syndromic diagnoses a more accurate long-
term prognosis specific to their particular form of epilepsy. 
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8.3 The long-term prognosis of people with febrile seizures (Study 2)
It is well recognised that children with febrile seizures are at increased risk of 
developing epilepsy. In prospective community based studies the reported risk is from 
two to seven percent depending on the duration of follow-up (and can be compared with 
the general population risk of 1.2% by age 24 (Hauser et al., 1993)). Children with 
CFSs are at higher risk than those with SFSs (Chungath and Shorvon, 2008). The main 
problem with the majority of such prospective cohort studies is the relatively short 
follow-up period (NCCP -seven years; Oakland Study – five years) therefore missing 
people who develop epilepsy later.  In addition, short-term studies cannot provide 
information about the risk of developing epilepsy compared with that in the age-
matched population. 
At 20 years after the index febrile seizure, the estimated percentage of people who had 
developed epilepsy was 6.7% (95% CI 4, 11%) with three additional people having a 
single afebrile seizure, a rate which is comparable to that of other long-term studies 
(Annegers et al., 1987; Vestergaard et al., 2008).  In the previous reported analysis, 12 
children (6%) had developed epilepsy after a median follow-up of 11.2 years while two 
had a single epileptic event (one person had two seizures within a 24 hour period)
(MacDonald et al., 1999). In this follow-up, two additional people had developed 
epilepsy while one further person had a single epileptic seizure. Of these one who 
developed epilepsy and the person with a single seizure did so within the follow-up 
period of the last analysis (within a median follow-up of 11.2 years) but further follow-
up information was not available at the time (MacDonald et al., 1999). Consequently 
only one further person with a history of febrile seizures developed epilepsy during an 
additional ten years of follow-up. In the last analysis the only factor associated with a 
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significantly increased risk of developing subsequent epilepsy was a history of four or 
more febrile seizures (OR 9.4 (95% CI 1.5, 5.7), p< 0.015).
In the Danish study the risk of developing epilepsy increased with increasing number of 
hospital admissions for febrile seizures (19.7; 95% CI 17.9, 21.7) compared with
children without a history of febrile seizures (Vestergaard et al., 2008). In this study the 
risk of newly developing epilepsy decreased the longer the length of time since the 
febrile seizure. The rate of epilepsy was increased 26-fold in the first three months 
following a febrile seizure, decreasing to a three-fold increase after eight years but 
remaining significantly elevated throughout the 23 years of follow-up (Vestergaard et 
al., 2008). 
In contrast, in the NGPSE we found that the incidence of epilepsy was no longer 
significantly elevated in the 15-20 age group, which corresponds to 10 to 20 years of 
follow-up; numbers are small, however, with only one person with febrile seizures 
developing epilepsy in this age group and contributing to the SIR. Such a finding 
suggests that the risk of developing epilepsy after a febrile seizure may be comparable 
to that of the general population after 20 years. 
Others have suggested three possible reasons for the association between febrile 
seizures and later epilepsy (Vestergaard, 2008): that febrile seizures are the first 
manifestation of epilepsy; that they may be an age-specific marker of susceptibility to 
seizures; and that prolonged febrile seizures may damage the brain with the consequent 
potential for the development of epilepsy.  Our data and that of others suggest that most 
febrile seizures are not the first manifestation of epilepsy.  Our view would tend towards 
the second and third proposed reasons – that people with febrile seizures may have an 
inherent susceptibility to seizures or that prolonged febrile seizures may damage the 
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brain in some.  We suggest that other factors also affecting seizure susceptibility may 
influence or indeed determine whether or not epilepsy develops. The current concept of 
epileptogenesis suggests that it is a progressive dynamic process of molecular and 
cellular changes that can occur after an acute insult (febrile seizure, head injury, acute 
stroke) which alters neuronal excitability with, in some people, a resultant latency 
period (an operational term referring to the period of time between an acute insult and 
the first spontaneous epileptic seizure) (Pitkanen and Lukasiuk, 2011; Pitkanen, 2010). 
In experimental models of epilepsy the latency period and the proportion of animals 
which develop epilepsy vary depending on the epileptogenic insult (Pitkanen et al., 
2007). Our data suggest that febrile seizures (and other insults) may induce a time-
dependent process where, if spontaneous seizures do occur, they will do so within a 
predictable time frame as in experimental models, but that, on their own, febrile 
seizures are insufficient to result in epilepsy. This view of a multi-factorial 
epileptogenic process is supported by the finding in some studies that people with a 
positive family history of epilepsy are at higher risk of developing spontaneous seizures 
after febrile seizures (Vestergaard et al., 2008) or a head injury (Christensen et al., 
2009).
In summary it is clear that this finding needs to be confirmed by further large long-term 
prospective incident cohort studies of children with febrile seizures, with clinical 
information on seizure numbers, duration and seizure type. Such large cohorts will 
clearly need to be stratified by ethnic groups, particularly as children from certain ethnic 
backgrounds (Asian) and regions (Guam) appear to be at higher risk of febrile seizures 
which may be genetically pre-determined. It may therefore be true that children of 
different ethnicities have similarly different rates of people developing epilepsy long-
term. If the findings in this study are confirmed by other long-term studies, this would 
218
218
be of significant value in counselling anxious parents of the long-term risk of their child 
developing epilepsy in the aftermath of a febrile seizure.
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8.4 The prognosis of chronic epilepsy (Studies 3 & 4)
8.4.1 Seizure patterns in chronic epilepsy
Whilst it is fully accepted that the majority of people with epilepsy who attain seizure 
remission do so early in the course of treatment , the related proposition that, if early 
treatment is unsuccessful, then the individual is likely to develop chronic epilepsy 
resistant to any treatment is more contentious (Kwan and Brodie, 2002). Based on this 
proposition, the ILAE Commission on Therapeutic Strategies has proposed that drug 
resistant epilepsy be defined as failure of adequate trials of two tolerated, appropriately 
chosen AED schedules (Kwan et al., 2010). There is, however, evidence that many 
people enter remission after several years of continuous seizure activity and after trials 
of more than two drugs (Annegers et al, 1979, Berg et al., 2006; Sillanpaa and Schmidt, 
2006; Callaghan et al, 2007; Luciano and Shorvon, 2007; Del Felice et al., 2010), but
how these data fit into the view of prognosis has not been established. Research on 
prognosis has largely focused on early predictors of subsequent intractability and 
identified factors have included: failure to respond to the first two appropriate AEDs 
tried (Kwan and Brodie, 2000), high seizure density prior to commencing treatment 
(MacDonald et al., 2000), epilepsy syndrome and seizure type and aetiology (Semah et 
al., 1998). 
We identified patterns of remission and relapse during the course of their epilepsy in 
people with chronic epilepsy (defined here as those with active epilepsy at least five 
years after diagnosis). All participants had, by definition, drug resistant or refractory 
epilepsy at the time of recruitment and yet we found that a period of remission (seizure 
freedom for two years or more) had occurred in 30% (i.e. these people had the 
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‘intermittent pattern’ of epilepsy). The clinical and demographic features of this group 
were similar to those who had a continuous pattern of epilepsy, except that those with 
the intermittent pattern had less frequent seizures (as judged by the number in the 
previous year) and had taken a smaller total number of antiepileptic drugs – although 
this may simply reflect the shorter time period of active epilepsy.
We did not include people in early or late terminal remission in the analyses as the 
majority of such individuals are unlikely to be attending a tertiary epilepsy clinic. An 
estimate of the numbers of these people can only be gathered from population-based 
cohorts of people followed from the onset of their condition. Several such studies have 
been carried out; in one population-based study of 6,000 people, 93 people with a 
history of epilepsy were identified, of whom 25 (27%) had a continuous pattern of 
seizures, 13 (14%) an intermittent seizure pattern and 55 (59%) were in remission 
(Goodridge and Shorvon, 1983).  Similarly in a prospective cohort of 144 children with 
epilepsy followed for a median of 40 years, 97 (67%) achieved terminal remission and 
27 (19%) had a continuous pattern of seizures (Sillanpaa and Schmidt, 2006). 
In the current study neuro-imaging findings were confined to three principal pathologies 
(hippocampal sclerosis, cortical dysplasia and cerebro-vascular disease), which 
collectively accounted for 83% of abnormalities identified in people with a continuous 
seizure pattern and 77% in those with an intermittent seizure pattern (Table 20, Page 
140). We found no difference in the proportion of people with these findings or with 
normal imaging between the two seizure pattern groups. 
In conclusion, there seems to be considerable heterogeneity in seizure patterns in people 
who do not enter long-term remission in the early years after diagnosis. About one third 
will attain significant periods of seizure freedom, and these are people with less severe 
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epilepsy (measured by seizure frequency in the year before remission and who had 
previously taken fewer AEDs). Entering early remission does not, however, guarantee 
long-term seizure freedom; in this study, each person had refractory epilepsy, yet one 
third of the intermittent group had had an initial remission in the first years after 
diagnosis. Similarly in a prospective study of early seizure pattern, 40% of people with 
early remission (of at least one year) had relapsed after five years with 25.3% ultimately 
developing drug-resistant epilepsy (Schiller, 2009).
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8.4.2 The impact of medication change in chronic epilepsy 
In the study of medication changes, of the 139 people on whom prolonged follow-up 
was available, 67 (48 %) had a greater than 50% reduction in seizure frequency 
compared with 51 (36.7%) at the previously published follow-up. This underlies the 
importance of persevering with treatment as eventually almost half will have a sustained 
period of significant improvement in seizure control. We found, however, that a 
significant proportion (approximately 50%) of people who achieve remission will 
subsequently relapse on extended follow-up, which is similar to what others have found 
(Callaghan et al., 2007; Choi et al., 2008; Berg et al., 2009). In one of these studies, 
10.7% attained at least one year seizure remission with 25% of those subsequently 
relapsing within 3.8 years. In an extended follow-up, 60% (15/25) (13% of total) who 
had one or more years seizure freedom subsequently relapsed with an 81% probability 
of seizure relapse after five years. No factors were found to be predictive of subsequent 
relapse (Choi et al., 2011). On the other hand in the extended follow-up period in the 
current study there were some people who became seizure free who had not been 
seizure free in the previous study (Luciano and Shorvon, 2007). 
Indeed six (25%) of those who relapsed after becoming seizure free during the study 
were in remission again at the end of follow-up. In addition two people had two periods 
of seizure freedom (of at least one year) with a further relapse, while two people with 
JME had a recurrence of their myoclonus but no generalised tonic-clonic seizures. 
Similarly two other people, both of whom had significant periods of seizure freedom 
(one with a seizure-free period of six months and the other with two separate periods of 
one year and eighteen months of seizure freedom) but were not seizure free at either end 
point, had a complete cessation of generalised seizures, suggesting that even in those 
who subsequently relapse, their seizure control can be significantly better as a result of 
medication changes.
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Of the 16 people in whom no further follow-up information was available, five were 
seizure-free, five had a greater than 50% improvement while the remainder (six) had no 
significant change in seizure frequency at the time of the last analysis (2004). It is 
possible that some of this group are no longer attending a tertiary referral centre because 
their seizures remain under complete control or significantly improved. 
In the original analysis three factors (epilepsy duration, number of previous AEDs and 
epileptic syndrome) were found to be predictive of a better outcome. In this analysis, 
the only factor associated with seizure outcome at the end of follow-up was seizure 
outcome at the end of the earlier follow-up, suggesting that even in refractory epilepsy, 
the earlier that seizure remission is attained the higher the probability that seizure 
freedom will be maintained. The previous number of AEDs (< or ≥ 5 AEDs) tried 
approached statistical significance with a lower number of concomitant AEDs 
statistically significant in predicting a better long-term seizure prognosis, underlying the
importance of the number of previous drug failures in predicting seizure prognosis, a 
finding replicated in some (Callaghan et al., 2007; Schiller and Najjar, 2008) but not by 
others (Choi et al., 2008; Berg et al., 2009).  In one of these studies, 42% of 478 people 
with newly treated epilepsy responded to the first AED, 17% to the next two to five
AEDs, while no one became seizure free after six or more AEDs (Schiller and Najjar 
2008), leading to the suggestion that absolute drug-resistance occurs after failure of five 
AEDs. In this study 31% (8) of those seizure-free at last follow-up had six or more 
previous drug failures although only three had tried more than six previous AEDs. 
Moreover one third of people seizure-free at last follow-up had relapsed after attaining 
initial seizure remission before becoming seizure free again.  Similarly we identified 32 
individuals in the seizure patterns study (study 3) with previously chronic epilepsy who 
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had entered late terminal remission, and in this group the median number of AEDs was 
6 (IQR 4.5, 8) suggesting that there is always a chance of becoming seizure-free 
irrespective of the number of AEDs tried previously. 
Neither epilepsy duration nor the epilepsy syndrome was predictive of long-term seizure 
outcome. Similarly no factors were identified to predict subsequent relapse once a 
person had become seizure free. (The finding of a higher proportion of people with a 
longer duration of epilepsy in the seizure free group is likely to be due to the small 
numbers).
The number of previous AED failures is central to the recently proposed definition of 
drug-resistant epilepsy by the ILAE (Kwan et al., 2010). It is recommended that 
epilepsy be classified as treatment resistant when a person continues to have seizures 
despite trials of at least two appropriately selected AEDs, assessed for a sufficient 
length of time to allow an accurate evaluation of seizure frequency. AEDs which are 
discontinued because of side-effects are not considered drug failures. Moreover 
treatment success is defined as a subsequent seizure freedom of one year or a period of 
seizure freedom three times the duration of the previous inter-seizure interval, 
whichever is longer (Kwan et al., 2010). One of the problems with this proposal is that 
for an individual with infrequent seizures a classification of drug resistant epilepsy may 
take several years to be established. 
The principal rationale for identifying early predictors of potentially refractory epilepsy 
is so that the evaluation of alternative means of treatment (e.g. surgery) can be initiated 
earlier in the course of epilepsy. One possible means of predicting treatment failure is 
through the use of trans-cranial magnetic stimulation to measure cortical excitability 
before and after initiation of drug treatment in people with active epilepsy. Failure of 
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normalisation of cortical excitability four to 16 weeks after starting the AED was 
predictive of pharmaco-resistance (Badawy et al., 2010). This is based on experimental 
data and is therefore speculative, with its potential application to the clinical 
management of people with pharmaco-resistant epilepsy yet to be established. Moreover 
this is likely to be available only in a small number of tertiary referral centres. This 
does, however, raise the interesting possibility of identifying people with treatment 
resistant epilepsy by means other than clinical response to sequential AED trials in the 
future.
Only a small proportion of people with treatment resistant epilepsy are suitable 
candidates for epilepsy surgery (Lhatoo et al., 2003). In this cohort less than four 
percent underwent epilepsy surgery despite all people with appropriate epileptic 
syndromes being evaluated for the possibility of epilepsy surgery. Consequently further 
medication changes offer the only real prospect of seizure freedom for the majority of 
people with treatment resistant epilepsy. This type of study demonstrates the 
heterogeneity of chronic epilepsy but more importantly that persistence with medication 
changes in the face of apparent intractability will result in nearly half having a 
significant reduction in seizure frequency while approximately one third will become 
seizure free for one or more years. Given the complexity of their epilepsy such 
individuals are best managed in dedicated specialist epilepsy clinics. Long-term 
prospective cohort studies of people with chronic epilepsy are needed to determine 
prognosis and the effect of treatment. Despite this, it is clear that even if a significant 
proportion of people with chronic epilepsy who become seizure-free will subsequently 
relapse, long-periods of seizure freedom or significantly improved seizure control in the 
absence of complete seizure control are of great value and worth striving for.
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8.4.3 A prognostic model of epilepsy (Studies 2-4)
The main objective of these studies is to contribute to an understanding of the temporal 
patterns of the prognosis of epilepsy. A fairly consistent picture is emerging. The 
findings from these studies that the ratio of intermittent: continuous patterns in chronic 
epilepsy is approximately 1:2 and that about a quarter of people with apparent refractory 
epilepsy will achieve late long-term remission, can be added to those of others allowing 
a synoptic model of prognosis to be developed (Figure 9).
Figure 9: Proposed prognostic model of epilepsy.
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In this model, about 60% of people developing epilepsy will go into long-term 
(probably permanent) remission within five years of diagnosis (pathway a). This has 
been long suggested by epidemiological and prospective clinic based studies (Annegers 
et al., 1979; Goodridge and Shorvon, 1983; Sander, 1993; Cockerell et al., 1997; Kwan 
and Brodie, 2000; Berg et al., 2001; Lindsten et al., 2001, Kwan and Sander, 2004). To 
what extent this good prognosis simply represents the natural history of benign epilepsy 
or is a treatment effect is not known – but it is probable that both play a part. Studies 
from resource-poor settings suggest that at least a third of people with epilepsy will 
enter spontaneous remission without remission (Sander, 1993; Placencia et al., 1994; 
Nicoletti et al., 2009). It could therefore be postulated that treatment directly induces 
seizure freedom in only about half of those with early remission, although direct 
comparisons of different populations are not possible. 
Other people (thus approximately 40% of the total) still have active epilepsy at five 
years after onset (i.e. are classified as having ‘chronic’ epilepsy; pathway b). A 
proportion of these people will enter subsequent long-term remission (pathway c). 
Exactly how large this group is not entirely clear, but interpreting data from the 
epidemiologically-based studies it can be suggested that this may apply to about ten
percent of all people with epilepsy (Annegers et al, 1979; Sillanpaa and Schmidt, 2006). 
Included in this group are people with some of the age-specific epilepsy syndromes. 
Other people have continuous epilepsy, with no periods of remission (pathway d), or 
epilepsy with an intermittent pattern (pathway e). Our study suggests that the proportion 
of people following these two pathways is about 2:1 (Neligan et al., 2011b). On this 
basis, one can estimate that about ten percent of people with epilepsy overall follow an 
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intermittent pattern (pathway e) and about 20% a pattern of continuous epilepsy 
(pathway d). 
The influence of treatment on long-term prognosis is not known, in the absence of 
comparative studies with untreated groups at each of these pathways. Clinical 
experience, however, suggests that therapy can have a significant effect in people with 
chronic epilepsy, as in those newly diagnosed. Of course, it needs to be emphasised that 
seizure freedom is not the only good outcome, and therapy will often reduce the 
severity, duration or frequency of seizures in beneficial ways which are not represented 
in this model. 
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8.5 The prognosis of status epilepticus (Study 5)
The over-arching theme of this thesis is concerned with various aspects of the long-term 
prognosis of epilepsy yet in considering the prognosis of status epilepticus, outcome is 
primarily defined as short-term mortality (30-day case fatality rates in most studies). 
Indeed there is only study that examines long-term prognosis (ten-year mortality) 
following an episode of SE, suggesting that status epilepticus alone does not influence 
long-term mortality (Logroscino et al., 2002). Consequently any examination of long-
term prognosis following an episode of SE is therefore better defined in terms of 
morbidity (for example resultant neurological or cognitive deficits or the development 
of resultant epilepsy) in survivors (Neligan and Shorvon, 2011).
The primary aim of carrying out a systematic review of the prognosis of SE was to 
examine the impact of the underlying cause on outcome. We found that the underlying 
aetiology is the primary determinant of prognosis of SE (Neligan and Shorvon, 2010).
SE associated with certain aetiologies such as low AED levels and alcohol abuse have a 
relatively good prognosis with a reported mortality in the case series of <10%, while 
other aetiologies such as metabolic disorders, cerebrovascular disease and particularly 
anoxia/hypoxia are associated with much poorer outcomes. The relative frequencies and 
associated mortality rates are summarised in Table 32.
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Aetiology Proportion of cases of SE Associated acute mortality 
in people with SE 
Drug reduction/withdrawal, 
poor compliance or low AED 
levels
10-20% 0-10%
Cerebrovascular disease 10-40% 20-60%
Metabolic disorders 5-15% 10-35% 
Acute CNS infections 0-10% 0-30%
Anoxia 5-10% 60-100%
Alcohol 5-15% 0-10%
Head trauma 0-10% 0-25%
Drug overdose/toxicity 0-10% 10-25%
Brain tumours 0-10% 0-20%
Cryptogenic/idiopathic* 5-15% 5-20% 
Table 32:  Approximate frequency and mortality of status epilepticus in different 
aetiologies in representative Western populations
(Amalgamated figures from papers cited with an emphasis on representative studies and 
those with large sample sizes)
*The immune mediated encephalopathies with associated status epilepticus are likely to 
be responsible for a small number of these cases (<1% of total) although exact figures 
for their prevalence do not exist.
It is also clear that when status epilepticus occurs in the setting of an acute neurological 
insult, the prognosis is worse than in people without an acute neurological insult, 
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particularly in cases of stroke (Knake et al., 2006; Waterhouse et al., 1998), meningitis
(Zoons et al., 2008) and post-anoxic SE (Thomke et al., 2005; Wijdicks et al., 1994). Of 
course, this may not be a direct causal relationship as the occurrence of status may itself 
also reflect the severity of the underlying pathology.
The relationship of factors other than aetiology (duration of SE, EEG findings, level of 
consciousness and age) to the prognosis of SE is less clear, in part because of the 
influence of the underlying aetiology on the other factors. It does however appear that 
the longer the seizure persists (typically more than an hour), the more likely is the 
seizure to be unresponsive to antiepileptic drug therapy, the higher the mortality and the 
worse the prognosis in survivors. 
In contrast the clinical significance to the prognosis of PLEDs (PEDs) or persistent 
evidence of electrographic seizures post SE on EEG remains controversial. Their 
prognostic predictive value may, however, be more due to that of the underlying 
aetiology than to any independent influence. A lower level of consciousness with SE is 
clearly and consistently associated with a poorer prognosis, although this probably 
reflects the underlying aetiology, in particular anoxic damage.
The outcome and mortality of SE in children and in adults varies, with the best 
outcomes in young children and the worst in the elderly. The reason is partly related to 
the different underlying aetiologies at different ages, for example febrile status 
epilepticus in children and post-anoxic brain injury and degenerative brain disease in 
the elderly, which have different prognoses. Despite this, children and young adults 
appear to have consistently better outcomes (morbidity and mortality) following an 
episode of SE when analysed by individual aetiologies compared with older adults and 
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the elderly (DeLorenzo et al., 1996; Chin et al., 2006) (Table 31, Page 188). It is likely 
therefore (although not definitively demonstrated in published studies) that age is an 
important prognostic factor in SE, independent of aetiology.
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8.6 Problems facing epidemiological research in the UK: lessons 
from the NGPSE 
The experience of the NGPSE research team offers a window on the obstacles that 
epidemiologists currently face in the UK, in particular with regard to multi-centre 
research. British epidemiology has a proud pedigree with the pioneering work of Sir 
Richard Doll in the 1950s (Doll and Hill, 1954) among others, yet the UK of today 
appears to be a particularly hostile environment for prospective epidemiologists as a 
result of the bureaucratic quagmire of multi-level approvals by different health 
authorities which are necessary before any research can be undertaken. 
The European Data Protection Act 1998 (UK Parliament Acts 1998) and the Health and 
Social Care Act 2001 (British Parliament 2001) irrevocably altered the research 
environment in the UK, increasing the time, cost and effort required before all the 
necessary approvals can be obtained (Lawlor and Stone 2001). Such a changing 
environment is also reflected in the dwindling number of UK patients recruited into 
clinical trials, decreasing from six percent of global numbers in 2000 to two percent in 
2006 (Lancet, 2011).
In 2007 it seemed appropriate to send a further follow-up to GPs about survivors of the 
792 people with definite or possible epilepsy and the 220 people with febrile seizures in 
the NGPSE.  When the NGPSE was set up in 1984, full ethics approval was obtained 
from the local ethics committee but, as was usual at the time for purely observational 
studies, consent was not required from each individual recruited.  Following receipt of 
ethics approval for the study in November 2007, application was made to the Patient 
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Information Advisory Group for Section 60 exemption of the Health and Social Care 
Act 2001 for the study as it was felt that obtaining full informed consent from all people 
in the study would be profoundly detrimental to case ascertainment. This was 
subsequently conclusively demonstrated by our experience in Scotland where Section 
60 exemption was not applicable. 
PIAG is a body created by Section 60 of the Health and Social Care Act 2001 to advise 
the Secretary of State on cases where it may be justifiable to allow the release of patient 
identifiable information for research or NHS activities to proceed without patient 
consent (Higgins, 2003).  The application for Section 60 exemption is necessarily 
detailed, taking several months to complete (Coleman et al., 2003). Overall it took 
approximately eight months from original submission to written confirmation of Section 
60 exemption, a timescale comparable to, or more favourable than, the experience of 
others (in part influenced by the fact that the committee now meets bi-monthly as 
opposed to quarterly as previously) (Malfroy et al., 2004; Metcalfe et al., 2008). 
Approval of PIAG in granting Section 60 to the study was contingent on a significant 
reduction in the amount of clinical information that could be requested (see Appendices 
1 and 2) in addition to the requirement for consent in certain cases. It must nevertheless 
be acknowledged that Section 60 exemption was critical for this stage of the study 
without which we would have struggled to get information from adequate numbers of 
individuals, to the point of rendering any conclusions drawn from the study 
meaningless. 
Without Section 60 exemption, consent would have been required from all people 
included in the study; a situation we anticipated would be the case in Scotland (where 
the Health and Social Care Act 2001 and therefore the provision of Section 60 
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exemption did not apply, as this law was enacted after Scottish devolution).  We did 
not, however, anticipate the decision that without Section 60 exemption (or a 
comparable provision), we would not be allowed access to individual’s GP’s details. 
Consequently, in Scotland, all correspondence was sent to the GPs via an intermediary 
service with no direct contact with the GPs. We were advised that for us to have access 
to an individual’s GP’s details would be a breach of patient confidentiality. It is,
however, difficult to understand how such knowledge in any way poses a threat to 
confidentiality. In the end this decision sounded the death knell for the study in 
Scotland, for without the means of personally promoting the study to GPs with the need 
for consent from all individuals, the response rate was inevitably extremely poor (26%). 
One of the reasons given by PIAG for not granting Section 60 exemption following the 
original submission was the contention that a valid alternative to Section 60 exemption 
was to ask GPs to obtain consent, as stated in their original decision letter.  “…the 
Group noted that you are intending to contact patient’s GPs and this is an ideal 
opportunity to ask them to publicise the study and to attempt to obtain consent”
Without Section 60 exemption, we would not have been allowed access to individual 
GP’s details in England and Wales (as was the case in Scotland) which raises the 
question of how we could ask the GPs to obtain consent or indeed promote the study to 
the relevant GPs.
The PIAG’s original contention that GPs can reasonably be expected to obtain consent 
from individuals for their continued participation in a study in existence for over twenty 
years is certainly debatable. Moreover the blanket requirement of consent for all people 
in the study raises the risk of selection bias with people with ongoing seizures more 
likely to consent to inclusion in a study that is directly relevant to them (as opposed to 
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people in long-term remission who may even be offended by their inclusion in such a 
study) (Al-Shahi et al., 2005).
The study was adopted onto the NIHR CRN and the PCRN in England (which almost 
certainly would not have happened without Section 60 approval). As a result the study 
was eligible for Service Support Costs. It was agreed that GP practices would be paid if 
the questionnaire was returned completed and with consent where required. In certain 
cases, when we contacted GP practices by telephone after failure to return the 
questionnaire (or returning it incomplete), we discovered that many had simply 
forwarded the information onto the individual patient without explanation or support for 
the study where consent was required to complete the study (and in many cases where 
consent was not required). Failure of patients to return questionnaires/consent forms or 
reply to invitations to participate in studies is assumed by regulatory authorities to be 
the same as refusal to give consent yet surveys of the UK public on the use of patient 
identifiable information does not support this interpretation. Only 2-3% of people 
typically refuse outright involvement (Barrett et al., 2006; Jackson et al., 2008) with up 
to 20% wishing to be informed prior to the use of their information in national 
databases or registries (Campbell et al., 2007). In the NGPSE we are aware of only four 
people who explicitly refused consent although the true figure is almost certainly 
higher. Nevertheless this is significantly less than the 50-60% who typically fail to 
respond to invitations to participate in research (Tu et al., 2004; Al-Shahi et al 2005) 
with higher rates achieved when the person requesting consent is directly involved in 
the research rather than an intermediary (Tu et al., 2004). The exclusive reliance on GPs 
to obtain consent in longitudinal studies is problematic with many GPs not wishing to 
broach the sometimes problematic issue of consent for research even when there is a 
financial incentive to do so.  In addition, a proportion of people invited to participate in 
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research will not respond because of an incomplete explanation of the study. Of note,
every person who contacted the NGPSE research team for further information on the 
study gave consent. 
Following receipt of ethical approval of the final necessary amendment to the study, 
application was made to all PCT R&D departments where it was assumed that people in 
the study currently resided. Application was also made to the Information Centre (IC) 
NHS (formerly the ONS). Despite the fact that the study had been granted Section 60 
exemption more than five months previously, this decision was not communicated to 
the IC NHS. Consequently the study had to be reviewed by the ethics committee of IC, 
resulting in a minor change to the patient consent form (see appendix). Similarly final 
release of GP details from the Data Protection Managers was subject to review by the 
local Caldicott Guardian in several instances.  For multi-centre epidemiological project 
like the NGPSE, approval is required from all PCT R&D departments, a very time-
consuming process varying from several weeks to many months depending on the PCT.  
This involves a process of checks and validations duplicated by other Trusts as well as 
ethical committees (Ethics, IC, PIAG). In some instances it appeared that the primary 
motivation of the R&D department was to protect the Trust from future possible legal 
action rather than evaluating the validity and clinical need for the research project. In 
one instance an R&D department refused approval for the study, a decision that was 
only reversed on appeal when it was demonstrated that patient consent was unlikely to 
be required from the people in the study in that PCT. 
In total it took almost two years from the time of submission of the ethics application to 
when the first questionnaires were sent out, a delay largely accounted for by the time 
needed to obtain all the required approvals to proceed with the study. If this was the 
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norm for other epidemiological multi-centre studies, it would have disastrous 
consequences for case ascertainment not to mention the probability of obtaining 
research funding for such projects which would be seen as prohibitively expensive due 
to administrative delays. In the end while a further follow-up of the cohort has been 
completed, permission to allow this to happen was contingent on the permanent closure 
of the study upon completion of this follow-up and the destruction of the study records 
(both paper and electronic).  While such a decision safe-guards individual patient data, 
we would strongly contend that it is clearly not in the best interests for people with 
epilepsy in general.
Fortunately change appears to be at hand with the recognition of the need to reduce the 
duplication and bureaucracy in the regulation of clinical research in the UK with the 
recent publication of a white paper (Liberating the NHS: report of the arm’s-length 
bodies review) by the Academy of Medical Sciences. This paper proposes the creation 
of a new Health Research Agency which will incorporate the current National Research 
Ethics Service as well as other specialist research ethic approvals (PIAG?). In so doing, 
it is proposed that this will reduce the need for local checks by the PCTs other than local 
feasibility checks (Rawlins, 2011). It is hoped that such changes will reduce the 
bureaucracy and administrative delays that plagues multi-centre clinical research, thus 
safeguarding it for future generations.
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Chapter 9: Conclusions and future directions
The principal aims of this thesis were to study different aspects of the prognosis of 
people with epilepsy, in particular the long-term prognosis with regard to the risk of 
premature mortality, seizure prognosis and changing seizure patterns over time and the 
response to medication in people with established refractory epilepsy. In addition the 
prognosis (both short and long-term) of status epilepticus, the “maximal expression of 
epilepsy”, is reviewed with emphasis on determining which factors determine 
prognosis.
Based on the data presented in this thesis there are several issues with regard to the 
prognosis of epilepsy that need to be addressed.
1) Further population-based studies are needed to examine the temporal changes in 
the number of deaths attributable to epilepsy, in particular since 1990, to gauge 
the impact on mortality rates of the increasing number of treatment options
2) Prospective incident studies such as the NGPSE suggest that the long-term risk 
of premature mortality remains significantly elevated despite the fact that the 
majority of people achieve terminal remission.  Further prospective incident 
cohort studies are urgently needed to verify such a finding and to provide clues 
as to why people with a history of epilepsy have a persistently higher risk of 
premature mortality despite good control. More importantly, better 
understanding of the mechanisms of mortality will help determine if this higher 
risk can be modified.
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3) There is a paucity of long-term follow-up data in particular in adults with new
onset epilepsy. It is often stated that one third of people with epilepsy will have 
treatment resistant epilepsy, often as justification for the need for further AEDs 
or treatment modalities, yet the latest data from the NGPSE suggest that such 
estimates may be overly pessimistic. Moreover it is possible that a third of those 
with supposedly refractory epilepsy will in fact have significant periods of 
seizure freedom, probably as a result of medication changes.  Further long-term 
prospective incident cohort studies with both paediatric and adult populations 
examining prognosis in people with new onset epilepsy are needed. Such studies 
should be carried out with particular reference paid to aetiology and epileptic 
syndrome, changing seizure patterns and prognosis in refractory epilepsy in 
response to further AED changes.
4) Such questions may best be addressed by the creation of a national database 
(with patient consent) of all people with newly diagnosed or suspected epileptic 
seizures. The logistics and feasibility of such a project would need to be worked 
out but would clearly be in the best interests of all people with epilepsy, for 
whom much uncertainty regarding prognosis remains.
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Appendix 1
Version 0.3/17/10/2007
National General Practice Study of Epilepsy and Epileptic Seizures 
(NGPSE)
- Form: 20 Year Follow UP -
This is a follow up about a person who was registered by their then General 
Practitioner with the National General Practice Study of Epilepsy (NGPSE). 
This study was originally set up in 1983-84 with people registered in the 
study by their GPs between 1984 and 1987.
PLEASE RETURN THE COMPLETED FORM TO:    
Professor J. W.Sander,
FREEPOST,
National Society for Epilepsy,
Chalfont St Peter,
Bucks., SL9 0RJ.
1. General Practitioner 2. Patient
Date of last recorded seizure: (filled in by the research team)
Seizure type: (filled in by the research team)
Has this person had an epileptic seizure in the last five years?
Yes No  
Is this person currently taking anti-epileptic medication?
Yes No
290
290
If off medication, when was the medication withdrawn (year) …………..
Have they had any seizures since last follow-up (1997)? Please give details 
(approximate dates and frequency)
If seizures did occur, were these seizures similar to previous seizures or 
different? (Has the diagnosis changed?)
Please give details 
Please give details of current anti-epileptic medications, indicating doses
291
291
Since 1997, have other medications been tried? – if so, please give details 
(type of medication and dates)
Is this person still attending a hospital outpatient clinic for seizures?
Yes No 
Thank you for your cooperation
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Appendix 2:
Version 5: 16/01/2009
National General Practice Study of Epilepsy and Epileptic Seizures 
(NGPSE)
- Form: 20 Year Follow Up -
This is a follow up about a person who was registered by their then General 
Practitioner with the National General Practice Study of Epilepsy (NGPSE). This 
study was originally set up in 1983-84 with people registered in the study by their 
GPs between 1984 and 1987.
PLEASE RETURN THE COMPLETED FORM TO:    
Professor J. W.Sander,
FREEPOST,
National Society for Epilepsy,
Chalfont St Peter,
Bucks., SL9 0RJ.
1. General Practitioner 2. Patient
Date of last recorded seizure: (completed by the research team)
Seizure type: (completed by the research team)
1) Has this person had an epileptic seizure since October 2004?
        Yes
 No  
2) Has this person taken anti-epileptic medication since October 2004?
 Yes
 No  
 If currently off medication, when was the medication withdrawn (year) 
…………………
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If the answer to either of the above questions is YES we would like your 
assistance to seek and obtain the consent of the individual to obtain more 
information about them (see enclosed patient information sheet and consent 
form).
If the answer to both of the above two questions is NO, then we have approval 
under Section 251 of the NHS Act 2006 (formerly Section 60 of the Health and 
Social Care Act) to permit you to disclose the following information.
Has this person had any seizures since last follow-up (between 1997 & 2004
inclusive)? 
Please give details (approximate dates and frequency)
If seizures did occur, were these seizures similar to previous seizures or different? 
(Has the diagnosis changed?)
Please give details 
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Please provide information of all anti-epileptic medications taken between 1997 and 
2003 
with dates.
Please provide details of any known attendances at hospital outpatient clinics for 
seizures between 1997 and 2003
Thank you for your cooperation
